{"meta":{"query_hash":"0a6c9d7b2298","filters":{"venue":"JCO Precision Oncology"},"cohort_total":105,"direct_labels_cover":0,"predictions_cover":105,"exported":105,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/0a6c9d7b2298","api":"https://metacan.xera.ac/api/v1/cohort?venue=JCO+Precision+Oncology"},"results":[{"id":"W2598368982","doi":"10.1200/po.17.00127","title":"Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Enzalutamide; Taxane; Prostate cancer; Medicine; Docetaxel; Oncology; Internal medicine; Androgen receptor; Cabazitaxel; Androgen deprivation therapy; Cancer; Breast cancer","score_opus":0.16266761043451983,"score_gpt":0.4792556454121008,"score_spread":0.316588034977581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598368982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541163,0.00019968723,0.0000103770535,0.00083224324,0.00021294816,0.0013150324,0.00006511229,0.000013831813,0.0019391464],"genre_scores_gemma":[0.9953252,0.00014194276,0.0037704352,0.00005220236,0.000046494588,0.00011008327,0.00003175969,0.00001642254,0.00050545146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978701,0.00022856946,0.0007259693,0.00041041576,0.00043435424,0.0003306041],"domain_scores_gemma":[0.9976453,0.00069409626,0.0004911211,0.0005605089,0.00044303437,0.00016594362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010325212,0.00015324673,0.00064123457,0.000114256894,0.0001475717,0.000021888547,0.00017881028,0.00011508601,0.00012950957],"category_scores_gemma":[0.0012710205,0.000098171164,0.00006770511,0.00014142328,0.00040624596,0.00013991406,0.00010528904,0.00036283283,0.000007952127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059853937,0.0011973388,0.82614255,0.000072697105,0.000073902025,0.0000831184,0.00015856273,0.0000042323827,0.00021036052,0.0000060664192,0.00026667566,0.16579908],"study_design_scores_gemma":[0.011828143,0.0038488742,0.98135954,0.0003084562,0.00009172042,0.0000026355865,0.00006222046,0.00028309727,0.00046146728,0.00019764487,0.0014664944,0.00008973141],"about_ca_topic_score_codex":0.00063948636,"about_ca_topic_score_gemma":0.0010252821,"teacher_disagreement_score":0.16570935,"about_ca_system_score_codex":0.00019827996,"about_ca_system_score_gemma":0.0010339778,"threshold_uncertainty_score":0.4003304},"labels":[],"label_agreement":null},{"id":"W2652345243","doi":"10.1200/po.16.00031","title":"Homologous Recombination Deficiency in Breast Cancer: A Clinical Review","year":2017,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Homologous recombination; Breast cancer; Homologous chromosome; BRCA2 Protein; Medicine; DNA repair; Germline mutation; Germline; Cancer; Clinical significance; Bioinformatics; Mutation; Genetics; Biology; Internal medicine; DNA; Gene","score_opus":0.3056827032087479,"score_gpt":0.5919253871315462,"score_spread":0.2862426839227983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2652345243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000659242,0.97751313,0.000019642242,0.0042633903,0.003145135,0.0031366034,0.00011529006,0.00007367908,0.011726554],"genre_scores_gemma":[0.0000055252326,0.9936821,0.00034725128,0.0019168886,0.0006350143,0.0015015071,0.00014917176,0.000076437835,0.0016861445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936493,0.0015521557,0.0027619735,0.0010897556,0.00045201526,0.00049480563],"domain_scores_gemma":[0.99452,0.001319061,0.0021548897,0.0014317767,0.00032896549,0.00024527565],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004041131,0.00051881524,0.005325775,0.00051291805,0.00012345788,0.000022605773,0.0006711388,0.0014581612,0.0018404872],"category_scores_gemma":[0.0009779878,0.00040332234,0.0009994033,0.00045731594,0.0002968306,0.000115737006,0.00019788455,0.0017522707,0.00060876325],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009452931,0.00059769064,0.000114380004,0.013084238,0.00005141371,0.00021703949,0.000010104752,6.9889786e-8,8.471608e-8,0.000037553214,0.0495903,0.9362026],"study_design_scores_gemma":[0.0018194611,0.00058147364,0.00051812636,0.1300766,0.0006945495,0.0022292025,0.0000015119997,0.0000023818945,8.9513385e-8,0.00020902627,0.86357355,0.0002940251],"about_ca_topic_score_codex":0.000073849675,"about_ca_topic_score_gemma":0.0000744347,"teacher_disagreement_score":0.93590856,"about_ca_system_score_codex":0.002226204,"about_ca_system_score_gemma":0.0040158504,"threshold_uncertainty_score":0.99984187},"labels":[],"label_agreement":null},{"id":"W2728001194","doi":"10.1200/po.17.00027","title":"Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Urinary and Genital Oncology Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"National Cancer Institute","keywords":"MSH6; Microsatellite instability; Adenocarcinoma; MSH2; MLH1; Immune checkpoint; Cancer research; Medicine; Colorectal cancer; Oncology; DNA mismatch repair; Internal medicine; Biology; Cancer; Immunotherapy; Genetics; Gene","score_opus":0.06723622734382263,"score_gpt":0.3636070110342152,"score_spread":0.2963707836903926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2728001194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989014,0.0011142369,0.00008074331,0.0026143813,0.00033434434,0.00060055614,0.00006753586,0.00003313245,0.0061410572],"genre_scores_gemma":[0.99717015,0.00023696171,0.00087471114,0.0004315945,0.00015335146,0.000105808205,0.000055388035,0.000024108136,0.0009479118],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985561,0.00015933099,0.0004051404,0.00033464894,0.0002570779,0.0002877356],"domain_scores_gemma":[0.9981822,0.00030784358,0.00053936243,0.00038751925,0.00047795486,0.000105163264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002018637,0.00021067828,0.00085676636,0.00011119398,0.00045216057,0.000016814533,0.00022856813,0.00021971086,0.000126924],"category_scores_gemma":[0.00016723604,0.00016646141,0.00008563998,0.0000860377,0.00054971373,0.00019340296,0.0003466724,0.0002570586,0.000016801607],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008062765,0.00068525324,0.34042078,0.00021336407,0.0005636546,0.000621235,0.001757341,0.000014178685,0.63170916,0.0006378653,0.0003925197,0.0149219055],"study_design_scores_gemma":[0.0033615278,0.0063710967,0.95063496,0.00021319253,0.00032314198,0.00036903855,0.0003656507,0.00009338223,0.025524875,0.00039220272,0.012142468,0.0002084552],"about_ca_topic_score_codex":0.00013085087,"about_ca_topic_score_gemma":0.000055374596,"teacher_disagreement_score":0.6102142,"about_ca_system_score_codex":0.00018009066,"about_ca_system_score_gemma":0.00024981442,"threshold_uncertainty_score":0.6788099},"labels":[],"label_agreement":null},{"id":"W2765106815","doi":"10.1200/po.17.00132","title":"Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Balance (ability); Real world evidence; Randomized controlled trial; Precision oncology; Medicine; Oncology; Internal medicine; Precision medicine; Pathology; Physical medicine and rehabilitation","score_opus":0.11517459532314453,"score_gpt":0.39121708773981617,"score_spread":0.27604249241667167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765106815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5672454,0.040867027,0.0005697816,0.066908196,0.005764444,0.0031302418,0.00005694946,0.000048247628,0.3154097],"genre_scores_gemma":[0.9352072,0.058205537,0.0007115052,0.0018456301,0.00048670778,0.00033715623,0.0000017350776,0.00002072119,0.003183795],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701035,0.000438406,0.0013256469,0.0006747121,0.00007796221,0.0004729435],"domain_scores_gemma":[0.9888412,0.0083401855,0.0014807677,0.0011620958,0.000095745694,0.0000800414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009649516,0.0002710838,0.0016217984,0.00022807314,0.000762903,0.00020208751,0.0012983669,0.00027102826,0.00020081147],"category_scores_gemma":[0.0077857017,0.00016581961,0.00019490819,0.00014182118,0.0012834307,0.0007216457,0.00046023537,0.000589634,0.00023706513],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02401711,0.0005384584,0.05842804,0.000076127646,0.00033208966,0.00015528454,0.014920856,0.00011691743,0.000029550618,0.5529589,0.081677236,0.2667494],"study_design_scores_gemma":[0.02569424,0.00049071107,0.16780315,0.00018599968,0.00003884805,0.000036639758,0.00030361302,0.0011717341,0.000021045225,0.26504833,0.53884655,0.00035915853],"about_ca_topic_score_codex":0.001163393,"about_ca_topic_score_gemma":0.004316156,"teacher_disagreement_score":0.4571693,"about_ca_system_score_codex":0.0005633639,"about_ca_system_score_gemma":0.00015969592,"threshold_uncertainty_score":0.93207747},"labels":[],"label_agreement":null},{"id":"W2767438024","doi":"10.1200/po.17.00154","title":"Targeted Error-Suppressed Detection of Circulating Paternal DNA to Establish a Diagnosis of Gestational Trophoblastic Neoplasm","year":2017,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neoplasm; Obstetrics; DNA; Medicine; Biology; Genetics; Pathology","score_opus":0.032786361760688644,"score_gpt":0.339348977761677,"score_spread":0.30656261600098833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767438024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929249,0.00005325666,0.004001884,0.00053398806,0.00061114226,0.00057667634,0.00011618073,0.000027052543,0.0011548856],"genre_scores_gemma":[0.9929595,0.000029068056,0.006458741,0.00006977419,0.00012312963,0.00017165778,0.000022703061,0.000026270476,0.00013916721],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978922,0.00011204518,0.0007219501,0.00037847477,0.0006311193,0.00026418667],"domain_scores_gemma":[0.9964845,0.0013251759,0.00068960746,0.0004310384,0.0008568619,0.00021278246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026369985,0.00019227191,0.00061925215,0.00028930485,0.0002109033,0.000021107175,0.00021923256,0.00013897609,0.00032660543],"category_scores_gemma":[0.0075131035,0.0001753798,0.00014961802,0.00014964795,0.00021308019,0.00014748114,0.00018784952,0.00016333771,0.000030137278],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006722977,0.0024044313,0.25491896,0.0006732458,0.0006465402,0.00019701639,0.0025938298,0.005146874,0.60056365,0.00028079716,0.0022242104,0.123627454],"study_design_scores_gemma":[0.0028802243,0.0022831485,0.9611529,0.0003205708,0.00020271887,0.000026658807,0.00021759674,0.0019956187,0.029078243,0.00058525905,0.0011134133,0.00014364898],"about_ca_topic_score_codex":0.00014193227,"about_ca_topic_score_gemma":0.00008757235,"teacher_disagreement_score":0.706234,"about_ca_system_score_codex":0.00016878566,"about_ca_system_score_gemma":0.00032034118,"threshold_uncertainty_score":0.8994429},"labels":[],"label_agreement":null},{"id":"W2782876837","doi":"10.1200/po.17.00098","title":"Reflex Testing for Germline<i>BRCA1</i>,<i>BRCA2</i>,<i>PALB2</i>, and<i>ATM</i>Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PALB2; Germline mutation; Medicine; Founder effect; Breast cancer; Internal medicine; Pancreatic cancer; Oncology; Cancer; Mutation; Genetics; Gene; Biology; Genotype; Haplotype","score_opus":0.10428491355846134,"score_gpt":0.45428596827818557,"score_spread":0.3500010547197242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2782876837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274683,0.0028270332,0.00028778045,0.0016066303,0.00048122555,0.00085803657,0.0004403387,0.000011995442,0.00074014947],"genre_scores_gemma":[0.9838072,0.0027088497,0.010818907,0.0010709942,0.00086361385,0.00024979812,0.00016345784,0.000036185844,0.0002809955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976344,0.00029627586,0.0006486548,0.00077018514,0.00016161615,0.0004888761],"domain_scores_gemma":[0.9954415,0.0031393708,0.00019022323,0.00039794232,0.0005398778,0.00029110472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014649923,0.00019618227,0.00038152805,0.00017232244,0.00031264313,0.000071740855,0.00022886378,0.00032308343,0.000022857494],"category_scores_gemma":[0.0059213736,0.00019313012,0.000060792052,0.00022557855,0.0005982508,0.000014945825,0.00019335261,0.00024577376,0.0000058861133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006596579,0.00012030705,0.8271946,0.000050103776,0.00010888705,0.000025627669,0.0004369333,0.000047587066,0.0070263753,0.0002691545,0.0066043376,0.15745646],"study_design_scores_gemma":[0.00603866,0.004547738,0.80359083,0.00021530027,0.00019121986,0.000032313386,0.00031880333,0.0014202251,0.0038434106,0.0077768536,0.17141816,0.000606477],"about_ca_topic_score_codex":0.040863518,"about_ca_topic_score_gemma":0.37084714,"teacher_disagreement_score":0.32998362,"about_ca_system_score_codex":0.00019838229,"about_ca_system_score_gemma":0.0012645262,"threshold_uncertainty_score":0.9655235},"labels":[],"label_agreement":null},{"id":"W2788554175","doi":"10.1200/po.17.00122","title":"Oncologists’ Use of Genomic Sequencing Data to Inform Clinical Management","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"National Center for Advancing Translational Sciences; National Human Genome Research Institute","keywords":"Medicine; Medical record; Documentation; Clinical Oncology; DNA sequencing; MEDLINE; Family medicine; Cancer; Internal medicine","score_opus":0.20396029520431297,"score_gpt":0.4327402469800385,"score_spread":0.22877995177572552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788554175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334384,0.000115473296,0.007184869,0.00040569744,0.0014023872,0.000529924,0.00014711912,0.000012322263,0.006858347],"genre_scores_gemma":[0.9073391,0.0015716238,0.08399229,0.004251087,0.0011844384,0.00003130465,0.00031128482,0.00003453912,0.0012843668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982856,0.00008250407,0.00067118555,0.0005543976,0.00013876209,0.00026758199],"domain_scores_gemma":[0.99782956,0.000235717,0.00022155534,0.0013613608,0.0001949744,0.0001568164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009099123,0.00014082046,0.00030278912,0.00008433784,0.000072703275,0.00002262002,0.00074599386,0.00027560422,0.00008965387],"category_scores_gemma":[0.0008045579,0.00013322708,0.00007435182,0.00011310908,0.00020024838,0.000008329222,0.0021899226,0.000102031554,0.00014935179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016626272,0.00034356178,0.007053981,0.000026426062,0.0002303823,0.000034475845,0.00015141569,0.0003518867,0.11502908,0.00071088073,0.25295207,0.6214532],"study_design_scores_gemma":[0.0007335443,0.0029591266,0.017351832,0.0000131652505,0.000038851646,0.000013373149,0.00006043422,0.00026145455,0.0053162435,0.0000948769,0.97299325,0.00016386255],"about_ca_topic_score_codex":0.000057029647,"about_ca_topic_score_gemma":0.0004859376,"teacher_disagreement_score":0.72004116,"about_ca_system_score_codex":0.00014764907,"about_ca_system_score_gemma":0.00036680023,"threshold_uncertainty_score":0.54328424},"labels":[],"label_agreement":null},{"id":"W2796418582","doi":"10.1200/po.17.00125","title":"Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to <i>EGFR</i> Mutation Detection in Non–Small-Cell Lung Cancer","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Genotyping; T790M; KRAS; Liquid biopsy; Lung cancer; Epidermal growth factor receptor; Biomarker; Medicine; Oncology; Cancer; Biology; Cancer research; Internal medicine; Genotype; Gene; Genetics","score_opus":0.03265072183519806,"score_gpt":0.4358843568916937,"score_spread":0.4032336350564956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796418582","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06815306,0.90951914,0.0048914347,0.00029976244,0.0011818605,0.012237835,0.000110029214,0.000041091454,0.003565768],"genre_scores_gemma":[0.07927402,0.91047657,0.0018702723,0.00041936187,0.00048853393,0.006730639,0.00036938427,0.00008431729,0.0002868843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772644,0.00027291902,0.0009463942,0.0005397274,0.00024211397,0.00027238243],"domain_scores_gemma":[0.9984252,0.00041975707,0.0005626933,0.0003789699,0.00013538724,0.000078029705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051320763,0.0002936881,0.0010637341,0.0005272734,0.000069050315,0.0000131719735,0.00021190057,0.00043366622,0.000049317783],"category_scores_gemma":[0.00005959829,0.00020736751,0.00018278955,0.0008623157,0.00006509551,0.0000604349,0.000067588604,0.0003314207,0.000049452912],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029643116,0.00044040204,0.00006900024,0.0020017487,0.00008072353,0.000023097708,0.0023148963,0.000038838578,0.00039911133,0.000009024277,0.00014851587,0.99417824],"study_design_scores_gemma":[0.0033952405,0.0023936606,0.000495147,0.006085671,0.0016207072,0.00016528166,0.0006073366,0.0005991459,0.00065434957,0.000014972913,0.98364466,0.0003238226],"about_ca_topic_score_codex":0.00081371446,"about_ca_topic_score_gemma":0.0020283302,"teacher_disagreement_score":0.9938544,"about_ca_system_score_codex":0.0022351514,"about_ca_system_score_gemma":0.0008176902,"threshold_uncertainty_score":0.84562016},"labels":[],"label_agreement":null},{"id":"W2801588305","doi":"10.1200/po.17.00198","title":"Comparative RNA-Sequencing Analysis Benefits a Pediatric Patient With Relapsed Cancer","year":2018,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alex's Lemonade Stand Foundation for Childhood Cancer; Canadian Institutes of Health Research; National Cancer Institute; BC Cancer Foundation; St. Baldrick's Foundation; Canada Research Chairs","keywords":"Pediatric cancer; Gene; RNA; DNA sequencing; Computational biology; Biology; Cancer; Genome; Cancer genome sequencing; Genetics; Medicine; Genomics; Bioinformatics","score_opus":0.02454373684747535,"score_gpt":0.31008613930356066,"score_spread":0.2855424024560853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801588305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913609,0.0016005998,0.0018451585,0.0001372878,0.0003613142,0.00024208806,0.000060669416,0.000011595235,0.004380367],"genre_scores_gemma":[0.99468356,0.0011605748,0.0025473288,0.00061368424,0.00064283225,0.000081796,0.00006749809,0.000016888627,0.00018584776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868584,0.00007736158,0.00029969626,0.00049552287,0.00016316402,0.00027838943],"domain_scores_gemma":[0.99879354,0.00010321119,0.00023077696,0.0003712876,0.0003700292,0.00013113704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014151397,0.00017699749,0.00035677335,0.00015561552,0.0001315594,0.000022511764,0.00017991528,0.00019887087,0.00013538315],"category_scores_gemma":[0.000078991114,0.00014518984,0.000107324384,0.0004710406,0.00010475482,0.0000041343087,0.00015413715,0.00010692156,0.000024088906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010489774,0.0017034423,0.12022674,0.000059992803,0.0054536615,0.00018035577,0.009748558,0.082005806,0.23913889,0.001183637,0.09686197,0.43294716],"study_design_scores_gemma":[0.007400237,0.029732717,0.075563364,0.00006397095,0.0037358294,0.00010183146,0.0013034273,0.0044745603,0.32486036,0.00034028443,0.5503129,0.0021105558],"about_ca_topic_score_codex":0.00017666272,"about_ca_topic_score_gemma":0.003711525,"teacher_disagreement_score":0.4534509,"about_ca_system_score_codex":0.00018119405,"about_ca_system_score_gemma":0.0005092547,"threshold_uncertainty_score":0.592067},"labels":[],"label_agreement":null},{"id":"W2888423222","doi":"10.1200/po.17.00311","title":"Economic Evaluations of Next-Generation Precision Oncology: A Critical Review","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"MEDLINE; Medicine; Precision medicine; Precision oncology; Economic evaluation; Medical physics; Scope (computer science); Computer science; Oncology; Pathology","score_opus":0.14373500341559128,"score_gpt":0.46145102725154385,"score_spread":0.31771602383595254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888423222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005575013,0.9906202,0.00094157655,0.0003158873,0.0026310792,0.0016629526,0.00035475395,0.000012651757,0.0034051307],"genre_scores_gemma":[0.00003544422,0.9907439,0.00396579,0.0005406466,0.0023060974,0.00048223755,0.0015203132,0.000079152844,0.00032644536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99550974,0.00094904436,0.0018441888,0.0010563936,0.0002458594,0.00039477187],"domain_scores_gemma":[0.9959474,0.0012057273,0.0009722246,0.0011826375,0.0004782977,0.00021370286],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019078836,0.00050193106,0.0021572504,0.00020634607,0.00013194629,0.00003606238,0.0006796047,0.0014152746,0.00063776266],"category_scores_gemma":[0.003751953,0.00044920258,0.00077798724,0.00016260089,0.00031259027,0.000011711048,0.000578337,0.0003421582,0.00039629967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003533118,0.00018515221,6.0028407e-7,0.0022930626,0.000100213154,0.0000034622046,0.000010778897,0.000006507218,0.00032507908,0.00016961028,0.15877484,0.83809537],"study_design_scores_gemma":[0.0003811862,0.0025395977,0.0000013924624,0.005856411,0.0011074475,0.00011003583,0.000004798908,0.0000760962,0.00019899092,0.00019307523,0.989132,0.00039898924],"about_ca_topic_score_codex":0.000016379256,"about_ca_topic_score_gemma":0.00020188464,"teacher_disagreement_score":0.8376964,"about_ca_system_score_codex":0.0006597589,"about_ca_system_score_gemma":0.0041970015,"threshold_uncertainty_score":0.9998811},"labels":[],"label_agreement":null},{"id":"W2900293586","doi":"10.1200/po.18.00195","title":"Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology","year":2018,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Cetuximab; Panitumumab; V600E; Colorectal cancer; Cancer research; Medicine; Mutation; Mutant; Epidermal growth factor receptor; Kinase; Targeted therapy; Biology; Oncology; Cancer; Internal medicine; Genetics; Gene","score_opus":0.06216558966071428,"score_gpt":0.4363235543107215,"score_spread":0.3741579646500072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900293586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011234015,0.9737027,0.0014239531,0.0005253534,0.0016470342,0.01718665,0.00062139385,0.00011387746,0.0036556015],"genre_scores_gemma":[0.0005343747,0.96390206,0.013272437,0.0002029807,0.0013837506,0.017422844,0.0007320633,0.00019429001,0.002355217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995633,0.00030262404,0.0012067369,0.0016113509,0.0004246505,0.00082165655],"domain_scores_gemma":[0.9917939,0.0048591453,0.0010664266,0.00056597346,0.0014340825,0.0002804877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074541115,0.0009574988,0.004475931,0.0005849924,0.0006637243,0.000053206317,0.00036663713,0.0011789547,0.00030379766],"category_scores_gemma":[0.00078913785,0.0006046748,0.0010989642,0.0005948659,0.00075065705,0.00012163843,0.00013344156,0.00049836916,0.000040566774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013292359,0.000992307,0.000013191069,0.0012961258,0.002268112,0.00004091648,0.003205268,0.0000029630576,0.000010436439,0.000035117333,0.02177444,0.95706874],"study_design_scores_gemma":[0.010226568,0.059970897,0.00013949469,0.002817366,0.002297148,0.0002452367,0.001204732,0.000056112196,0.000040069972,0.00021598065,0.92222667,0.0005597282],"about_ca_topic_score_codex":0.00010913946,"about_ca_topic_score_gemma":0.0008762269,"teacher_disagreement_score":0.95650905,"about_ca_system_score_codex":0.006142507,"about_ca_system_score_gemma":0.006928295,"threshold_uncertainty_score":0.99964046},"labels":[],"label_agreement":null},{"id":"W2936145201","doi":"10.1200/po.18.00327","title":"Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"DNA repair; Mutation; Prostate cancer; Cancer research; Wnt signaling pathway; Cancer; Gene; Biology; Medicine; Adenocarcinoma; DNA sequencing; Germline mutation; Genetics","score_opus":0.016093856726091864,"score_gpt":0.2903022285146727,"score_spread":0.2742083717885808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936145201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967485,0.00059187727,0.00008123117,0.0003383393,0.00044073205,0.001481368,0.00016134868,0.000034197634,0.00012237027],"genre_scores_gemma":[0.99638724,0.00074082817,0.0014659876,0.00006789794,0.00004793528,0.00015299239,0.0001964011,0.00001912399,0.0009215827],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99858403,0.00009109324,0.0006051332,0.00033089967,0.0002276999,0.00016114322],"domain_scores_gemma":[0.998653,0.00020423833,0.00042676675,0.00038654957,0.0002612486,0.00006822205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020513235,0.00012947424,0.00047365084,0.000167367,0.000027893768,0.000004626224,0.00008538734,0.00010555329,0.00050473434],"category_scores_gemma":[0.00009578582,0.000109678534,0.00012222529,0.00016662163,0.00009811653,0.00011017256,0.000070784634,0.0000780517,0.000063609055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004610145,0.00062335975,0.34520328,0.00062258117,0.0001343484,0.00003127363,0.001085051,0.000013387519,0.648151,0.00013089241,0.000087757195,0.003456101],"study_design_scores_gemma":[0.0017274807,0.002299321,0.83561593,0.00019298885,0.00022860189,0.00005722983,0.000064170796,0.00012307419,0.1591789,0.00022505368,0.0002141905,0.000073045034],"about_ca_topic_score_codex":0.000030052279,"about_ca_topic_score_gemma":0.0000039425536,"teacher_disagreement_score":0.49041268,"about_ca_system_score_codex":0.000235089,"about_ca_system_score_gemma":0.00031798263,"threshold_uncertainty_score":0.5526487},"labels":[],"label_agreement":null},{"id":"W2944384594","doi":"10.1200/po.18.00373","title":"Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy–Resistant Early Breast Cancers","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"PTEN; Oncology; Breast cancer; Internal medicine; Hazard ratio; Medicine; Cancer research; Palbociclib; Tamoxifen; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Cancer; Biology; Bioinformatics; Signal transduction; Genetics","score_opus":0.008638226300876335,"score_gpt":0.27731147722765076,"score_spread":0.2686732509267744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944384594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914482,0.00043088853,0.005287273,0.00037063228,0.00039841817,0.0016130046,0.00035995225,0.000013917733,0.000077674405],"genre_scores_gemma":[0.9980789,0.00026732832,0.00060763524,0.00011943287,0.00012234552,0.0004850638,0.00019653901,0.000028558536,0.000094220115],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99873286,0.00006173897,0.00045266966,0.00042782148,0.00009584236,0.00022908524],"domain_scores_gemma":[0.9987274,0.00015235052,0.00029892504,0.00033725356,0.00040454778,0.00007952438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017365381,0.00014858769,0.00023419084,0.00009110912,0.00008474154,0.000025194202,0.0001824407,0.000118163225,0.000023505507],"category_scores_gemma":[0.00016671122,0.00013750758,0.000101646,0.00017411227,0.000052424748,0.0000079277,0.00007234498,0.00005063042,0.0000055456712],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074890297,0.00018356624,0.09774113,0.000014800721,0.000073419724,1.6707325e-7,0.00020405724,0.00055554486,0.8569731,0.00018738197,0.0013905839,0.041927334],"study_design_scores_gemma":[0.0011089061,0.0034245774,0.8599039,0.000019947907,0.00002999185,0.000008323579,0.0000972782,0.00016283039,0.103283145,0.0003855545,0.031350218,0.00022532637],"about_ca_topic_score_codex":0.00015986284,"about_ca_topic_score_gemma":0.00042074284,"teacher_disagreement_score":0.76216274,"about_ca_system_score_codex":0.00013866715,"about_ca_system_score_gemma":0.00022010479,"threshold_uncertainty_score":0.56073964},"labels":[],"label_agreement":null},{"id":"W2944851422","doi":"10.1200/po.18.00356","title":"Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"KRAS; Medicine; Oncology; ROS1; Internal medicine; Personalized medicine; Genetic testing; Medicaid; Bevacizumab; Bioinformatics; Cancer; Adenocarcinoma; Chemotherapy; Biology; Health care","score_opus":0.14300265678417756,"score_gpt":0.42021702317582477,"score_spread":0.2772143663916472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944851422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711343,0.0003166871,0.026078228,0.00003826155,0.0004162901,0.0014294672,0.00004682028,0.000016911807,0.0005230066],"genre_scores_gemma":[0.8853,0.000028304272,0.114286214,0.000066938774,0.00008647615,0.00007778882,0.000035217065,0.0000349708,0.000084092644],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982669,0.0000754534,0.0007161863,0.00047573834,0.00014660353,0.00031913578],"domain_scores_gemma":[0.9984858,0.00053214177,0.00028982176,0.0003555405,0.00017441144,0.00016230793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031381487,0.00022413164,0.00059736206,0.00057317223,0.000080850405,0.000037082627,0.000106819054,0.00010968192,0.00012797676],"category_scores_gemma":[0.00015665936,0.00019566115,0.00015145795,0.00036525683,0.000017793378,0.00020423574,0.00007004299,0.00014507731,0.000024870198],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034979108,0.000054752276,0.0029148413,0.00001621869,0.00008864448,0.0000074474306,0.00051805953,0.5464681,0.43559837,0.0000012098745,0.000020418365,0.013962161],"study_design_scores_gemma":[0.0047198706,0.0016454924,0.0026672957,0.00017760294,0.00057328556,0.000024179564,0.00010499562,0.97566944,0.014195243,0.000044703764,0.00000845269,0.00016942687],"about_ca_topic_score_codex":0.0027963244,"about_ca_topic_score_gemma":0.0022136003,"teacher_disagreement_score":0.4292014,"about_ca_system_score_codex":0.009728696,"about_ca_system_score_gemma":0.003690916,"threshold_uncertainty_score":0.9940728},"labels":[],"label_agreement":null},{"id":"W2952198271","doi":"10.1200/po.18.00325","title":"Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Kelowna General Hospital; University of British Columbia","funders":"Common Fund; National Institutes of Health; National Cancer Institute; BC Cancer Foundation; Genome British Columbia; American Society of Clinical Oncology","keywords":"Sarcoma; Biology; Copy-number variation; Cancer research; Transcriptome; Cancer; Carcinogenesis; Trabectedin; Genome; Gene; Medicine; Genetics; Pathology; Soft tissue sarcoma; Gene expression","score_opus":0.027120588246155212,"score_gpt":0.33847762245615637,"score_spread":0.31135703421000116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952198271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936323,0.0014275108,0.000061721934,0.0007945155,0.000118122036,0.00066164613,0.0000109697,0.000012670981,0.0032805472],"genre_scores_gemma":[0.997126,0.000334478,0.0020611503,0.00026197557,0.000019599596,0.000047622314,0.000024735253,0.00001372597,0.00011073094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900275,0.00008251941,0.0004196934,0.000200158,0.0001654768,0.00012939767],"domain_scores_gemma":[0.99856657,0.0005539024,0.00024983397,0.00040060346,0.00017627026,0.000052848834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016019194,0.00009970583,0.0005082914,0.00013637882,0.000011793846,0.0000018869118,0.000090118,0.0000788008,0.0007875317],"category_scores_gemma":[0.000044208733,0.00007089806,0.00012654577,0.000109414206,0.00003465296,0.00002634048,0.000039883904,0.00007024279,0.00019592121],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008896111,0.0023781748,0.49205056,0.000110460016,0.00034071918,0.000012779914,0.00040238557,0.000012030033,0.16411273,0.0023544475,0.00074249116,0.3365936],"study_design_scores_gemma":[0.0047672233,0.0028167241,0.95738864,0.00006335915,0.0002903966,0.00008467751,0.00017845568,0.0002499981,0.02618906,0.0011304263,0.0067636045,0.00007742624],"about_ca_topic_score_codex":0.00003298921,"about_ca_topic_score_gemma":0.000008191221,"teacher_disagreement_score":0.46533808,"about_ca_system_score_codex":0.00007750964,"about_ca_system_score_gemma":0.00011779099,"threshold_uncertainty_score":0.862292},"labels":[],"label_agreement":null},{"id":"W2953100444","doi":"10.1200/po.19.00014","title":"Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"China Scholarship Council; Tulane University","keywords":"Prostate cancer; Concordance; Somatic cell; COLD-PCR; Germline mutation; Germline; Biology; Digital polymerase chain reaction; Allele; Cancer research; DNA sequencing; Mutation; Gene; Cancer; Genetics; Oncology; Medicine; Point mutation; Polymerase chain reaction","score_opus":0.031891046241851226,"score_gpt":0.35677489044950844,"score_spread":0.3248838442076572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953100444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956674,0.0008562593,0.00003866356,0.000154702,0.00041698955,0.00065565284,0.00005618059,0.0000029248006,0.002151202],"genre_scores_gemma":[0.99874043,0.00018776314,0.00050899317,0.00024567705,0.00008846304,0.0001000453,0.000049500166,0.000016199501,0.000062895175],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99870956,0.00018094848,0.00038150832,0.00028365734,0.0002618201,0.00018250715],"domain_scores_gemma":[0.9989378,0.00023409005,0.00022089889,0.0002519304,0.00031358545,0.000041713876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013023292,0.00010686968,0.0002485506,0.00007481978,0.000020965956,0.000007822187,0.0001290249,0.000082383325,0.00017076825],"category_scores_gemma":[0.0010029473,0.00010484168,0.00005564574,0.00011467497,0.000038378745,0.000004015039,0.00011461888,0.00008555772,0.000014789731],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002276068,0.00037030486,0.09432195,0.000035927897,0.000046603727,0.000005172331,0.00033942665,0.010362777,0.6187883,0.00005051616,0.0010661174,0.27438533],"study_design_scores_gemma":[0.018384334,0.005381788,0.5571312,0.00030091667,0.0005010842,0.00006239793,0.0007548352,0.034028545,0.29667306,0.0035565747,0.08218979,0.0010354992],"about_ca_topic_score_codex":0.00018667018,"about_ca_topic_score_gemma":0.0012583531,"teacher_disagreement_score":0.46280923,"about_ca_system_score_codex":0.00016197289,"about_ca_system_score_gemma":0.00077799195,"threshold_uncertainty_score":0.427532},"labels":[],"label_agreement":null},{"id":"W2953511998","doi":"10.1200/po.18.00266","title":"Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Vemurafenib; Internal medicine; Cohort; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Progression-free survival; Cancer; Surgery; Clinical trial; Overall survival; Metastatic melanoma","score_opus":0.01430066329293688,"score_gpt":0.27751511090114606,"score_spread":0.26321444760820917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953511998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947349,0.00007666886,0.000050691135,0.000033312,0.00035096655,0.0028987199,0.00002453969,0.00000501645,0.001825207],"genre_scores_gemma":[0.9986949,0.000008892235,0.000488482,0.00012815365,0.0000313456,0.00013587376,0.000068543115,0.000030659226,0.00041313228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998101,0.0003216501,0.0004487523,0.00058727467,0.00028800103,0.0002533239],"domain_scores_gemma":[0.99831766,0.00007940884,0.00049477245,0.0007668611,0.0002663815,0.00007489816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036383915,0.00022038905,0.00049944385,0.00007473258,0.00005001831,0.000011349789,0.00070642267,0.00023919516,0.000056354475],"category_scores_gemma":[0.000029085144,0.00014497114,0.000028219192,0.00018466811,0.00010470934,0.000011670348,0.00035654442,0.00018035552,0.0000026481453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00502763,0.010353246,0.8721364,0.00004017642,0.00011509656,0.000011740014,0.00059698254,0.000366317,0.105190285,0.000006275466,0.00013544789,0.0060204114],"study_design_scores_gemma":[0.031439237,0.041885294,0.85407937,0.000099453195,0.00018019171,0.0000117715335,0.0002491673,0.000059688085,0.07049302,0.0000049309806,0.0011643101,0.00033358939],"about_ca_topic_score_codex":0.00015801466,"about_ca_topic_score_gemma":0.0019232255,"teacher_disagreement_score":0.03469726,"about_ca_system_score_codex":0.00010311559,"about_ca_system_score_gemma":0.00048070098,"threshold_uncertainty_score":0.59117514},"labels":[],"label_agreement":null},{"id":"W2974725190","doi":"10.1200/po.19.00119","title":"Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; European Hematology Association","keywords":"Decitabine; Medicine; Cohort; Confidence interval; Myelodysplastic syndromes; Internal medicine; Oncology; Azacitidine; Hypomethylating agent; Bioinformatics; Gene; Genetics; Biology; DNA methylation","score_opus":0.052698284647689414,"score_gpt":0.3537519948482408,"score_spread":0.3010537102005514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974725190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041164,0.000027502834,0.00475346,0.00065415906,0.00040726076,0.0024709608,0.00001798761,0.000042232154,0.0012148123],"genre_scores_gemma":[0.96173674,0.0000056214376,0.037170384,0.00048205716,0.00006935855,0.0000521096,0.000016879148,0.000056041376,0.00041082798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968007,0.00024015842,0.0007288136,0.0007993999,0.0007165812,0.00071432826],"domain_scores_gemma":[0.9976943,0.0008887697,0.00015504459,0.0005745063,0.0002565724,0.0004308122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009403641,0.00026102035,0.00065074867,0.0010210654,0.00007968569,0.000031456024,0.0003503603,0.00023197508,0.00035675266],"category_scores_gemma":[0.0014050738,0.00021962941,0.000056834593,0.0013586378,0.0000741963,0.000117715164,0.000379515,0.00043122418,0.0007409066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030755483,0.0011157651,0.7086263,0.00022875913,0.00028626097,0.0004718734,0.0018831176,0.009985133,0.032252636,0.00013627173,0.0020861372,0.21217227],"study_design_scores_gemma":[0.0029328675,0.0068767816,0.97177804,0.0010249509,0.00007200577,0.000038279602,0.0004584761,0.00788241,0.002223133,0.00031345797,0.005871825,0.00052779296],"about_ca_topic_score_codex":0.00006897689,"about_ca_topic_score_gemma":0.00014966633,"teacher_disagreement_score":0.26315174,"about_ca_system_score_codex":0.0027602601,"about_ca_system_score_gemma":0.0007038814,"threshold_uncertainty_score":0.9523102},"labels":[],"label_agreement":null},{"id":"W2976445677","doi":"10.1200/po.19.00123","title":"Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Astellas Pharma; Prostate Cancer Canada; Emil Aaltosen Säätiö; Prostate Cancer Foundation; Jane ja Aatos Erkon Säätiö; DOD Prostate Cancer Research Program; Medical Research Council; Movember Foundation","keywords":"Prostate cancer; Androgen receptor; Oncology; Castration; Internal medicine; Medicine; Prostate; Biology; Cancer; Cancer research; Hormone","score_opus":0.02958628538235672,"score_gpt":0.3815232097330643,"score_spread":0.35193692435070756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976445677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993748,0.00093499984,0.000021988915,0.0005372631,0.00033770592,0.001794842,0.00038286144,0.000033087403,0.0022092154],"genre_scores_gemma":[0.98075384,0.0031312716,0.003053806,0.00006191954,0.000034383524,0.00027949322,0.0003616304,0.000029854824,0.012293786],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99722403,0.00023087306,0.0007451006,0.0005777144,0.0006682571,0.0005540398],"domain_scores_gemma":[0.99795926,0.00039509166,0.00033995314,0.0004833456,0.00049871113,0.0003236457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045064426,0.00024362018,0.0009898867,0.00030286104,0.00009181119,0.0000127965595,0.0001369521,0.00014158759,0.014664332],"category_scores_gemma":[0.0001275651,0.0001794063,0.00026508447,0.0009728352,0.00014227597,0.00010966717,0.000120154626,0.00020743182,0.00042650203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01402488,0.0008357749,0.81669855,0.00020890636,0.0041711642,0.00011379767,0.0017508653,0.00047001793,0.12930937,0.000030499476,0.0056640604,0.026722124],"study_design_scores_gemma":[0.048342027,0.011764313,0.30938816,0.00056928856,0.012903925,0.000115374954,0.003693846,0.01482165,0.44182882,0.00022522395,0.15495344,0.0013939213],"about_ca_topic_score_codex":0.0007895362,"about_ca_topic_score_gemma":0.00090568373,"teacher_disagreement_score":0.50731033,"about_ca_system_score_codex":0.0006740436,"about_ca_system_score_gemma":0.0009369663,"threshold_uncertainty_score":0.9862364},"labels":[],"label_agreement":null},{"id":"W2980850490","doi":"10.1200/po.19.00221","title":"Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company","keywords":"Fibroblast growth factor receptor 1; Tolerability; Medicine; Fibroblast growth factor receptor; Cancer; Breast cancer; Oncology; Internal medicine; Cancer research; Pharmacology; Receptor; Adverse effect; Fibroblast growth factor","score_opus":0.007405147188545542,"score_gpt":0.2759090181197813,"score_spread":0.26850387093123573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980850490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975107,0.000030888477,0.00026203814,0.00021490571,0.00003715745,0.0013635065,0.000037985446,0.000017200175,0.00052567356],"genre_scores_gemma":[0.9972256,0.00003477624,0.0018258045,0.00018900014,0.000036679874,0.0000967575,0.00024825457,0.00004641564,0.00029673026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980004,0.0002090731,0.00036293006,0.00068353635,0.00034204178,0.00040204913],"domain_scores_gemma":[0.9988789,0.000113810034,0.00018139843,0.0003897457,0.00025911792,0.0001770297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025191077,0.00029127873,0.00044609298,0.00018489195,0.00010277256,0.00007026433,0.00011974454,0.00023099754,0.000071199574],"category_scores_gemma":[0.00008898279,0.00018319786,0.000018970051,0.00023828859,0.00023697512,0.000040309387,0.0001909254,0.0002895447,0.00001147048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01924335,0.00061944406,0.88791406,0.00007924239,0.00008266364,0.000037022317,0.0005031982,0.0001190921,0.08667902,0.00006312714,0.00045359862,0.004206179],"study_design_scores_gemma":[0.032460436,0.07455087,0.8262172,0.0006876681,0.000054801414,0.00020723866,0.0004547154,0.0010416346,0.057298496,0.00008648108,0.00591399,0.0010264784],"about_ca_topic_score_codex":0.000049833718,"about_ca_topic_score_gemma":0.0013380487,"teacher_disagreement_score":0.073931426,"about_ca_system_score_codex":0.00006314149,"about_ca_system_score_gemma":0.0003512251,"threshold_uncertainty_score":0.74705917},"labels":[],"label_agreement":null},{"id":"W2985820722","doi":"10.1200/po.19.00235","title":"Parents’, Health Care Professionals’, and Scientists’ Experiences of a Precision Medicine Pilot Trial for Patients With High-Risk Childhood Cancer: A Qualitative Study","year":2019,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Precision medicine; Qualitative research; Psychosocial; Health care; Alternative medicine; Pilot trial; Transparency (behavior); Primary care","score_opus":0.03929112324080108,"score_gpt":0.43794867917744806,"score_spread":0.398657555936647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985820722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813523,0.0013316809,0.000086900174,0.0015874623,0.0024765863,0.01287437,0.00017882303,0.00004571644,0.00006610333],"genre_scores_gemma":[0.9955883,0.00010260701,0.0016654024,0.00059305766,0.0003089205,0.00144193,0.00013269609,0.00004311291,0.00012399716],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99385726,0.0015852621,0.0014475539,0.0010784093,0.001562901,0.00046859175],"domain_scores_gemma":[0.99382955,0.0028169686,0.0014910523,0.000625833,0.0008828988,0.00035368017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028970372,0.00037067622,0.0017719415,0.00036188186,0.00028367777,0.000014342732,0.00029547967,0.00015310656,0.0002225154],"category_scores_gemma":[0.0014574016,0.00024218234,0.000092709444,0.00047893077,0.0003619108,0.00017812011,0.0002142926,0.00034210386,0.0000047307203],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09292663,0.007010863,0.041657593,0.00029182676,0.00022083022,0.0000013788497,0.8220472,0.0000027871688,0.0000062389613,0.000034304936,0.0022103812,0.033589993],"study_design_scores_gemma":[0.1846038,0.15518643,0.12933582,0.0013860343,0.00017068008,0.000002565466,0.5278743,0.000007528168,0.000037505022,0.000115793766,0.0010189937,0.0002605423],"about_ca_topic_score_codex":0.0017588388,"about_ca_topic_score_gemma":0.0010719394,"teacher_disagreement_score":0.29417285,"about_ca_system_score_codex":0.00040547916,"about_ca_system_score_gemma":0.0014626799,"threshold_uncertainty_score":0.9875909},"labels":[],"label_agreement":null},{"id":"W3024577926","doi":"10.1200/po.19.00335","title":"Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Mount Sinai Hospital; McGill University Health Centre; Lakeridge Health; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T790M; Osimertinib; Concordance; Medicine; Epidermal growth factor receptor; Liquid biopsy; Internal medicine; Biopsy; Oncology; Cancer; Gefitinib","score_opus":0.10926900412114984,"score_gpt":0.47808154929876795,"score_spread":0.3688125451776181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024577926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783576,0.000016079819,0.00023037562,0.008711963,0.0006278202,0.0018951114,0.00006342753,0.000062647574,0.00055681355],"genre_scores_gemma":[0.98657036,0.000009778035,0.010694676,0.0020506452,0.0003659797,0.00016098871,0.00005445113,0.000021122323,0.00007198666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978962,0.00031628102,0.0008318381,0.00045864607,0.00024610237,0.0002509202],"domain_scores_gemma":[0.99807405,0.00097600726,0.00016070293,0.0001708766,0.00031826273,0.000300068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039984798,0.00015547698,0.0004616049,0.00009876331,0.00006960161,0.000021732638,0.00009332328,0.00009179253,0.0003839692],"category_scores_gemma":[0.003482084,0.00012388028,0.000054113287,0.0004349681,0.000018912644,0.000112923946,0.00012656364,0.00022421688,0.00020840646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095643505,0.001958433,0.906101,0.000018120305,0.000102456,0.00007365191,0.006903477,0.000019080784,0.00079454697,0.000021257729,0.004634223,0.07841734],"study_design_scores_gemma":[0.012943046,0.012997227,0.91439736,0.000072079296,0.00019500327,0.0000052632404,0.004102066,0.00037257635,0.0022304822,0.00001815294,0.052450012,0.00021674],"about_ca_topic_score_codex":0.00010654738,"about_ca_topic_score_gemma":0.0001112634,"teacher_disagreement_score":0.0782006,"about_ca_system_score_codex":0.00037403064,"about_ca_system_score_gemma":0.00039282313,"threshold_uncertainty_score":0.50516915},"labels":[],"label_agreement":null},{"id":"W3028415293","doi":"10.1200/po.19.00298","title":"Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; SickKids Foundation; University of Toronto; Stollery Children's Hospital; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medicine; CDKN2A; Glioma; Internal medicine; Oncology; Discontinuation; Concomitant; V600E; Chemotherapy; Cancer research; Mutation; Cancer; Gene","score_opus":0.024815737788784174,"score_gpt":0.2994300955933155,"score_spread":0.27461435780453136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028415293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909962,0.00037032846,0.000070937065,0.0059655923,0.00008820385,0.00071567576,0.000030439183,0.00010768109,0.0016549398],"genre_scores_gemma":[0.99721336,0.0001109307,0.0012912856,0.0009775752,0.00013752209,0.00006956324,0.00010183942,0.000031163177,0.00006677951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835867,0.000108937566,0.00050478143,0.00041191836,0.00036261152,0.00025308254],"domain_scores_gemma":[0.99857926,0.00040332373,0.00026804337,0.0002636147,0.00021069536,0.00027508664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011936789,0.00022972716,0.00077921635,0.0002694524,0.00005034253,0.000008526637,0.00007347263,0.00022627888,0.00054085674],"category_scores_gemma":[0.0002537271,0.00015083738,0.00015318338,0.0007232839,0.00006246839,0.00008104764,0.00006445698,0.00015944065,0.00011914634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00190461,0.0025627266,0.9429617,0.000081981925,0.0002982955,0.0012169863,0.0005751599,0.000034325614,0.018450702,0.000120472316,0.011021869,0.020771198],"study_design_scores_gemma":[0.01683294,0.011572249,0.8883642,0.000051893327,0.00085430144,0.00013383107,0.00015906175,0.00017027822,0.07454718,0.000085256695,0.0069750855,0.00025371273],"about_ca_topic_score_codex":0.000047802012,"about_ca_topic_score_gemma":0.00002404508,"teacher_disagreement_score":0.05609648,"about_ca_system_score_codex":0.00012949783,"about_ca_system_score_gemma":0.0001621659,"threshold_uncertainty_score":0.615097},"labels":[],"label_agreement":null},{"id":"W3034002596","doi":"10.1200/po.19.00295","title":"Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute","funders":"National Cancer Institute","keywords":"Epidermal growth factor receptor; Medicine; Oncology; Context (archaeology); Internal medicine; Missense mutation; Tyrosine-kinase inhibitor; Clinical trial; Cancer research; Mutation; Gene; Biology; Cancer","score_opus":0.12207920875486032,"score_gpt":0.348671926389238,"score_spread":0.22659271763437766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034002596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825732,0.0001306308,0.000041691037,0.015086464,0.00050378975,0.0008739222,0.000022612176,0.000054941494,0.0007127371],"genre_scores_gemma":[0.9974429,0.000090856134,0.00093257596,0.001009464,0.00015059041,0.00031190968,0.000007952269,0.00002534027,0.000028437733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979636,0.00028316304,0.0006651595,0.00045696192,0.0003307734,0.00030033683],"domain_scores_gemma":[0.9978917,0.0011335958,0.00014022233,0.00031437396,0.000104796934,0.00041531128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052547985,0.00018756665,0.00066552067,0.00035193493,0.000028180044,0.0000067818755,0.00014810328,0.00012531014,0.0002232007],"category_scores_gemma":[0.0016884081,0.00014196137,0.00012761116,0.00062555424,0.000039608854,0.000078453006,0.00017888576,0.00021497595,0.00015091687],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15926701,0.0061570574,0.114924006,0.00015466682,0.00028151725,0.0017880735,0.015535452,0.00046560308,0.18846382,0.00016362357,0.041175105,0.47162408],"study_design_scores_gemma":[0.016779609,0.04169192,0.39218122,0.0006701809,0.00015688101,0.00005541638,0.001234921,0.00024542783,0.1428858,0.000056873923,0.40369523,0.00034651195],"about_ca_topic_score_codex":0.000014300327,"about_ca_topic_score_gemma":0.00003457932,"teacher_disagreement_score":0.47127756,"about_ca_system_score_codex":0.00032504785,"about_ca_system_score_gemma":0.00019182383,"threshold_uncertainty_score":0.5789017},"labels":[],"label_agreement":null},{"id":"W3062793978","doi":"10.1200/po.19.00301","title":"Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Breast cancer; Medicine; Cancer; Oncology; Germline mutation; Internal medicine; Mutation; PALB2; Mutation rate; Genetics; Biology; Population; Gene","score_opus":0.01344799936803707,"score_gpt":0.29623009112087556,"score_spread":0.28278209175283847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3062793978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964395,0.0006851883,0.0002807738,0.0013710135,0.00017080599,0.0007210998,0.00017258633,0.000013438324,0.00014558852],"genre_scores_gemma":[0.99614125,0.00031163346,0.0015370644,0.0011514489,0.00014870279,0.00045393972,0.00018396332,0.000035369478,0.000036634094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982921,0.00016182796,0.0003430176,0.0006850335,0.00021606541,0.00030198283],"domain_scores_gemma":[0.99916,0.000060732164,0.00017357034,0.000249571,0.0002556864,0.00010042386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015337345,0.00021273278,0.0003021667,0.00008237701,0.00004658935,0.000014106218,0.00019828524,0.00021038658,0.0001324979],"category_scores_gemma":[0.00005297736,0.00017135049,0.000031855332,0.0003879237,0.00013905481,0.000019859692,0.00009501179,0.00018314902,0.0000038876665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003989807,0.0001721256,0.8736326,0.00003151437,0.00003970944,0.000007729865,0.00042488295,0.031266496,0.011542674,7.4740984e-7,0.0006955651,0.078196116],"study_design_scores_gemma":[0.005547666,0.0011070593,0.9770874,0.00005248626,0.000019965473,0.0000036408162,0.0001723446,0.0006350055,0.009484224,0.000008402182,0.005595077,0.00028674278],"about_ca_topic_score_codex":0.0016533001,"about_ca_topic_score_gemma":0.04268325,"teacher_disagreement_score":0.103454754,"about_ca_system_score_codex":0.0011988657,"about_ca_system_score_gemma":0.0015556231,"threshold_uncertainty_score":0.97478527},"labels":[],"label_agreement":null},{"id":"W3083461000","doi":"10.1200/po.20.00016","title":"Systematic Assessment of Tumor Purity and Its Clinical Implications","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Prostate cancer; Concordance; Cancer; Computational biology; Biology; Transcriptome; Bioinformatics; Oncology; Medicine; Genetics; Gene expression; Gene","score_opus":0.047370018260806356,"score_gpt":0.40446640975225373,"score_spread":0.3570963914914474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083461000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98679876,0.0026171908,0.0041641355,0.0037010042,0.00026685555,0.00074582105,0.00008498476,0.000009545976,0.001611716],"genre_scores_gemma":[0.99484056,0.0015246039,0.0021458806,0.0012170207,0.00017046877,0.000049381655,0.000022042772,0.000009285725,0.00002074702],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988925,0.00014069404,0.0005172143,0.00027910282,0.0000671099,0.000103399216],"domain_scores_gemma":[0.9990026,0.0002928679,0.00022697808,0.00021854848,0.00012276464,0.00013626108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038371098,0.000081603124,0.0003273618,0.0000170615,0.000033874636,0.000008244367,0.0001526904,0.00012474426,0.000015755619],"category_scores_gemma":[0.0010571164,0.00007307601,0.00007665849,0.00005263046,0.00004782271,0.0000018002187,0.00023123604,0.00008805768,0.0000059906624],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007056683,0.0019650166,0.07564982,0.0063805175,0.00069603435,0.00003229804,0.00036502795,0.00035772868,0.8066522,0.022686552,0.048210382,0.03629878],"study_design_scores_gemma":[0.014201063,0.03068252,0.48397404,0.0018903585,0.0012142982,0.0003624611,0.0005795037,0.021070765,0.088987514,0.0059503266,0.34900215,0.0020850115],"about_ca_topic_score_codex":0.000002524286,"about_ca_topic_score_gemma":0.000010474308,"teacher_disagreement_score":0.71766466,"about_ca_system_score_codex":0.000017630804,"about_ca_system_score_gemma":0.0002288764,"threshold_uncertainty_score":0.2979953},"labels":[],"label_agreement":null},{"id":"W3087896793","doi":"10.1200/po.20.00115","title":"Personalized Multimodal Demarcation of Peritumoral Tissue in Glioma","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Glioma; Exome sequencing; Magnetic resonance imaging; Medicine; Biopsy; Pathology; Brain tissue; Histology; Infiltration (HVAC); Neuroimaging; Biology; Radiology; Gene; Cancer research; Anatomy","score_opus":0.039032026238928014,"score_gpt":0.35805033617922705,"score_spread":0.319018309940299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087896793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877131,0.0004916132,0.00010758587,0.009701516,0.00009416685,0.0005157902,0.0000075403677,0.000022712575,0.0013459977],"genre_scores_gemma":[0.9952674,0.00004190479,0.004017988,0.00045565818,0.000076760065,0.000068276895,0.000029179206,0.000012078196,0.000030780837],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989392,0.000101912636,0.00035329445,0.00025436652,0.00019807351,0.0001531363],"domain_scores_gemma":[0.99932,0.00020899181,0.000106604166,0.00013692386,0.000087366134,0.00014013515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014549262,0.000106933134,0.0004535711,0.00013272275,0.00001930054,0.000003805236,0.00006885237,0.00012893378,0.00070687546],"category_scores_gemma":[0.00033220748,0.000087361295,0.000074481984,0.00026971605,0.00006410542,0.000042884556,0.000049880233,0.000105609215,0.000072110335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036017112,0.0037518085,0.15399933,0.00014023726,0.00010421034,0.001440847,0.0058857184,0.00006965386,0.46575594,0.001105218,0.0046020965,0.35954323],"study_design_scores_gemma":[0.03361507,0.009718125,0.61842096,0.00023758081,0.00023249812,0.00028626458,0.0011406647,0.007706414,0.22148971,0.0003849939,0.10642626,0.0003414908],"about_ca_topic_score_codex":0.00007095338,"about_ca_topic_score_gemma":0.00003168822,"teacher_disagreement_score":0.4644216,"about_ca_system_score_codex":0.00014225095,"about_ca_system_score_gemma":0.00012427368,"threshold_uncertainty_score":0.77397907},"labels":[],"label_agreement":null},{"id":"W3090984898","doi":"10.1200/po.20.00087","title":"Nearly Half of <i>TP53</i> Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children’s Oncology Group","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Sanger sequencing; Exome sequencing; Genetics; Germline; Exact test; Gene; Biology; Copy-number variation; Mutation; Medicine; Internal medicine; Genome","score_opus":0.020590188654738488,"score_gpt":0.28020910921499936,"score_spread":0.25961892056026087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090984898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97339857,0.00026753717,0.00016492832,0.023389364,0.00016841092,0.00201339,0.00032903047,0.000050782786,0.00021800048],"genre_scores_gemma":[0.9845355,0.000043603282,0.0052771037,0.009148859,0.00019409903,0.00026037818,0.00048275088,0.00004490361,0.000012774255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969869,0.00042245188,0.0009263517,0.0007264001,0.0005076148,0.00043023133],"domain_scores_gemma":[0.99708045,0.0011068251,0.00051385845,0.0006850065,0.00023607288,0.00037778477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042807098,0.0002909345,0.0009989253,0.000113967355,0.00006542613,0.000012907532,0.00029538802,0.00034130272,0.00020310609],"category_scores_gemma":[0.0010505957,0.00018500083,0.00014385988,0.00051371986,0.00010187617,0.000067079454,0.00025249564,0.00040738907,0.00002238934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004707351,0.0038718467,0.9313328,0.000007635127,0.0002272564,0.0022351686,0.0015444688,0.000015223806,0.0006337028,0.000012330645,0.0029443982,0.05246782],"study_design_scores_gemma":[0.012286067,0.008607288,0.963475,0.00013744936,0.00030812077,0.00027781999,0.00013208829,0.000046580077,0.00024194253,0.00003051997,0.0143037215,0.0001533987],"about_ca_topic_score_codex":0.0007568404,"about_ca_topic_score_gemma":0.0013944731,"teacher_disagreement_score":0.052314423,"about_ca_system_score_codex":0.00046651385,"about_ca_system_score_gemma":0.00047215394,"threshold_uncertainty_score":0.75441146},"labels":[],"label_agreement":null},{"id":"W3091309223","doi":"10.1200/po.20.00050","title":"Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ottawa Hospital","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Internal medicine; Hazard ratio; Cetuximab; Colorectal cancer; Oncology; Odds ratio; Cohort; Epidermal growth factor receptor; Univariate analysis; Progression-free survival; Multivariate analysis; Cancer; Overall survival; Confidence interval","score_opus":0.03191056901264257,"score_gpt":0.30157792678446776,"score_spread":0.2696673577718252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091309223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925183,0.0005237432,0.0000024531475,0.0031754263,0.00008541146,0.0031580348,0.00033109507,0.000051674553,0.00015386827],"genre_scores_gemma":[0.997117,0.0002142612,0.000052478306,0.0018075021,0.00006237221,0.0005583516,0.0001441362,0.000036533096,0.000007396561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980468,0.00023554328,0.00035804982,0.0005882278,0.00043905535,0.0003323249],"domain_scores_gemma":[0.99898607,0.00028316048,0.00021866856,0.00013454889,0.00021542814,0.00016214665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000085547304,0.00034138208,0.00090030394,0.000051155108,0.00015921058,0.00003401023,0.00009538735,0.00015391331,0.00009994363],"category_scores_gemma":[0.000039902403,0.00016140846,0.000059129376,0.0004205475,0.00025975914,0.00009061088,0.000031928048,0.0002849707,0.0000012981683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20161864,0.0014084475,0.7646421,0.0000047428816,0.0007243141,0.00008475765,0.0046050036,0.0000059902045,0.00020816411,3.364068e-7,0.0005173605,0.026180154],"study_design_scores_gemma":[0.09948381,0.05074189,0.8450776,0.00013147107,0.00025609083,0.0000039737065,0.0003317379,0.000048945298,0.002366976,0.0000024406356,0.0013422477,0.00021281546],"about_ca_topic_score_codex":0.0007189149,"about_ca_topic_score_gemma":0.003430461,"teacher_disagreement_score":0.102134824,"about_ca_system_score_codex":0.00037207728,"about_ca_system_score_gemma":0.00024838513,"threshold_uncertainty_score":0.6582046},"labels":[],"label_agreement":null},{"id":"W3093179741","doi":"10.1200/po.20.00013","title":"Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate","year":2020,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Decipher Biosciences (Canada)","funders":"","keywords":"Nomogram; Prostate cancer; Prostatectomy; Medicine; Logistic regression; Oncology; Cohort; Internal medicine; Prostate; Cancer; Urology","score_opus":0.03633023327856901,"score_gpt":0.2947791237358805,"score_spread":0.2584488904573115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093179741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957156,0.0003320225,0.000027689071,0.002691542,0.00005575499,0.0010299043,0.0000104368655,0.000005834126,0.00013119822],"genre_scores_gemma":[0.99558216,0.00010850239,0.0037342499,0.00042823452,0.000020018275,0.000089758076,0.0000077372915,0.000007729392,0.000021620726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990626,0.000054616863,0.00040178164,0.00021319118,0.0001585227,0.00010928791],"domain_scores_gemma":[0.9995005,0.00009816409,0.00013340803,0.00013319566,0.00005685469,0.00007783828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021645994,0.00008105,0.00027723465,0.000057505342,0.000020617032,0.0000029416785,0.00006463718,0.00005749325,0.00002767249],"category_scores_gemma":[0.00012544269,0.00005457574,0.000029057062,0.00015588602,0.00003388461,0.000032455864,0.00014981447,0.000073748335,0.0000056554954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017843926,0.0003801692,0.6102674,0.0001558841,0.000038792812,0.00002469487,0.011149946,0.00008512485,0.14492956,0.00002633504,0.00081789785,0.23033978],"study_design_scores_gemma":[0.0018260967,0.0014478205,0.64991397,0.00015937029,0.000028098464,0.000009389263,0.00018255625,0.00006740679,0.34035796,0.000027470836,0.005938065,0.000041775507],"about_ca_topic_score_codex":0.000014986272,"about_ca_topic_score_gemma":0.000012539893,"teacher_disagreement_score":0.23029801,"about_ca_system_score_codex":0.0002067747,"about_ca_system_score_gemma":0.00032491153,"threshold_uncertainty_score":0.22255342},"labels":[],"label_agreement":null},{"id":"W3118235744","doi":"10.1200/po.20.00218","title":"Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Vector Institute; Hospital for Sick Children; University of Toronto","funders":"Hyundai Hope On Wheels; Canadian Institutes of Health Research; University of Toronto; National Cancer Institute; National Institutes of Health; Consejo Nacional de Ciencia y Tecnología; Children’s Oncology Group; Hope Foundation; Huntsman Cancer Institute; Cancer Prevention and Research Institute of Texas","keywords":"Germline; Genetics; Biology; Exome; CHEK2; Exome sequencing; Germline mutation; Cancer; Fusion gene; Oncology; Gene; Medicine; Mutation","score_opus":0.015798789811242317,"score_gpt":0.3125947657448777,"score_spread":0.2967959759336354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118235744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98821205,0.00945351,0.000008715575,0.0012709895,0.00012116395,0.00069549,0.000032491178,0.000017549892,0.00018802869],"genre_scores_gemma":[0.99343,0.0038829765,0.0019823785,0.00029243412,0.000078270255,0.00018122968,0.00006091346,0.000018815099,0.00007295314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828506,0.00021262062,0.0004035814,0.0006114065,0.00019096029,0.00029639917],"domain_scores_gemma":[0.9990864,0.00024082768,0.000085402804,0.00035509834,0.000106333726,0.00012593085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029997935,0.00018182928,0.0005647533,0.0001483226,0.00003312072,0.000010663918,0.00006096832,0.00018678045,0.00032637938],"category_scores_gemma":[0.00012517966,0.00013471252,0.000051960807,0.00032937512,0.00006634731,0.000059375318,0.0001068162,0.00021029226,0.000008770791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007303431,0.0015805077,0.72634757,0.000012048325,0.000041298317,0.0009540598,0.00025392813,0.0000054687716,0.00093988416,0.000011060857,0.000057003308,0.2690668],"study_design_scores_gemma":[0.00979497,0.00075669435,0.986651,0.00022495224,0.00006682085,0.00089288404,0.00010988879,0.00011627649,0.00085867604,0.00007930895,0.00031996597,0.0001285861],"about_ca_topic_score_codex":0.0014209007,"about_ca_topic_score_gemma":0.024524882,"teacher_disagreement_score":0.26893824,"about_ca_system_score_codex":0.00035194223,"about_ca_system_score_gemma":0.00036653818,"threshold_uncertainty_score":0.993275},"labels":[],"label_agreement":null},{"id":"W3120676907","doi":"10.1200/po.20.00214","title":"Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies","year":2021,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Allison University; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Oncology; Adverse effect; Meta-analysis; Cancer","score_opus":0.7534315246724375,"score_gpt":0.6499043875348117,"score_spread":0.10352713713762574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120676907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021292268,0.98417485,0.0037581695,0.0004205573,0.00018731323,0.010249423,0.0009279721,0.000008294651,0.00006050094],"genre_scores_gemma":[0.000103253966,0.90698117,0.09179846,0.00012136106,0.00007680976,0.0008402485,0.000019415183,0.00004502332,0.000014245869],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.8438208,0.12473465,0.028579911,0.0011990778,0.0012369183,0.00042861918],"domain_scores_gemma":[0.42815986,0.5502293,0.019744435,0.001207193,0.0005613231,0.00009788782],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.24706167,0.00076370675,0.07393263,0.0011381264,0.000044092176,0.000021931508,0.0008141618,0.0011213863,0.000947232],"category_scores_gemma":[0.71053785,0.00037457098,0.0040557436,0.0028199614,0.00059020997,0.000065807,0.0003567927,0.0011771797,7.264392e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027814467,0.0010063193,0.0000034089767,0.30843216,0.051807452,0.000029563918,0.0011394509,0.0000010692243,0.0000131192,0.0022866153,0.0000806191,0.6349221],"study_design_scores_gemma":[0.00306891,0.0022383505,0.0000083908935,0.13746962,0.8106579,0.00001949379,0.0002402588,0.000020208563,0.000007913918,0.04186647,0.0040933574,0.00030909502],"about_ca_topic_score_codex":0.00009565233,"about_ca_topic_score_gemma":0.000054631186,"teacher_disagreement_score":0.75885046,"about_ca_system_score_codex":0.00021876508,"about_ca_system_score_gemma":0.00036793848,"threshold_uncertainty_score":0.999966},"labels":[],"label_agreement":null},{"id":"W3130023215","doi":"10.1200/po.20.00419","title":"Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Medicine; Cohort; Oncology; Osimertinib; Internal medicine; KRAS; T790M; Lung cancer; Digital polymerase chain reaction; Cancer; Biology; Polymerase chain reaction; Genetics","score_opus":0.011309667848475131,"score_gpt":0.31052400366877686,"score_spread":0.2992143358203017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130023215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713117,0.00065490254,0.00006701033,0.00022067052,0.00030675717,0.000239937,0.000060194583,0.0000045814804,0.0013147811],"genre_scores_gemma":[0.996203,0.00085355516,0.0014138815,0.00028096742,0.00007270588,0.000059058362,0.000061535524,0.000021145208,0.0010341161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857,0.00039445236,0.0003067636,0.00043239188,0.00008203916,0.0002143563],"domain_scores_gemma":[0.9987733,0.00044212924,0.000102922386,0.0004925493,0.0000956193,0.000093512055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034845943,0.00015834688,0.0003239602,0.00007010412,0.000027500904,0.000010078123,0.00012949035,0.00026273317,0.00009945842],"category_scores_gemma":[0.00047957854,0.00014075835,0.00010969589,0.00011251579,0.00004937246,0.0000042495617,0.0001212884,0.00006980278,0.0000134969905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011026729,0.00035824467,0.011490187,0.0000063614366,0.000040125597,0.00006995962,0.00023460804,0.000188646,0.7589783,0.000012866233,0.000822454,0.21677153],"study_design_scores_gemma":[0.005381912,0.014510708,0.06870525,0.000028517337,0.00002483913,0.000023993849,0.00007669349,0.00012961072,0.74873406,0.00010908596,0.16206124,0.00021408981],"about_ca_topic_score_codex":0.000055252585,"about_ca_topic_score_gemma":0.00040294812,"teacher_disagreement_score":0.21655744,"about_ca_system_score_codex":0.00017142382,"about_ca_system_score_gemma":0.00047891826,"threshold_uncertainty_score":0.5739959},"labels":[],"label_agreement":null},{"id":"W3134802082","doi":"10.1200/po.20.00370","title":"Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University Health Network; Toronto General Hospital; University of Toronto; McMaster University; Juravinski Hospital","funders":"Canadian Institutes of Health Research","keywords":"Myocarditis; Immune checkpoint; Medicine; Immune system; Immunology; Inflammation; Cancer research; Immunotherapy; Internal medicine","score_opus":0.02483418104461527,"score_gpt":0.30841904254623725,"score_spread":0.283584861501622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134802082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598349,0.029568741,0.00001852472,0.0037975502,0.0020544748,0.0015724694,0.00031426377,0.00011491194,0.0027242128],"genre_scores_gemma":[0.9654994,0.02288104,0.00046334602,0.0015460321,0.00040728596,0.00091921526,0.0011176227,0.00012848288,0.0070375996],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603885,0.00050132175,0.001234649,0.0010057329,0.00053423137,0.00068522827],"domain_scores_gemma":[0.99745566,0.0003942216,0.00049938785,0.0010082243,0.00029677324,0.00034575997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034143246,0.0006438226,0.0012710183,0.00018325512,0.0002638802,0.000073303665,0.00020466032,0.0005698551,0.0020981813],"category_scores_gemma":[0.000095325704,0.00051641115,0.0012763067,0.0003114688,0.00017524199,0.00014511793,0.00015134606,0.0003208866,0.00013812483],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008950615,0.0020111136,0.00043102753,0.00002800745,0.0021596563,0.00020424165,0.0023515043,8.589588e-7,0.52503496,0.0000015310359,0.04417647,0.41465],"study_design_scores_gemma":[0.016789282,0.011609829,0.0060891914,0.00030998565,0.0005483373,0.00029652222,0.0014704921,0.000050967534,0.3804539,0.000012486043,0.5819117,0.00045727813],"about_ca_topic_score_codex":0.00034945188,"about_ca_topic_score_gemma":0.00004552353,"teacher_disagreement_score":0.5377352,"about_ca_system_score_codex":0.005205568,"about_ca_system_score_gemma":0.0011482754,"threshold_uncertainty_score":0.99972874},"labels":[],"label_agreement":null},{"id":"W3157171213","doi":"10.1200/po.20.00348","title":"Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Alectinib; Medicine; Cancer research; Internal medicine; Oncology; Lung cancer; Crizotinib","score_opus":0.02582143413691037,"score_gpt":0.35746795894768646,"score_spread":0.3316465248107761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157171213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812389,0.00043233845,0.0013320175,0.011784041,0.00027790156,0.0015554256,0.000032056672,0.00013311833,0.0032141972],"genre_scores_gemma":[0.9673145,0.0001073585,0.017474506,0.0026497578,0.00019984806,0.00027378488,0.000043239972,0.00011401714,0.011823001],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946758,0.0013245271,0.0005887824,0.0011440351,0.0011130811,0.0011537689],"domain_scores_gemma":[0.9955718,0.001737795,0.00018895857,0.0010128318,0.000612779,0.00087586505],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000502723,0.0004147524,0.0009326624,0.0004290571,0.00021857563,0.00004620808,0.00027089776,0.000020202182,0.0010474265],"category_scores_gemma":[0.0016340142,0.00029734534,0.00011987179,0.0011985257,0.00012118456,0.00016864027,0.00046132677,0.0007074342,0.00019801735],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1490592,0.004950818,0.023126224,0.00026078417,0.00017881794,0.37678605,0.00047098615,0.00040334827,0.40765396,0.00004620079,0.019038696,0.018024886],"study_design_scores_gemma":[0.01926942,0.024802562,0.007738638,0.00014173174,0.00027774894,0.03449242,0.00051967707,0.00048337094,0.34957698,0.000026334745,0.56226057,0.00041054463],"about_ca_topic_score_codex":0.000034367516,"about_ca_topic_score_gemma":0.00039268995,"teacher_disagreement_score":0.5432219,"about_ca_system_score_codex":0.00033965337,"about_ca_system_score_gemma":0.0016909738,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W3194774701","doi":"10.1200/po.20.00489","title":"Ethical and Analytic Challenges With Genomic Sequencing of Relapsed Hematologic Malignancies Following Allogeneic Hematopoietic Stem-Cell Transplantation","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Canadian Blood Services; Dalhousie University; SickKids Foundation; University of Toronto; University of Ottawa; Hospital for Sick Children","funders":"","keywords":"Transplantation; Hematopoietic stem cell transplantation; Germline; Oncology; Leukemia; DNA sequencing; Stem cell; Cancer; Haematopoiesis; Biology; Medicine; Immunology; Bioinformatics; Internal medicine; Genetics; Gene","score_opus":0.023030350924798763,"score_gpt":0.2738923576790774,"score_spread":0.2508620067542786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194774701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848845,0.011408528,0.0019653332,0.00062875,0.00013761008,0.0001698028,0.000014089137,0.000008813248,0.000782572],"genre_scores_gemma":[0.9840522,0.012269064,0.0030720585,0.00038463177,0.000038325375,0.000022098808,0.00004123649,0.000022006969,0.00009838991],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986205,0.00017010675,0.00037026117,0.0004742888,0.00014090525,0.00022389946],"domain_scores_gemma":[0.9990477,0.00028065292,0.00016743201,0.0003034518,0.000114524046,0.00008626467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003718957,0.00017158697,0.0004033106,0.00005809217,0.000066932575,0.00001407375,0.00012058206,0.00045425774,0.000010976251],"category_scores_gemma":[0.00006632746,0.00015186045,0.00010389955,0.000083611645,0.00009788199,0.0000039434126,0.000094060415,0.00017773494,0.0000026474784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027637606,0.00008986233,0.0015913318,0.00022405296,0.00009748467,0.000276838,0.0009007766,0.0005542364,0.9910918,0.00062834524,0.00009579302,0.0041731154],"study_design_scores_gemma":[0.0038410013,0.002750068,0.0057069315,0.00023915387,0.0004247428,0.0014257407,0.002945247,0.00014095049,0.97373474,0.001223163,0.0069732047,0.00059504015],"about_ca_topic_score_codex":0.000009565641,"about_ca_topic_score_gemma":0.00021518003,"teacher_disagreement_score":0.01735703,"about_ca_system_score_codex":0.000063638785,"about_ca_system_score_gemma":0.0004628696,"threshold_uncertainty_score":0.619269},"labels":[],"label_agreement":null},{"id":"W3197515132","doi":"10.1200/po.21.00153","title":"Upfront Adjuvant Immunotherapy of Replication Repair–Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Adjuvant; Glioblastoma; Replication (statistics); Immunotherapy; Oncology; Internal medicine; Cancer research; Cancer; Virology","score_opus":0.018086391426018276,"score_gpt":0.29517537609717054,"score_spread":0.2770889846711523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197515132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901092,0.003205569,0.0012661231,0.00064152014,0.00014199429,0.0006151159,0.0000069050548,0.0000867305,0.0039268415],"genre_scores_gemma":[0.98275757,0.0007916561,0.015664605,0.00018430973,0.0001189954,0.0002059032,0.000068009525,0.000028590426,0.00018038855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818695,0.00009439571,0.0005204357,0.0006052243,0.00037042613,0.00022259848],"domain_scores_gemma":[0.99799025,0.00021723552,0.0003251722,0.0009718455,0.00038942372,0.00010609594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033400938,0.00017089193,0.0005628492,0.00019971465,0.00007026557,0.00001009174,0.00008355931,0.00016071371,0.00013350094],"category_scores_gemma":[0.00017833823,0.00012823,0.00016170114,0.00053396093,0.000041251125,0.000054748212,0.000057771143,0.00013777941,0.000020970303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004833076,0.01726863,0.5288167,0.00033058593,0.00075193035,0.00049271184,0.0022769296,0.0023323917,0.04908589,0.0014757669,0.010103126,0.38223225],"study_design_scores_gemma":[0.017765827,0.007984469,0.7981627,0.00015135271,0.00076811353,0.00096032984,0.0006150464,0.0063334466,0.1257185,0.00013204351,0.040943976,0.0004641656],"about_ca_topic_score_codex":0.00002855944,"about_ca_topic_score_gemma":0.000019008583,"teacher_disagreement_score":0.3817681,"about_ca_system_score_codex":0.00034264746,"about_ca_system_score_gemma":0.00037682967,"threshold_uncertainty_score":0.5229068},"labels":[],"label_agreement":null},{"id":"W3198276706","doi":"10.1200/po.21.00112","title":"Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma","year":2021,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology; Ohio State University; Pennsylvania Department of Health","keywords":"Methylation; Temozolomide; Oncology; Hazard ratio; Internal medicine; Glioma; ATRX; Proportional hazards model; Medicine; Progression-free survival; Radiation therapy; Cancer research; Biology; Gene; Overall survival; Genetics; Confidence interval; Mutation","score_opus":0.022589782427132058,"score_gpt":0.3559463888212738,"score_spread":0.3333566063941417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198276706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955855,0.0026909704,0.000027604614,0.00048529543,0.000083968116,0.0010662888,0.00002087101,0.000008772114,0.00003070418],"genre_scores_gemma":[0.99845564,0.0006479935,0.0006079592,0.000055776687,0.000016286855,0.00010547834,0.00008748302,0.000014558068,0.000008841887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972643,0.0005478752,0.0011173796,0.00061536336,0.00023977768,0.00021529708],"domain_scores_gemma":[0.9979626,0.0006065411,0.0006652957,0.0004572939,0.00018292351,0.00012533707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004914436,0.00020579848,0.0014596209,0.0010612805,0.00005981922,0.0000053152394,0.0000652925,0.0002471905,0.00003894732],"category_scores_gemma":[0.00028770792,0.00018386907,0.00011871377,0.0010345033,0.00010795234,0.00004982218,0.00027558274,0.00020432431,5.501933e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012103762,0.01710431,0.7850017,0.000036019068,0.0011820373,0.018591225,0.0027928594,0.00028036255,0.08953589,0.000013541132,0.000031477935,0.084220216],"study_design_scores_gemma":[0.030911183,0.01319413,0.92946994,0.000058712398,0.0018948311,0.00062513095,0.0008172044,0.00033237907,0.022368763,0.00009271193,0.00011033645,0.00012466453],"about_ca_topic_score_codex":0.0008613452,"about_ca_topic_score_gemma":0.002884308,"teacher_disagreement_score":0.14446828,"about_ca_system_score_codex":0.00034938415,"about_ca_system_score_gemma":0.00023494817,"threshold_uncertainty_score":0.7497963},"labels":[],"label_agreement":null},{"id":"W3217758388","doi":"10.1200/po.21.00543","title":"Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; PTEN; Prostate cancer; Prostate; Lung; Lung cancer; Internal medicine; Pathology; Cancer; Biology; Genetics","score_opus":0.026086967435030754,"score_gpt":0.377235857640557,"score_spread":0.35114889020552625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217758388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723028,0.015292311,0.0000086765285,0.0038468577,0.00072307396,0.0013977314,0.00025388369,0.000037339418,0.006137324],"genre_scores_gemma":[0.98509985,0.0039829146,0.00023405215,0.0003171632,0.00013368824,0.000488778,0.00011891157,0.000027238828,0.009597387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99837214,0.00021152437,0.00029820556,0.00034615738,0.00044229455,0.0003296883],"domain_scores_gemma":[0.99906915,0.00020067467,0.00015616423,0.00024844534,0.00018778814,0.00013774914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036570104,0.00014427197,0.0004586251,0.0002194928,0.00016019063,0.0000055412697,0.00012567626,0.000078629484,0.00069065427],"category_scores_gemma":[0.000051153376,0.00011010311,0.00012321476,0.00026729898,0.00012591711,0.000033942557,0.0003337094,0.00045758538,0.000015417016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032207504,0.0017483783,0.014477994,0.00012324838,0.0006042359,0.00067907304,0.007299131,0.00019415823,0.12216752,0.00022607583,0.1926085,0.6276642],"study_design_scores_gemma":[0.016738625,0.015155084,0.44396392,0.00011422536,0.0004202292,0.00037407345,0.002163915,0.0006231896,0.029181197,0.00056695775,0.49026808,0.0004305244],"about_ca_topic_score_codex":0.00016301565,"about_ca_topic_score_gemma":0.00003380441,"teacher_disagreement_score":0.6272337,"about_ca_system_score_codex":0.0012015946,"about_ca_system_score_gemma":0.000848868,"threshold_uncertainty_score":0.756218},"labels":[],"label_agreement":null},{"id":"W4205496667","doi":"10.1200/po.21.00303","title":"Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Trametinib; Fusion gene; Kinase; Extracellular; Fusion protein; Sarcoma; Cell culture; Gene","score_opus":0.014707803517898384,"score_gpt":0.26693388961498593,"score_spread":0.2522260860970875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205496667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422324,0.0008959098,0.0007061746,0.0015068582,0.0010727132,0.0010684199,0.000049250288,0.000027427477,0.00045000185],"genre_scores_gemma":[0.9945373,0.00004168645,0.0012602533,0.00052518374,0.00025589156,0.00043225416,0.00009242726,0.000047152316,0.002807833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964053,0.0014616138,0.0005336353,0.00072615733,0.00032697464,0.0005463209],"domain_scores_gemma":[0.998565,0.00022532609,0.00017768712,0.00075099355,0.0000929134,0.00018805703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019393753,0.00026459433,0.0003251995,0.00024318247,0.0003336458,0.000028061062,0.00056211685,0.00026054282,0.00023255669],"category_scores_gemma":[0.0005489,0.00022708689,0.00014637531,0.00046425566,0.000048422393,0.0000065665495,0.0012012412,0.00042051513,0.000034710316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008406561,0.00048195792,0.00016271757,0.000008092329,0.000011520253,0.00023056888,0.0006742311,0.00049315963,0.96934456,0.000011733308,0.004161244,0.016013663],"study_design_scores_gemma":[0.0018691053,0.002648375,0.00090162276,0.0000064436263,0.000008925722,0.000048445454,0.0007930647,0.000110667956,0.56366134,0.000025253563,0.42972568,0.00020111936],"about_ca_topic_score_codex":0.000054791468,"about_ca_topic_score_gemma":0.00006139142,"teacher_disagreement_score":0.4255644,"about_ca_system_score_codex":0.00025345964,"about_ca_system_score_gemma":0.00045746355,"threshold_uncertainty_score":0.92603344},"labels":[],"label_agreement":null},{"id":"W4214884454","doi":"10.1200/po.21.00286","title":"Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"St. Baldrick's Foundation; Hospital for Sick Children; Bristol-Myers Squibb","keywords":"Somatic hypermutation; Immune checkpoint; Immune system; Medicine; Oncology; Immunology; Immunotherapy; Antibody; B cell","score_opus":0.04808232243282154,"score_gpt":0.35595393747601456,"score_spread":0.30787161504319305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214884454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886605,0.000643334,0.00039152353,0.0011330124,0.0009038496,0.0028014844,0.00003508466,0.00010970634,0.0053214747],"genre_scores_gemma":[0.99377245,0.00006127782,0.0014684779,0.0021215472,0.00038365787,0.0012368147,0.00031131122,0.000050920265,0.00059352495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977201,0.0003222155,0.00065645773,0.0005712612,0.00038580896,0.0003441091],"domain_scores_gemma":[0.9986372,0.0003621049,0.00029295118,0.0003887916,0.00017132267,0.00014764295],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010014276,0.00020462839,0.00053562305,0.00020557822,0.00052494876,0.000024548115,0.00013120438,0.00010326128,0.00279135],"category_scores_gemma":[0.00014173894,0.00019929053,0.00016451676,0.00022921413,0.000062172316,0.0001954785,0.000109361696,0.00035891656,0.000016782713],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008494086,0.0029969371,0.0007527857,0.000033163735,0.00014675717,0.00021179966,0.00855598,0.0013304874,0.27028608,0.000043627188,0.0012519967,0.7058963],"study_design_scores_gemma":[0.07830066,0.2003094,0.032570213,0.0001182913,0.00039818964,0.0017759851,0.06999581,0.009634104,0.085646085,0.0017209445,0.51808727,0.0014430244],"about_ca_topic_score_codex":0.00039026022,"about_ca_topic_score_gemma":0.00011927133,"teacher_disagreement_score":0.7044533,"about_ca_system_score_codex":0.0028803288,"about_ca_system_score_gemma":0.0012563777,"threshold_uncertainty_score":0.99812025},"labels":[],"label_agreement":null},{"id":"W4220893093","doi":"10.1200/po.21.00444","title":"Perspectives and Experiences of Parents and Adolescents Who Participate in a Pediatric Precision Oncology Program: \"When You Feel Helpless, This Kind of Thing Is Very Helpful\"","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pediatric oncology; Psychology; Precision oncology; Medical education; Medicine; Precision medicine; Internal medicine; Pathology; Cancer","score_opus":0.04581433474278136,"score_gpt":0.38000507260566985,"score_spread":0.3341907378628885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220893093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047685,0.0054764026,0.000022463491,0.0016091365,0.0004829032,0.0013922144,0.000027358368,0.000037506892,0.00047519582],"genre_scores_gemma":[0.99600154,0.0014851658,0.0014640467,0.00037526203,0.00013697478,0.00038446015,0.000008867452,0.000028936942,0.00011476342],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9956201,0.0010488551,0.0011893298,0.0008192194,0.0008662699,0.00045624212],"domain_scores_gemma":[0.9976083,0.00079061126,0.0007448692,0.0004252695,0.0002033562,0.00022761042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020701184,0.00027951918,0.0012628643,0.00051975215,0.00016256768,0.000017237926,0.0002916422,0.0002634544,0.00035267317],"category_scores_gemma":[0.00086516613,0.00026038842,0.000120572215,0.0005100655,0.000391805,0.00018909802,0.00083500874,0.00059397606,0.0000023859268],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041459105,0.0034964224,0.29447076,0.00043792,0.000070212955,0.000057323356,0.5763328,0.000008079302,0.00028692166,0.000023330727,0.0015387944,0.11913151],"study_design_scores_gemma":[0.014229052,0.01953147,0.5435215,0.00097418966,0.00038303182,0.00019124204,0.40583414,0.00096150953,0.0014933399,0.0008520151,0.011376522,0.00065197254],"about_ca_topic_score_codex":0.00054747745,"about_ca_topic_score_gemma":0.00022384357,"teacher_disagreement_score":0.24905075,"about_ca_system_score_codex":0.00038569942,"about_ca_system_score_gemma":0.00057333615,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W4224233487","doi":"10.1200/po.21.00450","title":"Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Public Health Ontario; Women's College Hospital; University of Toronto","funders":"","keywords":"ALDH2; Breast cancer; Penetrance; Allele; Genotype; Odds ratio; Cancer; Aldehyde dehydrogenase; Oncology; Internal medicine; Genetics; Medicine; Cancer research; Biology; Gene; Phenotype","score_opus":0.0101542968579992,"score_gpt":0.2856685276857461,"score_spread":0.2755142308277469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224233487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513626,0.0007783761,0.00013293068,0.001311657,0.00071130274,0.00046197997,0.00029610182,0.0000030061224,0.0011683882],"genre_scores_gemma":[0.9987104,0.0003892867,0.00015606597,0.00021688525,0.00005619069,0.00028106544,0.000013731933,0.000016927801,0.00015946287],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99776316,0.00096822367,0.00050607265,0.00031365402,0.00023728474,0.00021161177],"domain_scores_gemma":[0.9986756,0.00019632153,0.00038534112,0.00063237484,0.000081736835,0.000028633789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010786739,0.00012854039,0.00028278946,0.00009340979,0.000125178,0.0000050975323,0.0006499495,0.00016292739,0.00023439457],"category_scores_gemma":[0.00014482527,0.00008782542,0.000110949506,0.0003986949,0.00030063567,0.0000046485534,0.0006589137,0.0003692254,5.7163123e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002001709,0.000932323,0.37425053,0.000045014676,0.0004066033,0.00006532428,0.008943846,0.40700963,0.09267806,0.0007626869,0.011112799,0.101791486],"study_design_scores_gemma":[0.0029211568,0.00061287655,0.91558194,0.00005237837,0.00011108072,0.00021051164,0.0035714954,0.005201595,0.020615444,0.0017438909,0.049059432,0.000318171],"about_ca_topic_score_codex":0.004984043,"about_ca_topic_score_gemma":0.011359067,"teacher_disagreement_score":0.54133147,"about_ca_system_score_codex":0.00029422526,"about_ca_system_score_gemma":0.00069783983,"threshold_uncertainty_score":0.7534415},"labels":[],"label_agreement":null},{"id":"W4282915006","doi":"10.1200/po.22.00111","title":"Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Citation; Cancer; Library science; Medicine; History; Internal medicine; Computer science","score_opus":0.024669997840590898,"score_gpt":0.3091589239311139,"score_spread":0.284488926090523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312645,0.00071245246,0.00011755738,0.00038216054,0.00060686877,0.0011694615,0.00007830121,0.000050593037,0.0037561383],"genre_scores_gemma":[0.99478465,0.000033223827,0.0033353486,0.0004104662,0.00007509169,0.0003599724,0.000040433577,0.0000351509,0.00092564616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99707687,0.0003371124,0.0007914293,0.0005075627,0.0009605424,0.00032647408],"domain_scores_gemma":[0.9979813,0.00037928254,0.0005328947,0.0008199588,0.00016719873,0.000119348675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074810896,0.00022931806,0.00078460824,0.00013028938,0.000086171014,0.0000024127344,0.00035640525,0.00022582755,0.0024804717],"category_scores_gemma":[0.0001675537,0.00021418906,0.00028175113,0.0002495009,0.00024407991,0.000019662988,0.00043922468,0.00057093694,0.00000992586],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018703716,0.0040313187,0.13820921,0.0012598366,0.00039762206,0.00049329275,0.0022323672,0.0004259663,0.6364637,0.000008668938,0.012098377,0.18567592],"study_design_scores_gemma":[0.009675981,0.016929895,0.59438044,0.0006834033,0.00025715513,0.0011949361,0.00055057905,0.00029827323,0.3428357,0.00061927445,0.031909272,0.0006650675],"about_ca_topic_score_codex":0.00011681832,"about_ca_topic_score_gemma":0.000005938581,"teacher_disagreement_score":0.45617127,"about_ca_system_score_codex":0.0009906032,"about_ca_system_score_gemma":0.0007613765,"threshold_uncertainty_score":0.9984314},"labels":[],"label_agreement":null},{"id":"W4283016030","doi":"10.1200/po.21.00561","title":"Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of <i>BRAF</i> and <i>MEK</i> Inhibitors","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont; Université de Sherbrooke","funders":"","keywords":"Mucosal melanoma; Medicine; Melanoma; Cancer research; MEK inhibitor; Trametinib; Dermatology; Oncology; Internal medicine; Biology; Genetics; MAPK/ERK pathway","score_opus":0.005415797021471048,"score_gpt":0.21854370826433173,"score_spread":0.21312791124286068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283016030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565417,0.00044997767,0.00013863802,0.00030273607,0.00018473556,0.00047858982,0.00013426287,0.000007799819,0.0026490772],"genre_scores_gemma":[0.9985128,0.0000720382,0.00045854232,0.00027972483,0.00003991623,0.00007594706,0.00012323476,0.000019489276,0.00041828153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986186,0.00029087788,0.00033164112,0.00033839833,0.00025586595,0.00016460249],"domain_scores_gemma":[0.9990396,0.00010818455,0.00034619603,0.00030655158,0.00014268249,0.000056775894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024044325,0.00015383384,0.00027762388,0.00006588749,0.00013490432,0.0000041589733,0.00024105376,0.00012494922,0.000031429932],"category_scores_gemma":[0.000050133014,0.00011203499,0.000083763305,0.00016971648,0.0002111334,0.000007514435,0.0003854569,0.00014171172,7.5148046e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020958264,0.0006109289,0.01740189,0.000024559806,0.00006665793,0.000017655777,0.00014216371,0.00015001197,0.9436401,0.0005987172,0.0031902425,0.03206126],"study_design_scores_gemma":[0.007153764,0.013125567,0.045338143,0.000046399215,0.00009153878,0.00046525456,0.0003036583,0.00008878102,0.84168035,0.0005185712,0.0908541,0.0003338692],"about_ca_topic_score_codex":0.000027314398,"about_ca_topic_score_gemma":0.000042176052,"teacher_disagreement_score":0.10195973,"about_ca_system_score_codex":0.00003659974,"about_ca_system_score_gemma":0.00019545827,"threshold_uncertainty_score":0.45686543},"labels":[],"label_agreement":null},{"id":"W4289531577","doi":"10.1200/po.22.00105","title":"Response to Alpelisib in an Adolescent With <i>PIK3CA</i>-Mutated Metastatic Gastrointestinal Stromal Tumor","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Sick child; Citation; Medicine; Associate editor; University hospital; Stromal tumor; Family medicine; Editorial board; Pediatrics; Internal medicine; Oncology; Library science; Stromal cell","score_opus":0.04098127799607804,"score_gpt":0.3651710420074702,"score_spread":0.32418976401139216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289531577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926448,0.00003179108,0.000596587,0.004498218,0.000056691064,0.0016710898,0.000053286425,0.00008567038,0.000361903],"genre_scores_gemma":[0.952445,8.3181874e-7,0.04531565,0.0012480909,0.000032774824,0.00047712948,0.00006967012,0.000047841506,0.00036305477],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955908,0.001409789,0.00054114236,0.00071005395,0.00092351984,0.00082467805],"domain_scores_gemma":[0.9976482,0.0006360856,0.00014039966,0.00051980274,0.00022633914,0.000829175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015797463,0.0002937682,0.00062237994,0.00064795214,0.00016873368,0.000028760773,0.0002833281,0.000016216034,0.000874419],"category_scores_gemma":[0.0008831783,0.00023024804,0.00008415695,0.0007791255,0.00009896541,0.00009507347,0.0003364624,0.0007806747,0.000089891495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3945238,0.020239213,0.31356436,0.00008022551,0.00009189658,0.14298357,0.00085668697,0.006277583,0.089864776,0.000065846085,0.007107227,0.024344819],"study_design_scores_gemma":[0.027551802,0.25098366,0.6235349,0.00063999713,0.00014366764,0.075031675,0.0036194222,0.004590674,0.0017650346,0.00009813145,0.011553116,0.00048787548],"about_ca_topic_score_codex":0.00011211796,"about_ca_topic_score_gemma":0.0002288467,"teacher_disagreement_score":0.366972,"about_ca_system_score_codex":0.0014225123,"about_ca_system_score_gemma":0.0011967352,"threshold_uncertainty_score":0.95742744},"labels":[],"label_agreement":null},{"id":"W4290719500","doi":"10.1200/po.22.00165","title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Gefitinib; Estrogen receptor; Epidermal growth factor receptor; Phases of clinical research; Clinical trial; Chemotherapy","score_opus":0.06288459229454123,"score_gpt":0.4389085319902534,"score_spread":0.3760239396957122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290719500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815204,0.000015343998,0.00016334372,0.0006288624,0.00012243965,0.01963357,0.0010988619,0.000021663034,0.00016390248],"genre_scores_gemma":[0.97459906,0.0000019110225,0.0011036142,0.0002452222,0.00011454043,0.022684071,0.0011649334,0.000028236875,0.000058429105],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997366,0.00032210955,0.00081344787,0.0005437156,0.00073862384,0.00021608258],"domain_scores_gemma":[0.9973691,0.0009861643,0.00074479333,0.00025767443,0.0005702105,0.00007206623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038589217,0.00022098735,0.0006045207,0.00033205212,0.00054753316,0.000016281752,0.00018604782,0.000059581875,0.00037934518],"category_scores_gemma":[0.00048056818,0.0001396287,0.000109936394,0.0008610047,0.00008362003,0.00016859779,0.00007172349,0.00025453782,4.0849426e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39359757,0.05869985,0.40628874,0.00002755945,0.007869871,0.000033762695,0.030772036,0.013665593,0.00172313,0.00012899935,0.00053864194,0.08665425],"study_design_scores_gemma":[0.5274307,0.07624798,0.38624766,0.000067890156,0.00080554606,0.000001103831,0.0021344938,0.000269627,0.0009956914,0.00009426678,0.0054026535,0.0003024043],"about_ca_topic_score_codex":0.0029840951,"about_ca_topic_score_gemma":0.0019081637,"teacher_disagreement_score":0.13383313,"about_ca_system_score_codex":0.00072249543,"about_ca_system_score_gemma":0.0007241446,"threshold_uncertainty_score":0.56938934},"labels":[],"label_agreement":null},{"id":"W4290994299","doi":"10.1200/po.22.00010","title":"Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Oxaliplatin; Internal medicine; Hazard ratio; Oncology; Fluorouracil; Colorectal cancer; Proportional hazards model; Stage (stratigraphy); Chemotherapy; Cancer; Confidence interval","score_opus":0.018935429631523355,"score_gpt":0.3079839319114025,"score_spread":0.28904850227987916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290994299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941731,0.0019412868,0.0000062026215,0.0003083719,0.00018734345,0.0028357878,0.00025055776,0.00003089673,0.00026641457],"genre_scores_gemma":[0.9967786,0.0010651005,0.00019764404,0.00012150554,0.000057167683,0.0010238977,0.00009115399,0.000024776282,0.00064014446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997574,0.00039265494,0.0006484155,0.0006365873,0.00037996622,0.00036841098],"domain_scores_gemma":[0.99837947,0.00086268684,0.000320745,0.00022946915,0.0000791878,0.00012846569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057216367,0.00030105692,0.001039823,0.00035456373,0.00031279743,0.000017413735,0.00007923634,0.00013957093,0.00042001097],"category_scores_gemma":[0.00022665874,0.00022245242,0.00005313296,0.0004468652,0.00016106541,0.00008157812,0.00035587553,0.00061631604,0.000001794249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33792314,0.002911405,0.48949316,0.00003615981,0.00018050257,0.001300539,0.00623051,0.00006317174,0.00049632706,0.000019695824,0.00034147222,0.16100392],"study_design_scores_gemma":[0.35217866,0.05602562,0.580734,0.00014711772,0.00035839746,0.00015030631,0.0021712393,0.001438378,0.00021073129,0.00008375883,0.006182618,0.00031916468],"about_ca_topic_score_codex":0.009136252,"about_ca_topic_score_gemma":0.006081983,"teacher_disagreement_score":0.16068476,"about_ca_system_score_codex":0.00073397654,"about_ca_system_score_gemma":0.00039743213,"threshold_uncertainty_score":0.997462},"labels":[],"label_agreement":null},{"id":"W4292265616","doi":"10.1200/po.22.00107","title":"Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors","year":2022,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Association Neurofibromatoses et Recklinghause; American Society of Clinical Oncology; Conquer Cancer Foundation","keywords":"Medicine; MAPK/ERK pathway; Lung cancer; Melanoma; Targeted therapy; Oncology; Cancer; Cancer research; Internal medicine; Protein kinase A; Mutant; Kinase; Biology; Gene; Genetics","score_opus":0.038454183383332424,"score_gpt":0.34254752105524694,"score_spread":0.3040933376719145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292265616","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67962366,0.31567425,0.000049192306,0.0000116184965,0.0007015339,0.003209567,0.00024509034,0.000019283883,0.00046577284],"genre_scores_gemma":[0.096340865,0.8994677,0.00078307337,0.000064584005,0.00027085884,0.0010167208,0.0014227997,0.00017272696,0.00046068346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99553883,0.0015410918,0.0011660989,0.0009875544,0.00034676638,0.00041963693],"domain_scores_gemma":[0.99750924,0.00021708925,0.0011725374,0.00085040805,0.00011745125,0.00013330094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008307621,0.0005256865,0.0021502587,0.00023266369,0.00007508348,0.000010071057,0.0005910437,0.0009348075,0.0002540661],"category_scores_gemma":[0.00036269752,0.00038914825,0.00045593534,0.00036957848,0.00017350898,0.000007704073,0.0004979449,0.0007544455,0.0000099851995],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012866524,0.0014020551,0.00073263946,0.0007729828,0.00026099518,0.000040133324,0.000042739262,0.0000011817921,0.00984612,0.000003960543,0.00021423445,0.9853963],"study_design_scores_gemma":[0.0024019629,0.0072242087,0.0025021525,0.0009413943,0.00011246096,0.000011409898,0.0000141242745,0.0000011608203,0.005741089,0.000009401582,0.9805688,0.00047182266],"about_ca_topic_score_codex":0.000036752164,"about_ca_topic_score_gemma":0.00004922195,"teacher_disagreement_score":0.9849245,"about_ca_system_score_codex":0.00015365168,"about_ca_system_score_gemma":0.001235788,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W4292995296","doi":"10.1200/po.22.00129","title":"Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Agence Nationale de la Recherche","keywords":"Tensin; Stromal cell; Cancer research; Clinical significance; Phosphatase; Gene; Refining (metallurgy); Gene expression; PTEN; Biology; Pathology; Medicine; Cell biology; Chemistry; Genetics; Enzyme; Biochemistry; Signal transduction","score_opus":0.04381538820703224,"score_gpt":0.36730579661290774,"score_spread":0.3234904084058755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292995296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765456,0.00067854003,0.00017092779,0.00063957047,0.000053303163,0.0006165687,0.000058033842,0.000025203406,0.00010327033],"genre_scores_gemma":[0.95010597,0.00004885636,0.04939847,0.000114412716,0.000035624227,0.00017233999,0.000045168163,0.000019212255,0.000059965016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971579,0.0006354332,0.00076538237,0.00059888343,0.00041239263,0.00043001556],"domain_scores_gemma":[0.9977949,0.0012238849,0.00027690575,0.00024565507,0.0001226326,0.0003359993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013895365,0.00019252545,0.000727092,0.00020041411,0.00011219054,0.000009703035,0.00011580973,0.00004392603,0.00014887092],"category_scores_gemma":[0.0014505618,0.00015919565,0.00007427469,0.00021891318,0.0004397891,0.00005177866,0.00049735635,0.0006514371,0.0000034941904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009549902,0.0020376274,0.92739743,0.00006683013,0.000017577835,0.0100271,0.00005006686,0.000027312926,0.018596902,0.00002901763,0.00045771353,0.03174251],"study_design_scores_gemma":[0.022161385,0.05510151,0.8641656,0.00096781866,0.00010752736,0.032951966,0.00054799445,0.0025654216,0.019304281,0.00029161008,0.001546326,0.00028857353],"about_ca_topic_score_codex":0.00011730623,"about_ca_topic_score_gemma":0.000022015527,"teacher_disagreement_score":0.063231856,"about_ca_system_score_codex":0.00018955936,"about_ca_system_score_gemma":0.00037121095,"threshold_uncertainty_score":0.64918107},"labels":[],"label_agreement":null},{"id":"W4295957335","doi":"10.1200/po.22.00072","title":"Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Spectrum Pharmaceuticals; Merck KGaA; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Stage (stratigraphy); Adjuvant; Lung; Chemotherapy","score_opus":0.008945787073170643,"score_gpt":0.2801589057826575,"score_spread":0.2712131187094869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295957335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99158853,0.0056339833,0.000027883456,0.00031010198,0.00035437397,0.0011976601,0.00078980176,0.000017245427,0.00008043496],"genre_scores_gemma":[0.9945304,0.0035914686,0.000849484,0.00016702867,0.000040766972,0.0004910638,0.000104221326,0.000038387785,0.00018717167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811107,0.00015707241,0.0004668374,0.00053409574,0.00042381402,0.00030713726],"domain_scores_gemma":[0.9986376,0.00039765993,0.00038242328,0.0003174366,0.00014452964,0.00012033447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025340312,0.00025743622,0.0007791938,0.00019761788,0.00011742485,0.000018409522,0.00013874342,0.00008159807,0.0004778006],"category_scores_gemma":[0.000012373379,0.00018339213,0.000062195424,0.00024286647,0.00009190725,0.00012474855,0.00010334519,0.00036075996,0.0000010383301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044927136,0.0010347273,0.964886,0.00009613048,0.00027763288,0.00013335526,0.0041333763,0.00026789462,0.00010152469,0.0000075037815,0.00034902352,0.024220115],"study_design_scores_gemma":[0.008857474,0.0031511674,0.98310214,0.0004970238,0.000515266,0.000004995202,0.00037328101,0.00023546728,0.0014395486,0.000018402856,0.0015979372,0.00020728979],"about_ca_topic_score_codex":0.0120244855,"about_ca_topic_score_gemma":0.0042804563,"teacher_disagreement_score":0.024012825,"about_ca_system_score_codex":0.00063944823,"about_ca_system_score_gemma":0.0002767075,"threshold_uncertainty_score":0.9945545},"labels":[],"label_agreement":null},{"id":"W4306250689","doi":"10.1200/po.22.00355","title":"State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Defense","keywords":"Ovarian cancer; Medicine; Oncology; Biomarker; Cancer; Internal medicine; Medical physics; Biology","score_opus":0.30856198912367905,"score_gpt":0.5672117160136698,"score_spread":0.25864972688999077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306250689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96981,0.00083457405,0.00032780264,0.010509286,0.008375198,0.001149269,0.000104744315,0.000026924903,0.008862165],"genre_scores_gemma":[0.9951329,0.00023164196,0.0009886399,0.002112271,0.0003198887,0.0005963507,0.000008559863,0.000014894651,0.0005948554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497,0.0012313591,0.0018499009,0.00049799413,0.0011769721,0.00027375968],"domain_scores_gemma":[0.9963387,0.0015769239,0.001261314,0.00033388668,0.0003898555,0.000099281664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02421014,0.000117322874,0.00068570656,0.0003664105,0.00028573937,0.000010143165,0.0003429285,0.000081106395,0.0006492273],"category_scores_gemma":[0.0060486225,0.00008629613,0.00016683691,0.0012338981,0.0005782501,0.00012480828,0.00034577193,0.0005424258,0.0000013298115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008196748,0.0010480958,0.40180248,0.00004619326,0.00021905286,0.000548228,0.002407452,0.034221083,0.11980745,0.0003477387,0.027965387,0.40339008],"study_design_scores_gemma":[0.011601937,0.0005912846,0.44073153,0.0006065204,0.00007451034,0.00055730145,0.00021912836,0.0042869286,0.00755393,0.0026452406,0.5308853,0.00024641014],"about_ca_topic_score_codex":0.0005743124,"about_ca_topic_score_gemma":0.0002100246,"teacher_disagreement_score":0.5029199,"about_ca_system_score_codex":0.0018382927,"about_ca_system_score_gemma":0.007795554,"threshold_uncertainty_score":0.9978293},"labels":[],"label_agreement":null},{"id":"W4306957266","doi":"10.1200/po.22.00033","title":"Germline Testing and Somatic Tumor Testing for<i>BRCA1/2</i>Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Germline; Olaparib; PARP inhibitor; Ovarian cancer; Medicine; Genetic testing; Oncology; BRCA mutation; Germline mutation; Population; Internal medicine; Cancer; Biology; Genetics; Mutation; Polymerase; Poly ADP ribose polymerase","score_opus":0.09293274554144984,"score_gpt":0.3785759257374067,"score_spread":0.2856431801959569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306957266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874656,0.0025802576,0.0008906072,0.0055199564,0.0006977707,0.0020360015,0.00016256716,0.00006677853,0.0005804268],"genre_scores_gemma":[0.8901165,0.00010312769,0.10430122,0.0037325998,0.00027834953,0.0012778507,0.0000117382715,0.000056623787,0.000121964185],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99726915,0.00034834788,0.00094285543,0.0005677817,0.0004211247,0.000450721],"domain_scores_gemma":[0.9913171,0.007078435,0.00066610985,0.00045374283,0.00036798633,0.000116654206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020815732,0.00023469666,0.00065638195,0.00022372924,0.0003487916,0.000033860262,0.0002929242,0.00009846754,0.00025637558],"category_scores_gemma":[0.0029150967,0.00019474956,0.00007356068,0.0010758878,0.00023362713,0.0002039863,0.0002958568,0.0005269294,0.0000026269329],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097630604,0.0004369023,0.053628374,0.00022694565,0.00006151981,0.00020729327,0.0025241212,0.003556006,0.62652904,0.00007140638,0.00061636884,0.31116575],"study_design_scores_gemma":[0.05060912,0.02889894,0.26281306,0.0075039486,0.00097327185,0.015477233,0.007151074,0.55026513,0.032034434,0.026415013,0.015731942,0.0021268218],"about_ca_topic_score_codex":0.00029958863,"about_ca_topic_score_gemma":0.000026772874,"teacher_disagreement_score":0.5944946,"about_ca_system_score_codex":0.00064076664,"about_ca_system_score_gemma":0.0011795379,"threshold_uncertainty_score":0.7941657},"labels":[],"label_agreement":null},{"id":"W4310887545","doi":"10.1200/po.22.00245","title":"Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care","year":2022,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Medical Research Council; Deutschen Konsortium für Translationale Krebsforschung; Knut och Alice Wallenbergs Stiftelse; University of Twente; Karolinska Institutet; Radiumhemmets Forskningsfonder; Cancerfonden; ZonMw; National Institute for Health and Care Research; Vetenskapsrådet; Cancer Research UK","keywords":"Reimbursement; Health care; Test (biology); Medicine; Diagnostic test; Computer science; Biology","score_opus":0.0822959380479917,"score_gpt":0.4622204442496928,"score_spread":0.37992450620170104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310887545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033970762,0.9938055,0.00009419458,0.00003528344,0.0009241554,0.0007086518,0.0008188073,0.0000054641077,0.00021083833],"genre_scores_gemma":[0.00068659114,0.9963343,0.0005764115,0.00014798665,0.00043126024,0.00028897947,0.0014222232,0.000048362406,0.000063884436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976851,0.00032739813,0.0010066848,0.0006180368,0.00014598558,0.0002168386],"domain_scores_gemma":[0.9986405,0.00023566859,0.00054491556,0.00037889538,0.00008977763,0.000110254776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047599064,0.00026794602,0.0011158291,0.00011838811,0.00008966792,0.000013843876,0.0002929046,0.00047849768,0.0002693236],"category_scores_gemma":[0.00008942373,0.00025456617,0.0003641514,0.000116829084,0.00010763592,0.0000029811583,0.00035628543,0.0002942837,0.0000029892126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031526644,0.000024616007,0.00006128596,0.0013322614,0.00012787252,0.000005912466,0.00031233468,0.0000064098836,0.001056945,0.00001226926,0.00058644224,0.99644214],"study_design_scores_gemma":[0.00058894354,0.0011956646,0.000042246178,0.0001881569,0.00041066614,0.000019238589,0.00070443575,6.8392666e-7,0.000050960167,0.000024898927,0.99653333,0.00024074415],"about_ca_topic_score_codex":0.00032089528,"about_ca_topic_score_gemma":0.0010168671,"teacher_disagreement_score":0.9962014,"about_ca_system_score_codex":0.00039675165,"about_ca_system_score_gemma":0.0019606948,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W4315750714","doi":"10.1200/po.22.00342","title":"Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer","year":2023,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Institutes for BioMedical Research; Genentech; Foundation Medicine; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Natera; Silverback Therapeutics; Moderna; Pfizer; Incyte; Agios Pharmaceuticals; Mirati Therapeutics; Abbott Laboratories; Clovis Oncology; Pacira Pharmaceuticals; Stryker; Ipsen; Array BioPharma; GlaxoSmithKline; Pacira BioSciences; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Invitae; AstraZeneca; Edwards Lifesciences; Amgen; Dana-Farber Cancer Institute; Revolution Medicines; Exelixis; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Puma Biotechnology; Advanced Accelerator Applications","keywords":"Medicine; Precision medicine; Clinical trial; Pancreatic cancer; Internal medicine; Gastrointestinal cancer; Oncology; Colorectal cancer; Cancer; Personalized medicine; Precision oncology; Targeted therapy; Bioinformatics; Pathology","score_opus":0.039852672956354564,"score_gpt":0.3876875231769671,"score_spread":0.3478348502206125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315750714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001034376,0.964792,0.015299827,0.000106700376,0.0036351343,0.012031019,0.0020556534,0.00013945674,0.0009058003],"genre_scores_gemma":[0.000016560383,0.9546064,0.03586373,0.00013409162,0.0009841257,0.0036057504,0.0033473806,0.00027331745,0.0011686058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539435,0.00024891307,0.0015208002,0.0014821963,0.00044970447,0.00090403826],"domain_scores_gemma":[0.99458665,0.0021252453,0.0012371494,0.0009788502,0.00070570945,0.00036639842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078340207,0.0008164983,0.0022384205,0.00034178887,0.00020010838,0.000078821635,0.0008714524,0.0010699511,0.0001164998],"category_scores_gemma":[0.0018670202,0.00061852776,0.0006639079,0.00038339675,0.00018450688,0.000009233725,0.0007156669,0.00047067698,0.00015432245],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010424862,0.00058775744,0.00009525886,0.0014715075,0.00017464346,0.000026041767,0.000017275446,0.00003685245,0.0000081037115,0.000017910863,0.02961573,0.9669064],"study_design_scores_gemma":[0.002563761,0.013909686,0.00006438206,0.004224661,0.0007295269,0.000117267555,0.000013301107,0.000032271928,0.0000081602875,0.0001881875,0.97750396,0.00064486754],"about_ca_topic_score_codex":0.000024423485,"about_ca_topic_score_gemma":0.00045198257,"teacher_disagreement_score":0.96626157,"about_ca_system_score_codex":0.0007514993,"about_ca_system_score_gemma":0.0035358006,"threshold_uncertainty_score":0.9996266},"labels":[],"label_agreement":null},{"id":"W4362703880","doi":"10.1200/po.22.00509","title":"Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Internal medicine; Immunotherapy; Hazard ratio; Medicine; Biomarker; Progression-free survival; Gastroenterology; Clinical trial; Tumor progression; Circulating tumor DNA; Oncology; Cancer; Overall survival; Confidence interval; Biology; Genetics","score_opus":0.07638013486350287,"score_gpt":0.44089207221425536,"score_spread":0.3645119373507525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362703880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975097,0.00008178246,0.00018792952,0.00011839104,0.00039725463,0.001371351,0.00019739961,0.0000313693,0.00010477973],"genre_scores_gemma":[0.9976249,0.00012247157,0.00066859304,0.00047558738,0.0002103908,0.0002907651,0.00037011877,0.00006634387,0.00017086948],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996232,0.001334302,0.0011251122,0.00071044074,0.00016921783,0.00042892867],"domain_scores_gemma":[0.9958125,0.0027819956,0.00047979716,0.0005187523,0.00023169216,0.00017526535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004500555,0.00024764639,0.000672451,0.00021106812,0.000100297286,0.000053838423,0.0002657975,0.00030298188,0.000030516092],"category_scores_gemma":[0.005897644,0.00020995924,0.00021585987,0.0002940504,0.00010798092,0.000011666095,0.00009984083,0.00014563766,0.000029277384],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15276965,0.003459712,0.15253124,0.000014829988,0.00029777572,0.000246689,0.00047853874,0.00007137244,0.38087568,0.000043809217,0.0034079507,0.30580276],"study_design_scores_gemma":[0.052237414,0.05776289,0.7817686,0.000082557264,0.00009242824,0.000029641047,0.0001547248,0.00097521185,0.022922503,0.00053166074,0.08264405,0.00079829275],"about_ca_topic_score_codex":0.00013222892,"about_ca_topic_score_gemma":0.00009810691,"teacher_disagreement_score":0.62923735,"about_ca_system_score_codex":0.00009906069,"about_ca_system_score_gemma":0.00047645142,"threshold_uncertainty_score":0.85618895},"labels":[],"label_agreement":null},{"id":"W4367042670","doi":"10.1200/po.22.00317","title":"Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Breast cancer; Cohort; Triple-negative breast cancer; Metastatic breast cancer; Tumor-infiltrating lymphocytes; Progression-free survival; Cancer; Immunotherapy; Chemotherapy","score_opus":0.034109530947823555,"score_gpt":0.37195274827056923,"score_spread":0.3378432173227457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367042670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99686205,0.00010696441,0.00007142434,0.0016834838,0.00018645647,0.0007632951,0.00023422229,0.000038834285,0.000053280724],"genre_scores_gemma":[0.99767804,0.0011946218,0.00040542652,0.00029438164,0.00003467579,0.0000747273,0.00008869601,0.00002484371,0.00020461265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973236,0.00054966204,0.0009618013,0.00041760388,0.0004684368,0.0002789427],"domain_scores_gemma":[0.99671865,0.0019824079,0.00067878555,0.00026405702,0.00024533906,0.00011076304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014874474,0.00020260285,0.0012486601,0.00082890585,0.000048559705,0.000010345933,0.00010542949,0.00022307342,0.00015725468],"category_scores_gemma":[0.00027080276,0.00014647156,0.00026224263,0.0018575222,0.00014820465,0.00012734058,0.00004277786,0.0002170453,0.000005450225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015302066,0.00030772685,0.8553271,0.000014518824,0.007511912,0.0000057116195,0.00042667516,0.000008459446,0.000022215138,6.0748977e-7,0.00063880376,0.120434165],"study_design_scores_gemma":[0.026316885,0.0016000995,0.96936554,0.0000521447,0.0015756147,5.9712016e-7,0.00026526817,0.00013841364,0.00004399017,0.000040096907,0.00045916438,0.0001422112],"about_ca_topic_score_codex":0.00060033624,"about_ca_topic_score_gemma":0.001002328,"teacher_disagreement_score":0.12029195,"about_ca_system_score_codex":0.0006474811,"about_ca_system_score_gemma":0.0003112383,"threshold_uncertainty_score":0.5972937},"labels":[],"label_agreement":null},{"id":"W4381487668","doi":"10.1200/po.23.00132","title":"Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface","year":2023,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Carcinogenesis; Haematopoiesis; Immune system; Cancer; Oncology; Population; Interface (matter); Biology; Epigenetics; Solid tumor; Immunology; Bioinformatics; Internal medicine; Cancer research; Computational biology; Medicine; Genetics; Stem cell; Gene; Environmental health","score_opus":0.10010566176435874,"score_gpt":0.46656861484103807,"score_spread":0.3664629530766793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381487668","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020993847,0.98781013,0.00005461598,0.006217579,0.000329613,0.0024168112,0.00012790179,0.00015170735,0.0026816702],"genre_scores_gemma":[0.000027464877,0.98195136,0.0003867908,0.00032422607,0.0003219018,0.0009947245,0.00028465348,0.00012810226,0.0155807985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963449,0.00060307956,0.0012234296,0.0008211001,0.0004052221,0.0006022743],"domain_scores_gemma":[0.9931287,0.0045511317,0.00051627064,0.0013294909,0.00021733691,0.00025706633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001575963,0.00047608928,0.002500886,0.00038593367,0.00034528747,0.0000492762,0.00072346436,0.0006263744,0.0008297698],"category_scores_gemma":[0.0013603821,0.00027695802,0.00044664572,0.00067682186,0.0005099676,0.0000556948,0.0022586563,0.0014562503,0.003525484],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010671647,0.00009407986,0.0000064937703,0.0033130033,0.00043330982,0.00012939751,0.00011838026,3.9033424e-7,0.00004888252,0.00023700726,0.13998519,0.85552716],"study_design_scores_gemma":[0.00057898724,0.00036182298,0.00009273626,0.003985934,0.00072128803,0.00431873,0.00008835633,0.000017660775,0.00003494553,0.00034262374,0.9892346,0.00022229664],"about_ca_topic_score_codex":0.000030600175,"about_ca_topic_score_gemma":0.000048708964,"teacher_disagreement_score":0.85530484,"about_ca_system_score_codex":0.0017477475,"about_ca_system_score_gemma":0.0017460013,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W4382051182","doi":"10.1200/po.23.00076","title":"Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Breast cancer; Oncology; Copy number analysis; Exome sequencing; Internal medicine; Cancer; Biology; Copy-number variation; Chemotherapy; Medicine; Mutation; Cancer research; Gene; Genetics; Genome","score_opus":0.004726130540452299,"score_gpt":0.2662725685712719,"score_spread":0.2615464380308196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382051182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997492,0.00030160183,0.0001157629,0.00073972566,0.00027341754,0.00036357436,0.00047417177,0.000007613051,0.0002320981],"genre_scores_gemma":[0.99629205,0.0019790458,0.00027451926,0.00068574026,0.00020105937,0.0002252794,0.000036480073,0.000030456144,0.00027535955],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99886686,0.000043716875,0.00029644946,0.0003852096,0.00009223057,0.0003155216],"domain_scores_gemma":[0.9994291,0.00005208241,0.00008237128,0.00022917391,0.000084394516,0.00012289327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002330282,0.00015414384,0.00030031372,0.00012259446,0.000028515376,0.000012445492,0.00012364922,0.00022676357,0.00005549368],"category_scores_gemma":[0.00003644716,0.00015115594,0.000048054113,0.00019446525,0.00006714911,0.0000039775346,0.00020534065,0.00008898135,0.000006987032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00832431,0.00033408077,0.0968186,0.00006623043,0.00019249816,0.00008173841,0.015441739,0.003470486,0.4438688,0.000054647335,0.004504982,0.42684188],"study_design_scores_gemma":[0.0037517333,0.0030438155,0.9496797,0.000059731035,0.000018836774,0.00007620338,0.0009314477,0.00020965448,0.018194633,0.0003508264,0.02331881,0.00036465525],"about_ca_topic_score_codex":0.00013232061,"about_ca_topic_score_gemma":0.0032889599,"teacher_disagreement_score":0.85286105,"about_ca_system_score_codex":0.00032061402,"about_ca_system_score_gemma":0.0002952602,"threshold_uncertainty_score":0.616396},"labels":[],"label_agreement":null},{"id":"W4382517901","doi":"10.1200/po.22.00633","title":"Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in <i>BRD4-NUTM1</i> NUT Carcinoma Harboring a <i>BRD4</i> Splice Site Mutation","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; Daiichi Sankyo Europe; AstraZeneca","keywords":"Bromodomain; Citation; BRD4; Cancer; Library science; Medicine; Cancer research; Internal medicine; Biology; Genetics; Computer science; Gene; Histone","score_opus":0.013570923099663098,"score_gpt":0.2839932525883621,"score_spread":0.270422329488699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382517901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99603826,0.00031019916,0.0008803652,0.0013864493,0.00021581938,0.0007689352,0.00003287978,0.00004609663,0.00032098978],"genre_scores_gemma":[0.99352646,0.00015872282,0.0039791237,0.0008544222,0.0003369165,0.00028951748,0.00014533008,0.00004236435,0.0006671385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976015,0.00051188044,0.00045362292,0.0007291176,0.00029792756,0.0004059376],"domain_scores_gemma":[0.99902767,0.00017359105,0.00014363501,0.0003493332,0.0001105608,0.00019520501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012453932,0.00026272904,0.0002957627,0.0003262243,0.00013527506,0.000042166837,0.00017844095,0.00030960992,0.000045000117],"category_scores_gemma":[0.00016043964,0.00023585805,0.00006023142,0.0004886296,0.00011134487,0.00002813503,0.00017106342,0.00019632836,0.000069522706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008285412,0.0001729115,0.003261936,0.000011014901,0.000012882394,0.000114387476,0.00058812054,0.000094717834,0.9672356,0.000028328654,0.0034917402,0.016702954],"study_design_scores_gemma":[0.010902417,0.008693831,0.21581675,0.00015208035,0.000015085876,0.000427044,0.0008390019,0.00042293794,0.42202795,0.00042768172,0.33934602,0.00092921674],"about_ca_topic_score_codex":0.00004246996,"about_ca_topic_score_gemma":0.0001977108,"teacher_disagreement_score":0.5452077,"about_ca_system_score_codex":0.00011427218,"about_ca_system_score_gemma":0.00026762104,"threshold_uncertainty_score":0.96180123},"labels":[],"label_agreement":null},{"id":"W4387382626","doi":"10.1200/po.23.00235","title":"Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carboplatin; Bromodomain; Medicine; Tolerability; ARID1A; Endometrial cancer; Ovarian cancer; Combination therapy; Internal medicine; Oncology; Phases of clinical research; Cancer; BET inhibitor; Clinical trial; Cancer research; Chemotherapy; Epigenetics; Mutation; Adverse effect; Cisplatin; Biology; Genetics","score_opus":0.023522442884728295,"score_gpt":0.35376435630881475,"score_spread":0.3302419134240865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387382626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973571,0.00013934415,0.000051590832,0.00008776879,0.00022552923,0.0018761475,0.00006796643,0.000015807393,0.00017877252],"genre_scores_gemma":[0.9990622,0.00010147711,0.00018785919,0.000035368645,0.000062645624,0.00035588528,0.00007079897,0.000024141333,0.00009963317],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99745536,0.00047546581,0.00086631416,0.00061290886,0.000295747,0.00029419837],"domain_scores_gemma":[0.99875504,0.00019210277,0.0004829925,0.00034345288,0.0001426356,0.000083780265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079640874,0.00024130897,0.00057129696,0.000399973,0.000065322885,0.000011767212,0.00020386069,0.00025031678,0.00006015006],"category_scores_gemma":[0.00034192938,0.00020408838,0.00003404544,0.00067586615,0.000115245355,0.00001805986,0.00016910615,0.00020740903,0.000001522914],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020296631,0.017609082,0.02890548,0.00007766704,0.0003077627,0.00037984998,0.012784568,0.009932161,0.7217092,0.00003356069,0.0006579137,0.18730615],"study_design_scores_gemma":[0.23905213,0.21529981,0.27510908,0.00036918643,0.0003224946,0.000033887256,0.04236665,0.013245548,0.20741153,0.00036441453,0.0048397477,0.0015855182],"about_ca_topic_score_codex":0.0023151634,"about_ca_topic_score_gemma":0.031461645,"teacher_disagreement_score":0.5142976,"about_ca_system_score_codex":0.00017373619,"about_ca_system_score_gemma":0.00043878605,"threshold_uncertainty_score":0.98621166},"labels":[],"label_agreement":null},{"id":"W4387786011","doi":"10.1200/po.23.00033","title":"Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing","year":2023,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Microsatellite instability; Endometrial cancer; Exact test; Oncology; Cohort; Internal medicine; Microsatellite; Medicine; Lynch syndrome; Genetic testing; Retrospective cohort study; Cancer; DNA mismatch repair; Biology; Genetics; Gene","score_opus":0.27233504926788493,"score_gpt":0.3875973513722165,"score_spread":0.11526230210433158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387786011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955007,0.00010938964,0.0017209214,0.00007781932,0.0012330726,0.0010405966,0.000020861551,0.00004203377,0.00025459682],"genre_scores_gemma":[0.9658018,0.00005850644,0.03371476,0.000042228432,0.00025325472,0.000035531833,0.000046149187,0.000018334644,0.000029470793],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985167,0.00014161195,0.000529604,0.0003399516,0.0002073265,0.00026480286],"domain_scores_gemma":[0.9978729,0.0013686529,0.0002135697,0.00018498108,0.0002951584,0.000064748674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011171871,0.00011844453,0.0003988492,0.000510456,0.000055103283,0.0000082407805,0.00007861381,0.00022858592,0.000033430937],"category_scores_gemma":[0.0030393437,0.00011819397,0.00007664242,0.0012062709,0.00008766923,0.000094184936,0.000064527274,0.00016305748,0.0000036880672],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000990169,0.000031605603,0.012679757,0.00006200227,0.000011869662,0.0000075606895,0.0005011521,0.011701346,0.87444156,0.000009195658,0.00006144374,0.09950231],"study_design_scores_gemma":[0.015637571,0.0067975232,0.056552183,0.0004848913,0.0001975946,0.000072006806,0.002190701,0.46655276,0.44313446,0.0006529667,0.0072311303,0.0004962172],"about_ca_topic_score_codex":0.0006137872,"about_ca_topic_score_gemma":0.00058678444,"teacher_disagreement_score":0.45485142,"about_ca_system_score_codex":0.0038005358,"about_ca_system_score_gemma":0.0015378328,"threshold_uncertainty_score":0.99382687},"labels":[],"label_agreement":null},{"id":"W4390603547","doi":"10.1200/po.23.00441","title":"Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Clinical trial; Clinical study design; Limiting; Medicine; Research design; Toxicity; Medical physics; Computer science; Internal medicine; Statistics; Mathematics; Engineering","score_opus":0.7710930725259459,"score_gpt":0.7075061255547076,"score_spread":0.06358694697123835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390603547","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85568506,0.00664962,0.08454189,0.00998527,0.03246893,0.006281411,0.00046569295,0.00070210994,0.003220026],"genre_scores_gemma":[0.0961214,0.0048598694,0.89177513,0.00051156426,0.00592483,0.00030827068,0.0000076209253,0.00011477335,0.00037653573],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9809581,0.012762968,0.0041684443,0.0010161089,0.0005512102,0.0005431911],"domain_scores_gemma":[0.6285784,0.3700326,0.0006450256,0.00038034588,0.00012990592,0.00023372266],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.054774866,0.00035687705,0.0022558447,0.00033015688,0.00013017304,0.00025111137,0.00032639384,0.0007449366,0.00046493084],"category_scores_gemma":[0.46362916,0.00024373253,0.00026903162,0.0005272851,0.00029493237,0.00029111654,0.00041164874,0.0018277518,0.0000773524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056409277,0.001080217,0.00039281702,0.0003098905,0.00013647335,0.0005664504,0.0011845845,9.3289896e-7,0.000042408297,0.023725023,0.004023665,0.9628966],"study_design_scores_gemma":[0.008919994,0.0044954796,0.0011145262,0.0011676695,0.00043485546,0.00013019437,0.0005095192,0.0030354613,0.00008718701,0.7488206,0.23081376,0.00047077963],"about_ca_topic_score_codex":0.0000086065675,"about_ca_topic_score_gemma":0.000039382216,"teacher_disagreement_score":0.9624258,"about_ca_system_score_codex":0.00019938896,"about_ca_system_score_gemma":0.0004967667,"threshold_uncertainty_score":0.9939124},"labels":[],"label_agreement":null},{"id":"W4392123065","doi":"10.1200/po.23.00411","title":"Association of RNF43 Genetic Alterations With BRAF<sup>V600E</sup> and MSI<sup>high</sup> in Colorectal Cancer","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Microsatellite instability; Oncology; Medicine; Colorectal cancer; Internal medicine; Retrospective cohort study; Cancer; Cohort; Mutation; Microsatellite; Genetics; Biology; Allele","score_opus":0.012431789788760805,"score_gpt":0.3153826187600332,"score_spread":0.3029508289712724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392123065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772454,0.004008959,0.00006548424,0.0042584464,0.00019412146,0.0008341606,0.00008148853,0.000052555282,0.002780212],"genre_scores_gemma":[0.9940862,0.0019994962,0.0010078979,0.00021742418,0.00021492597,0.00037571482,0.00002810777,0.00002840336,0.0020418235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982952,0.00013616608,0.00046524967,0.00046605736,0.0003328383,0.00030448294],"domain_scores_gemma":[0.9987271,0.00073073275,0.00011827197,0.00013907561,0.00018533222,0.000099520556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025848104,0.00021927153,0.0006347579,0.00026620322,0.00009603183,0.000031958705,0.00006424802,0.00022037329,0.00044340733],"category_scores_gemma":[0.00015388569,0.00016032743,0.00007184643,0.00043066894,0.00010178771,0.000102917744,0.0000849037,0.00026877393,0.000016487387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044674664,0.0014221439,0.47325507,0.0003652507,0.0018334236,0.0006199051,0.017810116,0.007094197,0.002679098,0.00046036634,0.022999708,0.46699327],"study_design_scores_gemma":[0.010273143,0.012715682,0.8521968,0.0009170168,0.001144718,0.000230819,0.0013543351,0.032487724,0.0019969235,0.00081320974,0.0853479,0.00052171166],"about_ca_topic_score_codex":0.0007910068,"about_ca_topic_score_gemma":0.0038071014,"teacher_disagreement_score":0.46647155,"about_ca_system_score_codex":0.0010748284,"about_ca_system_score_gemma":0.00048274623,"threshold_uncertainty_score":0.65379626},"labels":[],"label_agreement":null},{"id":"W4392795393","doi":"10.1200/po.23.00489","title":"Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Genentech; Swiss Re; Seagen; Mirati Therapeutics; Gilead Sciences; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; American Association for Cancer Research; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; Amgen; Doris Duke Charitable Foundation","keywords":"Medicine; Biomarker; Prostate cancer; Oncology; Hazard ratio; Internal medicine; Cohort; Cancer; Disease; Biomarker discovery; Breast cancer; Confidence interval; Biology","score_opus":0.30554007219725215,"score_gpt":0.45541324603401606,"score_spread":0.1498731738367639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392795393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97658354,0.013724946,0.007954445,0.00032206898,0.00072865194,0.00027450715,0.00022717105,0.000005547224,0.00017910507],"genre_scores_gemma":[0.98726696,0.010065915,0.0018678687,0.0002640185,0.00018925218,0.000039013343,0.00023921188,0.000010490431,0.000057244022],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989044,0.00009598832,0.00038266188,0.00041265323,0.00007300249,0.0001312678],"domain_scores_gemma":[0.999045,0.00038828977,0.00008817722,0.0003807731,0.00006416678,0.000033551605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009042491,0.000107393666,0.0001869809,0.00006394871,0.00006512313,0.00006688782,0.0002577003,0.00016943562,0.000030752508],"category_scores_gemma":[0.00073857605,0.00007678643,0.000040324212,0.00009360868,0.00028938966,0.000016039272,0.00046973483,0.000109039815,0.0000043315167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005073584,0.000054066684,0.00439949,0.00005696862,0.000093309405,0.000016765549,0.0004283263,0.005175736,0.79242814,0.00079126575,0.0028203623,0.19322821],"study_design_scores_gemma":[0.004538719,0.0003069494,0.0075790416,0.00018766156,0.00009009365,0.000059205813,0.00013463308,0.7795948,0.02839744,0.0005511915,0.17820108,0.00035921074],"about_ca_topic_score_codex":0.00034055486,"about_ca_topic_score_gemma":0.0015217725,"teacher_disagreement_score":0.77441907,"about_ca_system_score_codex":0.000110603694,"about_ca_system_score_gemma":0.00087856693,"threshold_uncertainty_score":0.31312597},"labels":[],"label_agreement":null},{"id":"W4393282846","doi":"10.1200/po.23.00487","title":"Human Epidermal Growth Factor Receptor 2–Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Immunohistochemistry; Oncology; Internal medicine; Progesterone receptor; Human Epidermal Growth Factor Receptor 2; Cancer; Estrogen receptor; Fluorescence in situ hybridization; Population; Cohort; Gynecology; Biology","score_opus":0.03903125623679429,"score_gpt":0.35698912556096823,"score_spread":0.3179578693241739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866398,0.0012474286,0.00036198788,0.0062420736,0.0009730421,0.0022939136,0.0020616075,0.00015135635,0.000028767714],"genre_scores_gemma":[0.9938757,0.0001129499,0.0022537427,0.00088670594,0.00027023378,0.0008213497,0.0015652169,0.00006137311,0.00015274875],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970207,0.00081983913,0.00080628257,0.00063063006,0.00030935486,0.0004131927],"domain_scores_gemma":[0.9983074,0.00065543974,0.0002073753,0.0003364545,0.00018353401,0.00030976118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082768773,0.00032069432,0.00081968465,0.00042356027,0.00012886475,0.000044226475,0.000109559856,0.00025282387,0.0014497912],"category_scores_gemma":[0.000225172,0.00023495014,0.00020947134,0.00030424396,0.000051632072,0.0002866794,0.000051232968,0.00026370966,0.00001628514],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034644727,0.00363773,0.018614957,0.0011877524,0.0012397531,0.00048930245,0.0055585545,0.00015782623,0.030248854,0.003784414,0.019392988,0.9122234],"study_design_scores_gemma":[0.032983832,0.026772,0.8463194,0.0039687008,0.0015209876,0.0015194495,0.0074959337,0.0052233455,0.006191301,0.007293294,0.058421027,0.00229078],"about_ca_topic_score_codex":0.002403115,"about_ca_topic_score_gemma":0.0006488676,"teacher_disagreement_score":0.9099326,"about_ca_system_score_codex":0.0009594568,"about_ca_system_score_gemma":0.00037511002,"threshold_uncertainty_score":0.999463},"labels":[],"label_agreement":null},{"id":"W4393282851","doi":"10.1200/po.23.00654","title":"Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Prostate Cancer Foundation","keywords":"Context (archaeology); Personalized medicine; Precision medicine; Overdiagnosis; Cancer; Germline; Genetic testing; Prostate cancer; Medicine; Genotyping; Bioinformatics; Computational biology; Biology; Genetics; Gene; Internal medicine; Genotype","score_opus":0.0799215156848305,"score_gpt":0.49077883953531504,"score_spread":0.41085732385048457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393282851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250907,0.0031415229,0.000048361326,0.0015451428,0.00042463833,0.00061945023,0.0000075576113,0.000028463,0.0016757796],"genre_scores_gemma":[0.99159163,0.006723236,0.00051269605,0.000082494225,0.00008399985,0.00009969644,0.000015070738,0.000010521553,0.0008806538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99891996,0.00008572782,0.0004883247,0.00022475423,0.00012958376,0.00015167112],"domain_scores_gemma":[0.9991453,0.0005570267,0.000064570624,0.00006803209,0.00008928386,0.000075728225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053407723,0.00007770824,0.0003241087,0.00025560157,0.000013868498,0.0000113526585,0.00003440897,0.00012802296,0.000117631505],"category_scores_gemma":[0.00027836824,0.000054972676,0.000049295686,0.00024263961,0.00007852445,0.00009880187,0.00004967389,0.0002683562,0.000014915326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029117696,0.00011469427,0.11850128,0.00023263623,0.000057479443,0.00005192412,0.0019106633,0.000021849859,0.0026917756,0.000030526393,0.0007799953,0.8726954],"study_design_scores_gemma":[0.0065149055,0.0053995787,0.89928097,0.0011181129,0.00010779229,0.00012295117,0.0003136471,0.03956303,0.0030757892,0.0010688587,0.043285236,0.00014913378],"about_ca_topic_score_codex":0.00013423315,"about_ca_topic_score_gemma":0.00040794088,"teacher_disagreement_score":0.87254626,"about_ca_system_score_codex":0.0003544071,"about_ca_system_score_gemma":0.0010743743,"threshold_uncertainty_score":0.22417207},"labels":[],"label_agreement":null},{"id":"W4394908620","doi":"10.1200/po.23.00687","title":"Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University","funders":"","keywords":"Radiomics; Multidisciplinary approach; Precision oncology; Drug development; Medicine; Medical physics; Clinical trial; Oncology; Precision medicine; Patient care; Internal medicine; Drug; Pathology; Pharmacology; Radiology","score_opus":0.030831788705128912,"score_gpt":0.4029483198222747,"score_spread":0.37211653111714577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394908620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95062184,0.00887627,0.0030237213,0.030512616,0.0026726918,0.0013248066,0.0000037953835,0.00011940263,0.0028448445],"genre_scores_gemma":[0.96730715,0.0016664915,0.02623677,0.0022982417,0.00029873024,0.0000934312,0.00005898195,0.00009101566,0.0019492011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99394685,0.0009210961,0.0026017928,0.0012189535,0.00070346287,0.00060781714],"domain_scores_gemma":[0.9829143,0.015198691,0.00066356355,0.00062669837,0.00020344932,0.0003932571],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010115843,0.0004170237,0.0015391019,0.00045919186,0.00022476038,0.000037230126,0.00038307044,0.00048143495,0.0001336819],"category_scores_gemma":[0.012568718,0.00027694265,0.00020363297,0.00091891707,0.0008916817,0.00012527652,0.0006417726,0.0020185497,0.000010598652],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027198428,0.00043048378,0.008690827,0.00017851502,0.00019981203,0.0049081678,0.013904188,0.000015017437,0.0041750777,0.000031347252,0.024724528,0.9400222],"study_design_scores_gemma":[0.009535665,0.0020121897,0.027194967,0.006516064,0.0004150651,0.009312927,0.008725965,0.0392699,0.0004998551,0.0005196112,0.8954502,0.0005475926],"about_ca_topic_score_codex":0.00026408202,"about_ca_topic_score_gemma":0.00015346154,"teacher_disagreement_score":0.9394746,"about_ca_system_score_codex":0.0011168739,"about_ca_system_score_gemma":0.0011348786,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W4399879771","doi":"10.1200/po.24.00174","title":"MEK Inhibition in a Pilocytic Astrocytoma With a Rare <i>KRAS Q61R</i> Mutation in a Young Adult Patient: A Case Report","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pilocytic astrocytoma; Medicine; Astrocytoma; KRAS; Cancer research; Internal medicine; Glioma; Cancer; Colorectal cancer","score_opus":0.01248254578821615,"score_gpt":0.3017933109536509,"score_spread":0.28931076516543475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399879771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949404,0.00039106308,0.00012986232,0.001196604,0.00022312587,0.0011886843,0.000013453164,0.00007865233,0.0018381549],"genre_scores_gemma":[0.99761474,0.000029031791,0.0011862952,0.00022034021,0.00005068585,0.00070949167,0.00011904723,0.00002954597,0.000040847175],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9980828,0.00013612665,0.00064677483,0.0005479079,0.00030325857,0.0002831356],"domain_scores_gemma":[0.9990478,0.00030310542,0.00012983024,0.0002483382,0.00015100373,0.00011992069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026061508,0.00020183848,0.00043132933,0.0006126992,0.000038754966,0.00003360168,0.000022707729,0.00017974286,0.000073510295],"category_scores_gemma":[0.00025408933,0.00014983464,0.00007287156,0.00071766885,0.000043513774,0.00016196926,0.000041086765,0.00027663214,0.00005018328],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016347923,0.0013399892,0.012383245,0.00009267622,0.00005196115,0.91548735,0.0033870384,0.00012997087,0.000712236,0.000101269434,0.00072634476,0.06395313],"study_design_scores_gemma":[0.02165104,0.018635476,0.033117786,0.0042123883,0.00038255373,0.8951658,0.0037562891,0.0074862097,0.011811377,0.00072407024,0.0025772366,0.00047977347],"about_ca_topic_score_codex":0.0007724041,"about_ca_topic_score_gemma":0.013705517,"teacher_disagreement_score":0.06347336,"about_ca_system_score_codex":0.0011363897,"about_ca_system_score_gemma":0.000359299,"threshold_uncertainty_score":0.7648},"labels":[],"label_agreement":null},{"id":"W4400073956","doi":"10.1200/po.24.00092","title":"Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Toronto","funders":"Seagen; Gilead Sciences; Sanofi; Genentech; Government of Ontario; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Princess Margaret Cancer Foundation; Amgen","keywords":"Tertiary care; Solid tumor; Center (category theory); Medical physics; Medicine; Patient care; Oncology; Internal medicine; Nursing; Cancer; Chemistry","score_opus":0.08487258725041298,"score_gpt":0.3691614437258927,"score_spread":0.28428885647547975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400073956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555516,0.0002757912,0.0023158216,0.000059412258,0.0004242249,0.00096450327,0.00021521255,0.000009284387,0.00018057323],"genre_scores_gemma":[0.9823451,0.00008075896,0.016624369,0.00024478819,0.0001534015,0.00018682302,0.00032780538,0.000020966758,0.000015995887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985491,0.000046991896,0.0006285326,0.00044515426,0.00010428726,0.00022592708],"domain_scores_gemma":[0.9987347,0.00050709833,0.00011300417,0.00027525635,0.0002640386,0.000105900835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022168382,0.00015650598,0.00028784946,0.00009521879,0.000055448418,0.000022927285,0.000117380856,0.00012828596,0.00000652278],"category_scores_gemma":[0.0011088708,0.0001229346,0.00009461504,0.00013440308,0.00003880308,0.000010612528,0.00011366138,0.00007531757,0.0000027922808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082474406,0.00035696375,0.116886884,0.000032108543,0.000035146262,0.000012677227,0.00045562763,0.0013123786,0.024532784,0.000008520097,0.00048434685,0.85505784],"study_design_scores_gemma":[0.019397072,0.05506383,0.5584406,0.001503933,0.00023490906,0.00005551535,0.0018979316,0.037124712,0.106094934,0.0003661974,0.21827629,0.0015440371],"about_ca_topic_score_codex":0.00003810474,"about_ca_topic_score_gemma":0.00077950244,"teacher_disagreement_score":0.8535138,"about_ca_system_score_codex":0.00024067791,"about_ca_system_score_gemma":0.00063882204,"threshold_uncertainty_score":0.50131273},"labels":[],"label_agreement":null},{"id":"W4401208972","doi":"10.1200/po.24.00094","title":"Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Ottawa; McGill University","funders":"","keywords":"Germline; Renal cell carcinoma; Medicine; Genetic predisposition; Oncology; Internal medicine; CHEK2; Odds ratio; Genetic testing; BAP1; Cancer; Kidney cancer; Germline mutation; Clear cell renal cell carcinoma; Biology; Genetics; Gene; Mutation","score_opus":0.05107389019641016,"score_gpt":0.3599442137011169,"score_spread":0.3088703235047067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401208972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95835286,0.002517122,0.029362526,0.006267223,0.0001857995,0.0015807482,0.000049831473,0.00008202485,0.0016018875],"genre_scores_gemma":[0.9054967,0.00004075597,0.09182622,0.00038596796,0.0002702252,0.00028487513,0.000045564855,0.00003092892,0.0016187313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99849075,0.0000665521,0.0003900526,0.0006357082,0.00012628676,0.0002906783],"domain_scores_gemma":[0.9983079,0.0007400264,0.000044071352,0.00044332398,0.00014867852,0.00031602976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034313675,0.00017253,0.00035493454,0.00020472387,0.00009257344,0.000029393681,0.00008631526,0.00015973915,0.00010845666],"category_scores_gemma":[0.00013325295,0.00013755442,0.00012950202,0.00020687692,0.000056217545,0.000036974834,0.000114775976,0.00015251216,0.000052529726],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010673001,0.0003741411,0.053944204,0.00026077827,0.000060101214,0.00013190822,0.00057110115,0.000059573,0.20695151,0.00022524962,0.019211054,0.71714306],"study_design_scores_gemma":[0.001596222,0.0049481303,0.8660266,0.00006159153,0.00026203177,0.00035200123,0.000045881723,0.0011798326,0.012534795,0.0008816979,0.11193947,0.00017178159],"about_ca_topic_score_codex":0.000036449965,"about_ca_topic_score_gemma":0.000052327086,"teacher_disagreement_score":0.81208235,"about_ca_system_score_codex":0.0002989709,"about_ca_system_score_gemma":0.00022258803,"threshold_uncertainty_score":0.5609306},"labels":[],"label_agreement":null},{"id":"W4401326937","doi":"10.1200/po.24.00167","title":"Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Pancreas Centre (Canada); University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Canada Research Chairs; AstraZeneca Canada; AstraZeneca; Pfizer","keywords":"Pancreatic carcinoma; Pancreatic ductal adenocarcinoma; Medicine; Carcinoma; Oncology; Internal medicine; Pancreatic cancer; Cancer","score_opus":0.08624623307428479,"score_gpt":0.4163307433603118,"score_spread":0.330084510286027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401326937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96529126,0.0011558319,0.00077152683,0.0040698894,0.0007634374,0.0010590245,0.000007055531,0.00013420076,0.0267478],"genre_scores_gemma":[0.98466796,0.00003512744,0.011625542,0.0008167406,0.0006907983,0.00023169049,0.000013493653,0.000039940598,0.0018787213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761564,0.00021689167,0.00058391044,0.00062027137,0.0003679393,0.00059535884],"domain_scores_gemma":[0.9963868,0.0027060776,0.00005105468,0.00036832655,0.00014730473,0.00034039404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011899322,0.00020238195,0.00075682515,0.0006667598,0.00007777312,0.00006222883,0.0002816788,0.0003032158,0.00057313615],"category_scores_gemma":[0.003030544,0.00016346085,0.0000810324,0.0009771403,0.000098029224,0.0002089077,0.00040934616,0.0006607864,0.00043528277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000733315,0.0003139528,0.7104585,0.00033438738,0.00006880585,0.009847191,0.0007983182,0.000015606953,0.010924212,0.00009735228,0.012476641,0.25393167],"study_design_scores_gemma":[0.0020142593,0.0035468664,0.95178336,0.0006749253,0.0001982391,0.0024464591,0.00033911984,0.026926594,0.00039107955,0.0008164188,0.010599521,0.00026318754],"about_ca_topic_score_codex":0.00096632267,"about_ca_topic_score_gemma":0.00023584224,"teacher_disagreement_score":0.2536685,"about_ca_system_score_codex":0.00082146085,"about_ca_system_score_gemma":0.0014854546,"threshold_uncertainty_score":0.666574},"labels":[],"label_agreement":null},{"id":"W4401412002","doi":"10.1200/po.24.00184","title":"“I Just Assumed This Was Already Being Done”: Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Provincial Health Services Authority; Queen's University; University of Toronto; Canada's Michael Smith Genome Sciences Centre; University of British Columbia; St. Michael's Hospital; Simon Fraser University","funders":"National Cancer Institute; National Institutes of Health; University of Toronto; Government of Ontario","keywords":"Focus group; Thematic analysis; Data sharing; Transparency (behavior); Qualitative property; Autonomy; Population; Psychology; Medicine; Qualitative research; Internet privacy; Medical education; Business; Computer science; Political science; Alternative medicine; Environmental health; Computer security","score_opus":0.6041546404413033,"score_gpt":0.6094429951412814,"score_spread":0.005288354699978126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401412002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5183333,0.006030154,0.068402246,0.09383628,0.026571583,0.02860416,0.0031599733,0.0010487635,0.25401354],"genre_scores_gemma":[0.9160974,0.0024666712,0.061349265,0.0023613123,0.0014991888,0.0018469921,0.0015270314,0.00016108691,0.012691076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937746,0.00032940833,0.0015347371,0.0021526942,0.0010163089,0.0011922349],"domain_scores_gemma":[0.93764377,0.057906043,0.000251434,0.0020333554,0.0011891989,0.00097621453],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0106979385,0.0003603706,0.0010931654,0.0006798436,0.00040810872,0.00015614343,0.0017143644,0.0018948579,0.0010173864],"category_scores_gemma":[0.053786185,0.0002902083,0.00024410686,0.00045299457,0.00030564854,0.00031927883,0.0013689754,0.0023130458,0.00023090746],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023127117,0.00042081016,0.00025169033,0.000637753,0.00025601793,0.00010376282,0.002012474,0.000015922866,0.005434829,0.0047813267,0.06134068,0.922432],"study_design_scores_gemma":[0.0028469851,0.010483209,0.00045032837,0.0014746054,0.00033192727,0.00004632414,0.0006452606,0.012096,0.0069495006,0.06669487,0.89758545,0.0003955253],"about_ca_topic_score_codex":0.005860867,"about_ca_topic_score_gemma":0.16382736,"teacher_disagreement_score":0.92203647,"about_ca_system_score_codex":0.0020985384,"about_ca_system_score_gemma":0.0072493735,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W4401803980","doi":"10.1200/po.24.00100","title":"Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Merck Canada; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Natera; Gilead Sciences; Eli Lilly and Company","keywords":"Pembrolizumab; Internal medicine; Oncology; Medicine; Biomarker; Immunotherapy; Progression-free survival; Cancer research; Cancer; Biology; Overall survival","score_opus":0.033039067890378006,"score_gpt":0.37552085143387254,"score_spread":0.3424817835434945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401803980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965356,0.00067590235,0.00017833989,0.001077412,0.00014130349,0.0006412751,0.000020253816,0.00013135209,0.0005985402],"genre_scores_gemma":[0.99832505,0.00013788794,0.00065986416,0.00028412754,0.000030075771,0.00007381349,0.000047700785,0.00004186904,0.0003996364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972928,0.0002603408,0.00093825965,0.0007394312,0.00035345068,0.00041570194],"domain_scores_gemma":[0.9981662,0.0010605735,0.00020960378,0.0002938001,0.00010978737,0.00016005654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009235855,0.00032126153,0.001444169,0.00068314356,0.000081968734,0.00005470298,0.0001032388,0.0002042105,0.00018078292],"category_scores_gemma":[0.00012908816,0.00020198636,0.00030976403,0.0014867716,0.0002701687,0.00015216599,0.000029420344,0.00038619287,0.0000052965383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022118734,0.0005182004,0.9257437,0.000060132283,0.0032714324,0.0012401991,0.00033690676,0.000022459746,0.0043874998,0.000010364007,0.000059569098,0.042230792],"study_design_scores_gemma":[0.013443105,0.0047562625,0.97593,0.00037998985,0.0013317765,0.00024649414,0.0002387614,0.0026633635,0.00022138686,0.00002801845,0.00049455353,0.0002663176],"about_ca_topic_score_codex":0.00020723157,"about_ca_topic_score_gemma":0.00081917964,"teacher_disagreement_score":0.050186258,"about_ca_system_score_codex":0.0003970658,"about_ca_system_score_gemma":0.00033811695,"threshold_uncertainty_score":0.82367647},"labels":[],"label_agreement":null},{"id":"W4401805383","doi":"10.1200/po.24.00031","title":"Kinetic Profiling of <i>RAS</i> Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of <i>RAS</i> Mutations in Neo-<i>RAS</i>-Wildtype Metastatic Colorectal Cancer Is Transient","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Neuroblastoma RAS viral oncogene homolog; KRAS; Cetuximab; Medicine; Internal medicine; Hazard ratio; Colorectal cancer; Panitumumab; Oncology; HRAS; Mutation; Cancer; Cancer research; Biology; Genetics; Gene; Confidence interval","score_opus":0.030536048013300253,"score_gpt":0.34769754583515433,"score_spread":0.3171614978218541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401805383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053216,0.003055931,0.0002836843,0.0018265793,0.0006967763,0.0023767082,0.00084208476,0.000008737396,0.00037732997],"genre_scores_gemma":[0.99659175,0.00059817126,0.0006045765,0.00074963854,0.00022742667,0.0010006536,0.00016652518,0.00004728558,0.000013963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99685574,0.0006985559,0.0011547316,0.00052279263,0.00033857982,0.00042957472],"domain_scores_gemma":[0.9971153,0.0018464236,0.0003966395,0.0003343476,0.00020033188,0.00010692859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019397142,0.00026679784,0.0006649589,0.00025681773,0.0001366492,0.000057640766,0.00037529663,0.00017831419,0.00006553918],"category_scores_gemma":[0.0006925474,0.00017923993,0.00019090678,0.0007275136,0.00031703597,0.000013981089,0.00004229712,0.00033710012,0.0000021030007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021605382,0.0020134987,0.019261926,0.0007794527,0.0013939074,0.00064344564,0.027158573,0.11505367,0.7452477,0.0027745937,0.0075713354,0.05649649],"study_design_scores_gemma":[0.12106472,0.02113033,0.057717536,0.0028966942,0.0042577046,0.0008115239,0.013056567,0.02278532,0.5889306,0.0065180375,0.15715128,0.0036796487],"about_ca_topic_score_codex":0.03936238,"about_ca_topic_score_gemma":0.50909424,"teacher_disagreement_score":0.4697319,"about_ca_system_score_codex":0.00031634068,"about_ca_system_score_gemma":0.0034437699,"threshold_uncertainty_score":0.9670346},"labels":[],"label_agreement":null},{"id":"W4401988220","doi":"10.1200/po.24.00269","title":"A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"EMD Serono; Regeneron Pharmaceuticals; Genentech; AstraZeneca; Pfizer; DOD Prostate Cancer Research Program; Sanofi; Foundation Medicine; Prostate Cancer Foundation; U.S. Department of Defense","keywords":"Overdiagnosis; Prostate cancer; Medicine; Oncology; Blood test; Disease; Internal medicine; Cancer research; Pathology; Cancer","score_opus":0.02480000990877935,"score_gpt":0.3183627302285673,"score_spread":0.293562720319788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401988220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854367,0.008323944,0.00047381604,0.0017844917,0.0011210502,0.0021445095,0.00046409116,0.00018316695,0.00006825179],"genre_scores_gemma":[0.9923816,0.002653489,0.0017492091,0.00023691272,0.0002397392,0.0024749523,0.00008642682,0.00006859473,0.00010907588],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99744964,0.00017252998,0.0006981399,0.00075146713,0.00051104795,0.00041720798],"domain_scores_gemma":[0.9972692,0.0013986089,0.000260065,0.00040278188,0.00030839565,0.0003609455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025506903,0.00033322183,0.00065255055,0.0004000586,0.000101474674,0.000050022838,0.000109276145,0.00021692413,0.00044040408],"category_scores_gemma":[0.00040419062,0.00027052776,0.00025205463,0.00055175635,0.00010442652,0.00018034756,0.000082542596,0.00031355652,0.000023941195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004169149,0.0058356994,0.091618605,0.0012924105,0.0013171874,0.00041563335,0.0020229844,0.0024935827,0.21019241,0.000034886307,0.0010861597,0.67952126],"study_design_scores_gemma":[0.007965489,0.004682564,0.39180136,0.001786241,0.0021369052,0.000005252409,0.00004035736,0.0044958815,0.5772229,0.00019227494,0.009316598,0.00035421847],"about_ca_topic_score_codex":0.0005675879,"about_ca_topic_score_gemma":0.00042558633,"teacher_disagreement_score":0.6791671,"about_ca_system_score_codex":0.0007970571,"about_ca_system_score_gemma":0.0010459217,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W4403709384","doi":"10.1200/po.24.00145","title":"Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology","year":2024,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; NRG Oncology","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Histopathology; Cancer; Clinical trial; Randomized controlled trial; Pathology","score_opus":0.10550044020706685,"score_gpt":0.4751473990672055,"score_spread":0.36964695886013865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403709384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030926152,0.9827672,0.00066211756,0.00025154746,0.0013064201,0.010826254,0.00027983022,0.00011489962,0.0006990672],"genre_scores_gemma":[0.00295184,0.98668534,0.001889873,0.00005009158,0.00042744758,0.0064056753,0.0008747498,0.00014526088,0.000569739],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98993725,0.0041353987,0.0034361382,0.0014479177,0.00038456896,0.0006587435],"domain_scores_gemma":[0.99010664,0.0059044287,0.0029392657,0.00050930714,0.00026678332,0.00027358846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004913829,0.00088033907,0.011125617,0.00093302573,0.00013571678,0.00008947961,0.00019730521,0.0011313932,0.00024625286],"category_scores_gemma":[0.002535067,0.0005312306,0.0010688773,0.00062134623,0.00041311252,0.00017844368,0.00014162905,0.0018306818,0.00007882237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05098229,0.0013987027,0.00005847892,0.0018636306,0.0007824064,0.001477351,0.0010032025,0.00014211687,0.000006428562,0.000025706011,0.00015738454,0.9421023],"study_design_scores_gemma":[0.1957075,0.0044048615,0.000007797674,0.009441952,0.0134275025,0.0006436392,0.00014679233,0.0016005144,0.0000057952657,0.00015003482,0.77397066,0.00049293245],"about_ca_topic_score_codex":0.00033260087,"about_ca_topic_score_gemma":0.00030624212,"teacher_disagreement_score":0.9416094,"about_ca_system_score_codex":0.0058719995,"about_ca_system_score_gemma":0.0040992163,"threshold_uncertainty_score":0.9997139},"labels":[],"label_agreement":null},{"id":"W4404125687","doi":"10.1200/po-24-00375","title":"DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; Pfizer; University of Texas MD Anderson Cancer Center; University of North Carolina at Chapel Hill; National Institutes of Health; Melanoma Institute Australia; Medical Research Council; National Health and Medical Research Council; Huntsman Cancer Foundation; Char and Chuck Fowler Family Foundation; National Cancer Institute; Melanoma Research Alliance; National Institute of Environmental Health Sciences; Memorial Sloan-Kettering Cancer Center","keywords":"Stage (stratigraphy); DNA methylation; Methylation; Primary (astronomy); Clinical significance; Biology; DNA; Cancer research; Oncology; Medicine; Genetics; Internal medicine; Gene; Gene expression; Paleontology","score_opus":0.03563761992787889,"score_gpt":0.3467736763202066,"score_spread":0.3111360563923277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404125687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98648745,0.0036847736,0.0019029488,0.0013776586,0.0004510987,0.000778421,0.000008795844,0.00007243559,0.005236437],"genre_scores_gemma":[0.992989,0.0021491682,0.0013143219,0.00023490451,0.00010845838,0.000026421336,0.000007726391,0.000014119347,0.0031559018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988058,0.00014943146,0.0004391836,0.00036961597,0.000115703144,0.000120256795],"domain_scores_gemma":[0.998282,0.0013144589,0.000093799135,0.00014758247,0.000052141913,0.00010997308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000729333,0.00012163913,0.0004201517,0.00015482212,0.000062915016,0.000019343584,0.000032508156,0.00016498695,0.000073467265],"category_scores_gemma":[0.0002674641,0.0000876572,0.000043140095,0.000114745606,0.00021962888,0.00005924797,0.00016023779,0.00019736691,0.0000029114467],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008597047,0.0002211632,0.005998978,0.0004133616,0.00014991035,0.00012491054,0.0007815745,0.0000012601502,0.029442834,0.00092787127,0.0016126244,0.9594658],"study_design_scores_gemma":[0.0036315662,0.009899479,0.19018069,0.0003795797,0.0003724428,0.0006943553,0.0009484861,0.003289083,0.005260578,0.0019736493,0.7830873,0.00028275436],"about_ca_topic_score_codex":0.000010436297,"about_ca_topic_score_gemma":0.000025751784,"teacher_disagreement_score":0.95918304,"about_ca_system_score_codex":0.00004234795,"about_ca_system_score_gemma":0.00010425893,"threshold_uncertainty_score":0.3574557},"labels":[],"label_agreement":null},{"id":"W4404125770","doi":"10.1200/po.24.00328","title":"Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pazopanib; Histone deacetylase; Histone deacetylase inhibitor; Medicine; Internal medicine; Oncology; Cancer research; Pharmacology; Biology; Cancer; Histone; Genetics; Sunitinib","score_opus":0.01511728436312147,"score_gpt":0.3375026105248496,"score_spread":0.3223853261617281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404125770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99475425,0.00017847586,0.00043541848,0.00025384728,0.0014598949,0.0023661423,0.0002947938,0.000023850087,0.0002333008],"genre_scores_gemma":[0.9970119,0.000016517104,0.00047281725,0.000074642405,0.00025015225,0.00032492972,0.000337605,0.000071962546,0.0014394859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972371,0.00035180539,0.00063404255,0.0007109988,0.0005558048,0.00051025214],"domain_scores_gemma":[0.9984243,0.00021730216,0.00020736996,0.0006070494,0.00041431503,0.00012964866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000769435,0.00030307152,0.00054313976,0.00019631216,0.00011447012,0.0000311302,0.00039270762,0.00027102113,0.000038082348],"category_scores_gemma":[0.0004408596,0.00019334508,0.00017172046,0.00043188053,0.00036224417,0.000017786586,0.00021704336,0.00030001136,0.0000086503205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37165642,0.0048383456,0.0014146591,0.00023973804,0.00035829365,0.0001181734,0.0009159503,0.00019453371,0.5462613,0.00014796112,0.052066106,0.021788508],"study_design_scores_gemma":[0.15425283,0.030569008,0.00089864235,0.00030774422,0.00011223452,0.000024344658,0.00017713234,0.00019286024,0.6920443,0.000044084612,0.1208097,0.000567101],"about_ca_topic_score_codex":0.000051730243,"about_ca_topic_score_gemma":0.0006929319,"teacher_disagreement_score":0.2174036,"about_ca_system_score_codex":0.00028195916,"about_ca_system_score_gemma":0.0011043452,"threshold_uncertainty_score":0.7884384},"labels":[],"label_agreement":null},{"id":"W4404625463","doi":"10.1200/po.24.00331","title":"Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Internal medicine; Meta-analysis; Epidermal growth factor receptor; Oncology; Cochrane Library; Adverse effect; Gastroenterology; Cancer; Gefitinib; Erlotinib","score_opus":0.05529877687620812,"score_gpt":0.39678806373164016,"score_spread":0.34148928685543206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404625463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010320988,0.99135697,0.000026945774,0.00025932144,0.00007022358,0.0066774357,0.00044330498,0.000016848137,0.00011683821],"genre_scores_gemma":[0.0020350718,0.9951584,0.0008159221,0.00015020247,0.00001719955,0.0010200288,0.00039183622,0.00005361824,0.00035776006],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996588,0.0004995061,0.0017066676,0.00070124853,0.00027131903,0.00023329027],"domain_scores_gemma":[0.9969286,0.0012587655,0.0010335197,0.00036093398,0.00023740402,0.00018079387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042670892,0.0005145421,0.0072118007,0.000602854,0.00005788235,0.000026983429,0.000094661875,0.00024019102,0.0001350745],"category_scores_gemma":[0.00027298118,0.0002837198,0.0005499975,0.00090995216,0.00010476009,0.00007955532,0.0001143603,0.00033138096,0.0000034395302],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001910166,0.0013361523,0.0013959173,0.85881674,0.0767877,0.00003501929,0.00073278433,0.0000025882655,2.7163114e-7,0.000009593149,0.00016916885,0.060523055],"study_design_scores_gemma":[0.0026515936,0.0013667104,0.0008098004,0.0842971,0.9043266,0.00002148469,0.000029867388,0.000022869794,7.572009e-7,0.000003842663,0.0061707683,0.00029859963],"about_ca_topic_score_codex":0.00015267612,"about_ca_topic_score_gemma":0.00013141904,"teacher_disagreement_score":0.8275389,"about_ca_system_score_codex":0.00048450413,"about_ca_system_score_gemma":0.00047115464,"threshold_uncertainty_score":0.9999615},"labels":[],"label_agreement":null},{"id":"W4405301403","doi":"10.1200/po-24-00407","title":"Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Hospital for Sick Children; University of British Columbia; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Observational study; Breast cancer; Family history; Internal medicine; Clinical trial; Cohort; Genetic testing; Genetic counseling; Oncology; Genetics; Biology","score_opus":0.14439222216664757,"score_gpt":0.4435259865020033,"score_spread":0.29913376433535577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405301403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458945,0.0019077876,0.00072417693,0.0000850362,0.0013841155,0.00081043795,0.0003123549,0.000014528192,0.0001721371],"genre_scores_gemma":[0.99669594,0.0002777343,0.001601565,0.00015328973,0.00054357655,0.00018123913,0.00031979376,0.000022006609,0.0002048849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843395,0.0001734817,0.00054802955,0.00055730494,0.00011799668,0.00016922003],"domain_scores_gemma":[0.99909294,0.0001896733,0.00009739183,0.0003420671,0.00017589095,0.000102029975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010422955,0.0001262845,0.0003040847,0.000044318695,0.000058300306,0.00001412053,0.00022534137,0.00021989006,0.00014932163],"category_scores_gemma":[0.00015912282,0.00010958724,0.00017497397,0.000052315852,0.00008013884,0.0000068089803,0.00013223314,0.00009706208,0.0000050052563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013480644,0.001917693,0.7665604,0.0001739082,0.0010364486,0.00012224715,0.0003192359,0.00052479166,0.076785825,0.000118544056,0.02309385,0.12799901],"study_design_scores_gemma":[0.0008596819,0.003205198,0.92463547,0.000025983676,0.00017435789,0.000040898343,0.00039901023,0.003684782,0.0006101526,0.00068915135,0.06545775,0.00021757014],"about_ca_topic_score_codex":0.00008284555,"about_ca_topic_score_gemma":0.00021980872,"teacher_disagreement_score":0.1580751,"about_ca_system_score_codex":0.00006390899,"about_ca_system_score_gemma":0.0010285521,"threshold_uncertainty_score":0.44688383},"labels":[],"label_agreement":null},{"id":"W4405302030","doi":"10.1200/po-24-00514","title":"Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V","year":2024,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; Margaret A. Cargill Foundation; National Institutes of Health; American College of Radiology Imaging Network","keywords":"Sunitinib; Medicine; Internal medicine; Renal cell carcinoma; Oncology; Gastroenterology; Clinical endpoint; Progressive disease; Clinical trial; Disease","score_opus":0.07533586281381977,"score_gpt":0.4325817661142351,"score_spread":0.35724590330041534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405302030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97717875,0.00005759053,0.000031065723,0.0023123166,0.000116436946,0.018573547,0.0001284913,0.000058456626,0.0015433215],"genre_scores_gemma":[0.9926725,0.0000069068537,0.0010949494,0.000070281494,0.00017391614,0.0053813914,0.00011979074,0.000029108067,0.00045115844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971375,0.0005480858,0.0008516676,0.0005113843,0.0005978103,0.00035354495],"domain_scores_gemma":[0.9961055,0.0028694456,0.00016062208,0.00050684466,0.00018988288,0.00016773374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011545605,0.000211695,0.00056964054,0.00023414449,0.00010639567,0.000038279588,0.00021007302,0.000062547784,0.0002211225],"category_scores_gemma":[0.0012996242,0.00011841741,0.000084875384,0.00058445433,0.0001491802,0.000099892655,0.00014817204,0.0005287792,0.000057195062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71265256,0.05698087,0.0043952977,0.00009702466,0.00043494947,0.017375253,0.013198821,0.000096695134,0.002366452,0.00010119414,0.00753409,0.1847668],"study_design_scores_gemma":[0.5591628,0.38923767,0.013853181,0.001680656,0.00033225692,0.00083138596,0.014504833,0.0008628811,0.0028677476,0.0010771942,0.015315463,0.0002739166],"about_ca_topic_score_codex":0.0015259581,"about_ca_topic_score_gemma":0.002029838,"teacher_disagreement_score":0.3322568,"about_ca_system_score_codex":0.00025712655,"about_ca_system_score_gemma":0.0008063419,"threshold_uncertainty_score":0.4828922},"labels":[],"label_agreement":null},{"id":"W4406854679","doi":"10.1200/po.24.00199","title":"Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers","year":2025,"lang":"en","type":"review","venue":"JCO Precision Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"National Cancer Institute; Conquer Cancer Foundation","keywords":"MAPK/ERK pathway; Mutant; Cancer; Mutation; Cancer research; Medicine; Kinase; Protein kinase A; Internal medicine; Oncology; Biology; Gene; Genetics","score_opus":0.033493044826011814,"score_gpt":0.3678672657524481,"score_spread":0.3343742209264363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406854679","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26931787,0.72039473,0.00020384166,0.000024134115,0.0018529139,0.006471658,0.00047986858,0.000031634696,0.0012233449],"genre_scores_gemma":[0.027060008,0.9671591,0.0013688578,0.00006740914,0.00021789943,0.00095707574,0.0015536384,0.00011733037,0.0014986936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99562156,0.0014848973,0.0012677616,0.0009508161,0.00027350365,0.00040147902],"domain_scores_gemma":[0.9975103,0.00031002003,0.0010831428,0.00071839406,0.00022749329,0.00015061726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067899283,0.00052256015,0.0022659611,0.00032203307,0.000042588086,0.00000985093,0.0004180703,0.0009574561,0.00003735101],"category_scores_gemma":[0.000688265,0.0003924854,0.0004143895,0.00051403913,0.00018154785,0.000007809184,0.00032690808,0.0005736972,0.000008621019],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012419802,0.000703468,0.00032864534,0.002724211,0.0003161376,0.00002775789,0.000013839041,0.0000042172373,0.0015197459,0.000004121956,0.0014136337,0.99170226],"study_design_scores_gemma":[0.003722354,0.004800444,0.0003797838,0.005283796,0.00042066813,0.0000048521088,0.000008514233,0.0000022297647,0.0094936155,0.00001899948,0.9753093,0.0005554479],"about_ca_topic_score_codex":0.00009126815,"about_ca_topic_score_gemma":0.00017189786,"teacher_disagreement_score":0.9911468,"about_ca_system_score_codex":0.00028078372,"about_ca_system_score_gemma":0.0029886535,"threshold_uncertainty_score":0.9998527},"labels":[],"label_agreement":null},{"id":"W4407011452","doi":"10.1200/po-24-00653","title":"Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Histopathology; Hazard ratio; Proportional hazards model; Medicine; Prostate cancer; Internal medicine; Oncology; Urology; Clinical trial; Confidence interval; Cancer; Pathology","score_opus":0.038948330216087804,"score_gpt":0.4126592573118778,"score_spread":0.37371092709579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407011452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989276,0.0005433585,0.0009397346,0.003125978,0.00013581963,0.005078106,0.00005905794,0.000020674048,0.0008212966],"genre_scores_gemma":[0.996084,0.0002514323,0.0011024566,0.00012038782,0.000022638369,0.0014869481,0.000056786048,0.000012718193,0.0008626288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978096,0.0003310792,0.0007944753,0.0004622386,0.0002561669,0.00034647543],"domain_scores_gemma":[0.9977246,0.0017391273,0.00014770062,0.00018557192,0.000104398976,0.00009858344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094973895,0.00021382551,0.0011728661,0.00058992766,0.000058437297,0.000049310223,0.00008080808,0.00013305392,0.00006464707],"category_scores_gemma":[0.0006643097,0.0001323738,0.000079908736,0.0004066333,0.00043492785,0.00012854509,0.00005331511,0.0002984515,0.0000031746056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089039,0.0016753731,0.0052467478,0.000044791534,0.000092482136,0.0007283658,0.00076027686,0.00012801097,0.0011217464,0.00009535328,0.00002361412,0.18117939],"study_design_scores_gemma":[0.97197837,0.004133047,0.00400128,0.0004327573,0.00015135207,0.000010800699,0.0007070473,0.01401105,0.002402807,0.0018787903,0.0001061732,0.00018654401],"about_ca_topic_score_codex":0.00032625181,"about_ca_topic_score_gemma":0.0018590952,"teacher_disagreement_score":0.18099284,"about_ca_system_score_codex":0.0003681558,"about_ca_system_score_gemma":0.0013200026,"threshold_uncertainty_score":0.53980464},"labels":[],"label_agreement":null},{"id":"W4407395562","doi":"10.1200/po-24-00675","title":"Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Tissue microarray; Medicine; Immunohistochemistry; Internal medicine; Oncology; Pathology; Cancer; Histology","score_opus":0.038866336250880235,"score_gpt":0.3938108376245462,"score_spread":0.35494450137366595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407395562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98646766,0.00050157565,0.000022863675,0.0012771608,0.00021235344,0.0005376529,0.00013913392,0.000019221921,0.010822377],"genre_scores_gemma":[0.9961549,0.0009100079,0.00071985426,0.0003745889,0.000098348006,0.000014317065,0.00008388746,0.00000885238,0.0016352326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979497,0.0006254912,0.0006768327,0.00032800378,0.00028151425,0.00013845578],"domain_scores_gemma":[0.9964991,0.0028790329,0.00028724383,0.00024865475,0.000038040736,0.000047900852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001560681,0.0001102939,0.00029313716,0.000088294684,0.000056640703,0.000008417586,0.00013381272,0.00014815372,0.000048107762],"category_scores_gemma":[0.0018723313,0.00006902798,0.00008181988,0.00015907406,0.00009446351,0.00008891807,0.00020556274,0.00020617255,0.00001731089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004317991,0.0005751828,0.90155226,0.000036142545,0.00004078536,0.000015501719,0.0002674571,0.000005655414,0.0020040974,0.000014010101,0.010234095,0.080936804],"study_design_scores_gemma":[0.002572714,0.00042292205,0.98777676,0.00038967034,0.000107615786,0.0000024042638,0.00013250421,0.00021631012,0.00061927305,0.0003614664,0.007338441,0.000059937625],"about_ca_topic_score_codex":0.000061912004,"about_ca_topic_score_gemma":0.000060570994,"teacher_disagreement_score":0.08622447,"about_ca_system_score_codex":0.00018214773,"about_ca_system_score_gemma":0.000104878396,"threshold_uncertainty_score":0.28148794},"labels":[],"label_agreement":null},{"id":"W4407828113","doi":"10.1200/po-24-00631","title":"Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health; Canada's Michael Smith Genome Sciences Centre; Queen's University; University of British Columbia; Simon Fraser University","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Oncology; Internal medicine; Population; Censoring (clinical trials); Survival analysis; Confidence interval; Pathology","score_opus":0.09579530884220487,"score_gpt":0.43047834553754183,"score_spread":0.33468303669533694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407828113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430675,0.00007625319,0.007033527,0.000055739987,0.0014123706,0.0042339894,0.000008034191,0.000050327875,0.0028229812],"genre_scores_gemma":[0.9955421,0.00010591006,0.003399944,0.000063926724,0.00007339002,0.00028215843,0.000044539884,0.000016343985,0.0004716835],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967785,0.0013737105,0.00090878876,0.00051834463,0.00020164602,0.00021901293],"domain_scores_gemma":[0.9953702,0.0038201376,0.0002666967,0.000296815,0.00015799038,0.00008817993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028800755,0.00018180792,0.00094582693,0.0006154471,0.00006527826,0.000008599565,0.00007505644,0.00026184373,0.00003739354],"category_scores_gemma":[0.0012820693,0.00016738317,0.00012412708,0.0005205573,0.00006973333,0.00007688367,0.00011460126,0.00028051873,0.0000048157826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15580906,0.0009723496,0.25661457,0.00062428,0.00019340354,0.00014330764,0.00014356012,0.004028272,0.01805213,0.001081377,0.00004415698,0.5622935],"study_design_scores_gemma":[0.053781994,0.0019085039,0.93290174,0.00051235803,0.00009487133,0.000019214267,0.00006461476,0.0052633164,0.0019232825,0.0011390658,0.0022556523,0.00013536491],"about_ca_topic_score_codex":0.0007198393,"about_ca_topic_score_gemma":0.0009815529,"teacher_disagreement_score":0.6762872,"about_ca_system_score_codex":0.0010791478,"about_ca_system_score_gemma":0.00028039442,"threshold_uncertainty_score":0.6825687},"labels":[],"label_agreement":null},{"id":"W4408245897","doi":"10.1200/po-24-00641","title":"Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Metastatic breast cancer; Subgroup analysis; Population; Cancer; Cohort; Brain metastasis; Gynecology; Metastasis; Meta-analysis; Confidence interval","score_opus":0.01767704248195932,"score_gpt":0.36299924804994055,"score_spread":0.3453222055679812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408245897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943474,0.000021264821,0.00005957652,0.0010387508,0.00008893999,0.003152273,0.00044929274,0.00003497912,0.00080750015],"genre_scores_gemma":[0.9965194,0.0000114800605,0.00094702246,0.00013431428,0.000059504015,0.00037218715,0.00012269522,0.000026192884,0.0018072181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968651,0.0005268466,0.0006430371,0.00057245075,0.0009401682,0.00045243074],"domain_scores_gemma":[0.99729294,0.0008316759,0.00030429623,0.00024910693,0.0010555869,0.00026637845],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013248082,0.00021086985,0.00093202776,0.00040242437,0.00015740251,0.000020470005,0.000135728,0.00016902832,0.0012591761],"category_scores_gemma":[0.0010869511,0.00016826355,0.000041143117,0.00056385377,0.00007996569,0.00011920253,0.00023608212,0.00034122402,0.000022315442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006378925,0.00070835487,0.9470504,0.00004665659,0.0008369052,0.0000030687654,0.0011084973,9.351812e-7,0.00032220592,0.0000023868836,0.007255263,0.04202745],"study_design_scores_gemma":[0.0035632793,0.0023353093,0.9893585,0.00018927766,0.0001688464,3.0228648e-7,0.00011087399,0.0000026746836,0.0011804957,0.0000116421015,0.0029378266,0.00014101095],"about_ca_topic_score_codex":0.000770636,"about_ca_topic_score_gemma":0.00069381617,"teacher_disagreement_score":0.042308077,"about_ca_system_score_codex":0.0040549105,"about_ca_system_score_gemma":0.0010160846,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W4409127671","doi":"10.1200/po-24-00546","title":"Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Translational Breast Cancer Research Consortium; Breakthrough Cancer Research; American Society of Clinical Oncology; Genentech; Breast Cancer Research Foundation","keywords":"Breast cancer; Trastuzumab; Pertuzumab; Immunohistochemistry; Immune system; Medicine; Oncology; Estrogen receptor; Stromal cell; Antibody; Internal medicine; Pathology; Cancer; Cancer research; Biology; Immunology","score_opus":0.015748799155744012,"score_gpt":0.36758629728602243,"score_spread":0.3518374981302784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409127671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344844,0.00036169097,0.00044067492,0.0026791824,0.000036986585,0.0019357423,0.00013581461,0.000043750126,0.00091772276],"genre_scores_gemma":[0.9962364,0.00009403178,0.0014170659,0.00021003923,0.000011224457,0.00028997273,0.00007142016,0.00001976446,0.0016500881],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99658024,0.0017265334,0.0004705598,0.00053206505,0.00034146602,0.00034913048],"domain_scores_gemma":[0.9970504,0.0016384022,0.00024993913,0.00048264663,0.00045730715,0.00012129218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011943404,0.00024084463,0.0010973284,0.00089828245,0.00008388465,0.000015451307,0.00015058128,0.00036731586,0.00010959656],"category_scores_gemma":[0.0013833354,0.00016809406,0.00016539502,0.001271468,0.0003316132,0.000032057855,0.00013409973,0.00035448786,0.000002608271],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061064895,0.0021706335,0.16093414,0.00005959473,0.00789798,0.0013191878,0.0012847414,0.00027560384,0.6316139,0.000106121624,0.00038750307,0.13288571],"study_design_scores_gemma":[0.004284887,0.007702122,0.93458307,0.00043406177,0.0011598008,0.00008365098,0.00018138174,0.00040346358,0.050812338,0.00008962915,0.00012771582,0.00013789083],"about_ca_topic_score_codex":0.0018311316,"about_ca_topic_score_gemma":0.00084189087,"teacher_disagreement_score":0.7736489,"about_ca_system_score_codex":0.0015930601,"about_ca_system_score_gemma":0.0010893202,"threshold_uncertainty_score":0.68546766},"labels":[],"label_agreement":null},{"id":"W4409318045","doi":"10.1200/po-24-00742","title":"<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Oncology; Breast cancer; Medicine; Internal medicine; Hazard ratio; Cancer; Hormone receptor; Placebo; Metastatic breast cancer; Confidence interval; Pathology","score_opus":0.015640053231237825,"score_gpt":0.3257295918809627,"score_spread":0.3100895386497248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283046,0.0020389033,0.0006103645,0.0011729349,0.00009108437,0.002497783,0.0003999043,0.00016668807,0.00019185779],"genre_scores_gemma":[0.99242705,0.0016457089,0.002707801,0.0007655887,0.00017912507,0.000993514,0.00009226718,0.00009702437,0.0010919345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99649584,0.0006342471,0.00076518755,0.0011132532,0.0004306043,0.0005608685],"domain_scores_gemma":[0.99798703,0.00037655924,0.00046599747,0.00057598756,0.00037756035,0.00021684627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003380465,0.0005889432,0.0016358204,0.00084259745,0.00023081999,0.000045065834,0.00021490935,0.00022703,0.001461564],"category_scores_gemma":[0.000026810998,0.00036185607,0.00010213034,0.0017271239,0.0003033245,0.0003151669,0.000096105396,0.000586172,0.0000056769836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043846257,0.0014101525,0.7721886,0.000030639254,0.0025536807,0.00006613446,0.0012979689,0.000056782694,0.0081623765,0.0000072517914,0.00012905835,0.17025113],"study_design_scores_gemma":[0.032236055,0.008115486,0.9486342,0.0001813952,0.0010936223,0.00010277757,0.0012267997,0.000060988554,0.0032061546,0.000033480974,0.00465283,0.0004562339],"about_ca_topic_score_codex":0.0050297333,"about_ca_topic_score_gemma":0.011300601,"teacher_disagreement_score":0.1764456,"about_ca_system_score_codex":0.00067025697,"about_ca_system_score_gemma":0.0004970844,"threshold_uncertainty_score":0.99988335},"labels":[],"label_agreement":null},{"id":"W4409721270","doi":"10.1200/po-24-00500","title":"Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada); Bayer (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Trk receptor; Oncology; Cancer; Hazard ratio; Progression-free survival; Lung cancer; Receptor; Confidence interval; Neurotrophin; Chemotherapy","score_opus":0.011398444702965325,"score_gpt":0.34334784540911234,"score_spread":0.33194940070614704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409721270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984308,0.0004220115,0.00010105544,0.0040617716,0.00093736843,0.0027406993,0.00011421045,0.000113604474,0.007201297],"genre_scores_gemma":[0.9775199,0.00048337007,0.008148278,0.0009982008,0.00023993052,0.0010559185,0.0004459905,0.00007734208,0.011031041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973257,0.0002533541,0.00064261083,0.000793839,0.00046759695,0.00051688054],"domain_scores_gemma":[0.99814373,0.00030092587,0.00030362443,0.0005540168,0.00047774817,0.00021995112],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018983555,0.00043203693,0.0009065876,0.0006850162,0.00025536967,0.000041390187,0.00017002062,0.00023067326,0.0010587543],"category_scores_gemma":[0.00006177688,0.00028685492,0.00009567926,0.001212684,0.00020409582,0.0001877384,0.00009057676,0.00043935032,0.000049298887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028485512,0.0057504307,0.7220641,0.00011832614,0.0006037072,0.00007073635,0.003318912,0.00011024009,0.0055349637,0.00022397997,0.045804333,0.18791477],"study_design_scores_gemma":[0.037128285,0.0064459224,0.6524257,0.0020931184,0.00047790218,0.000002854607,0.0010533913,0.000058384412,0.0062549305,0.0000596176,0.29349902,0.0005008923],"about_ca_topic_score_codex":0.003258975,"about_ca_topic_score_gemma":0.008631778,"teacher_disagreement_score":0.24769467,"about_ca_system_score_codex":0.0022196355,"about_ca_system_score_gemma":0.0012134173,"threshold_uncertainty_score":0.99995834},"labels":[],"label_agreement":null},{"id":"W4410390708","doi":"10.1200/po-24-00821","title":"Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Confidence interval; Genetic testing; Medicine; Descriptive statistics; Health care; Low Confidence; Genomic information; Family medicine; Psychology; Internal medicine; Genome; Statistics; Genetics; Biology","score_opus":0.09539806212524465,"score_gpt":0.42067178318017606,"score_spread":0.3252737210549314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410390708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945902,0.0025668682,0.000056008106,0.00023917345,0.0005353294,0.0016612692,0.00006539157,0.00002039067,0.00026535115],"genre_scores_gemma":[0.99761075,0.0008351449,0.00085417816,0.0002957645,0.000040990224,0.0002971341,0.00003305716,0.000016237978,0.0000167683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724215,0.00057258713,0.00084398413,0.0007310029,0.00026677412,0.00034349505],"domain_scores_gemma":[0.98163354,0.017431218,0.0003291151,0.0003629262,0.00017744643,0.000065724475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026558633,0.00022786066,0.0005454004,0.0002537525,0.00014596703,0.000055854736,0.00016786178,0.00013520088,0.00003366031],"category_scores_gemma":[0.007845293,0.00015829744,0.000039090217,0.00053345104,0.0001021354,0.000113751594,0.00022153958,0.00030812185,0.000002728759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062126,0.0000591074,0.64201605,0.00000435209,0.000013958201,0.000029486719,0.0043584295,0.0005213153,0.00067341846,0.0000015019255,0.000051156454,0.35165],"study_design_scores_gemma":[0.004255737,0.00033777545,0.9854144,0.0016277602,0.000045366203,0.0000058682363,0.0015108689,0.0053516366,0.000503322,0.00059903227,0.00021918991,0.00012906236],"about_ca_topic_score_codex":0.0057085576,"about_ca_topic_score_gemma":0.016607465,"teacher_disagreement_score":0.35152093,"about_ca_system_score_codex":0.0016008934,"about_ca_system_score_gemma":0.00092008023,"threshold_uncertainty_score":0.93921155},"labels":[],"label_agreement":null},{"id":"W4411085240","doi":"10.1200/po-24-00705","title":"Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Prostate cancer; Correlation; Medicine; Logistic regression; Oncology; Internal medicine; Prostate; Cancer; Mathematics","score_opus":0.03672518077381527,"score_gpt":0.38038659173792916,"score_spread":0.3436614109641139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411085240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321926,0.002946353,0.00029382843,0.00029774877,0.00018876708,0.0011517715,0.00020366779,0.000019107621,0.0016795204],"genre_scores_gemma":[0.9964399,0.00039098976,0.0020934348,0.0003452712,0.000014556566,0.00033938396,0.00019340964,0.000013721949,0.0001693724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750423,0.00017609658,0.0010274923,0.00054984854,0.00040170105,0.00034061095],"domain_scores_gemma":[0.9984735,0.0005734655,0.00031634312,0.00041709316,0.00012871665,0.00009085126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000476715,0.00022587553,0.0011668318,0.0012165777,0.000038085003,0.000019073128,0.00016609985,0.0003400496,0.00052282325],"category_scores_gemma":[0.00018683096,0.000172667,0.00017508269,0.0013038195,0.00010686615,0.00009206698,0.00022481223,0.0003177817,0.0000028428979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031671177,0.0020709424,0.86035573,0.000037795457,0.0005004711,0.00007130447,0.0012556253,0.005195048,0.0049669384,0.000028673287,0.0026407046,0.11970964],"study_design_scores_gemma":[0.007881057,0.0011651302,0.92846984,0.0003012147,0.00050065137,6.224002e-7,0.000120474884,0.0023518957,0.05268104,0.00041669785,0.0059812227,0.0001301454],"about_ca_topic_score_codex":0.00066134054,"about_ca_topic_score_gemma":0.0016218108,"teacher_disagreement_score":0.119579494,"about_ca_system_score_codex":0.00062064425,"about_ca_system_score_gemma":0.000287683,"threshold_uncertainty_score":0.70411557},"labels":[],"label_agreement":null},{"id":"W4412125701","doi":"10.1200/po-25-00200","title":"Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"DNA; Genome; Cell-free fetal DNA; DNA sequencing; Computational biology; Whole genome sequencing; Biology; Genetics; Gene","score_opus":0.012237026845153052,"score_gpt":0.30584458902256906,"score_spread":0.293607562177416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412125701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94420266,0.0006075813,0.006373481,0.0015133127,0.00044329453,0.0021289042,0.0004985777,0.00007061206,0.044161588],"genre_scores_gemma":[0.97724646,0.00031606588,0.018457841,0.00072024297,0.00008584618,0.00048496673,0.00015999567,0.00003341449,0.0024951857],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99781185,0.000156703,0.0006407716,0.0005740166,0.0003450544,0.000471623],"domain_scores_gemma":[0.996986,0.001265497,0.00039883435,0.0008414841,0.0003408171,0.00016741706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006435597,0.00029031,0.000858714,0.00025373773,0.00016114251,0.000019588795,0.00026541343,0.00028767716,0.00008154924],"category_scores_gemma":[0.00017616429,0.0002079395,0.00023260845,0.0002940141,0.0000657943,0.000073660485,0.000120704295,0.00011691549,0.000023181992],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009675591,0.056367163,0.16648331,0.0022691118,0.0022580677,0.0009905122,0.0026210924,0.00029863234,0.5369334,0.004956412,0.04852946,0.16861723],"study_design_scores_gemma":[0.14327085,0.015120341,0.19984142,0.00074724626,0.0023018424,0.00009358642,0.0015868521,0.0009181378,0.3133813,0.0019504834,0.32015705,0.0006308909],"about_ca_topic_score_codex":0.00009091435,"about_ca_topic_score_gemma":0.0000980962,"teacher_disagreement_score":0.27162758,"about_ca_system_score_codex":0.0017629619,"about_ca_system_score_gemma":0.0016375105,"threshold_uncertainty_score":0.8479527},"labels":[],"label_agreement":null},{"id":"W4412166395","doi":"10.1200/po-25-00130","title":"Prostate-Related Germline Variant Frequencies Detected in a Cohort of Men With Metastatic Prostate Cancer in Northern India","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University Health Network; Health Sciences North; University of Toronto; NOSM University; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Germline; Medicine; Oncology; Prostate; Cohort; Internal medicine; Cancer; Gynecology; Biology; Gene; Genetics","score_opus":0.010442309869281729,"score_gpt":0.3061228084469846,"score_spread":0.29568049857770284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412166395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901623,0.0024690926,0.000020233398,0.0015925579,0.0001165126,0.0033412566,0.00009808718,0.000036183246,0.0021637531],"genre_scores_gemma":[0.99453306,0.0020003312,0.00088634924,0.00016609541,0.000007897914,0.0016999224,0.00006660432,0.000027241002,0.000612517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976697,0.00021418727,0.0009304042,0.0005119275,0.00027546752,0.00039831415],"domain_scores_gemma":[0.99857074,0.00039655616,0.00031393938,0.0003390942,0.0002830145,0.00009667331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005691246,0.0002599189,0.00096284476,0.0005996479,0.000031375563,0.000009574395,0.0001142765,0.00015473604,0.000121308425],"category_scores_gemma":[0.00018468295,0.00018122372,0.000057669768,0.001256985,0.00015563067,0.00008968798,0.00007202232,0.00034250974,0.0000060507473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029248837,0.0013163422,0.92734736,0.00016416523,0.00044526465,0.0011691758,0.002232861,0.0007165486,0.002752085,0.00007720811,0.00015827939,0.06069584],"study_design_scores_gemma":[0.01305621,0.0028261852,0.9741844,0.0012856836,0.0003134695,0.00004648977,0.00037165708,0.0006091941,0.00549321,0.0007960842,0.0008360081,0.00018143118],"about_ca_topic_score_codex":0.002717151,"about_ca_topic_score_gemma":0.019103386,"teacher_disagreement_score":0.06051441,"about_ca_system_score_codex":0.0013130272,"about_ca_system_score_gemma":0.0018564159,"threshold_uncertainty_score":0.99879545},"labels":[],"label_agreement":null},{"id":"W4412831622","doi":"10.1200/po-25-00404","title":"Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Epithelioid sarcoma; Immunohistochemistry; Sarcoma; Alveolar soft part sarcoma; Pleural effusion; Retrospective cohort study; Oncology; Internal medicine; Cancer; Soft tissue sarcoma; Pathology","score_opus":0.03543992563335825,"score_gpt":0.3678757549915658,"score_spread":0.33243582935820754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412831622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749711,0.022496218,0.00072726153,0.0007402276,0.00009835532,0.00072451856,0.000030357736,0.000015924745,0.00019603038],"genre_scores_gemma":[0.992619,0.0054722447,0.0012644377,0.00024164942,0.00006672998,0.00015432763,0.000014911965,0.000017634005,0.00014909708],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985573,0.0002096346,0.0004997018,0.00044519678,0.00006111988,0.00022704413],"domain_scores_gemma":[0.99866205,0.0006409979,0.00014932766,0.00035539066,0.00014801063,0.000044195513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005543865,0.00015549708,0.00032103533,0.00025422403,0.000050251714,0.00000952719,0.00020398406,0.00026574265,0.000013601248],"category_scores_gemma":[0.0005881755,0.00014128932,0.000071845236,0.00036090697,0.00004650097,0.000007975172,0.00010575446,0.000114860755,0.0000013561427],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002560648,0.0012866358,0.060288794,0.00022815006,0.000056370827,0.000019097475,0.00040859016,0.00033908416,0.50360334,0.00034400984,0.0023006075,0.42856467],"study_design_scores_gemma":[0.030173732,0.006786223,0.5830125,0.00094026723,0.00016347977,0.00064384175,0.00036835563,0.008352986,0.32551715,0.0070456434,0.035603378,0.0013924275],"about_ca_topic_score_codex":0.00015545078,"about_ca_topic_score_gemma":0.0010662848,"teacher_disagreement_score":0.52272373,"about_ca_system_score_codex":0.00007856482,"about_ca_system_score_gemma":0.00026521386,"threshold_uncertainty_score":0.5761611},"labels":[],"label_agreement":null},{"id":"W4413273638","doi":"10.1200/po-24-00810","title":"Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Palbociclib; Genotyping; Biomarker; Breast cancer; Medicine; Oncology; Cancer; Gene; Internal medicine; Cancer research; Biology; Metastatic breast cancer; Genotype; Genetics","score_opus":0.013986420986430633,"score_gpt":0.31583188916411026,"score_spread":0.3018454681776796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413273638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647045,0.0005385356,0.0005261141,0.0006008797,0.00025975803,0.0012758245,0.00016458912,0.000042055104,0.000121804245],"genre_scores_gemma":[0.99305314,0.000030962918,0.006385458,0.00026746216,0.000055092733,0.000099600584,0.000047217964,0.000029420156,0.000031669595],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978585,0.00021495236,0.00079500675,0.0005993751,0.00025211618,0.00028001843],"domain_scores_gemma":[0.9981633,0.0006261477,0.00039266056,0.00041295076,0.00032240106,0.000082563216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032988362,0.0002202639,0.0006613622,0.00035392086,0.000109463406,0.000014534456,0.00011055534,0.00010704413,0.00004037368],"category_scores_gemma":[0.00032081467,0.00018540576,0.000037645354,0.0006062924,0.00010744381,0.00020898759,0.00015122397,0.00017774265,9.830518e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011045106,0.00060302234,0.45260474,0.000020171945,0.00017315288,0.00002324632,0.002216282,0.00013327504,0.018894477,0.000003468941,0.000008015046,0.514275],"study_design_scores_gemma":[0.01757826,0.00056725624,0.9786371,0.0006634992,0.0001014732,0.000010470767,0.0007173964,0.00023125536,0.0010776591,0.000101712205,0.00015950533,0.00015440189],"about_ca_topic_score_codex":0.0008055041,"about_ca_topic_score_gemma":0.0009347339,"teacher_disagreement_score":0.5260324,"about_ca_system_score_codex":0.0005116466,"about_ca_system_score_gemma":0.00033408558,"threshold_uncertainty_score":0.75606275},"labels":[],"label_agreement":null},{"id":"W4413774700","doi":"10.1200/po-24-00505","title":"Therapeutic Outcomes and Biomarker Potential of <i>CDKL3</i> of Neoadjuvant Chemotherapy in Patients With Stage IIIC Versus Stage IV Epithelial Ovarian Cancer","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Stage (stratigraphy); Oncology; Medicine; Chemotherapy; Epithelial ovarian cancer; Internal medicine; Ovarian cancer; Biomarker; Neoadjuvant therapy; Cancer research; Cancer; Breast cancer; Biology","score_opus":0.017229505671301132,"score_gpt":0.3313117407260863,"score_spread":0.31408223505478516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447125,0.0006264871,0.0001856081,0.0022412846,0.00057557813,0.0009445271,0.00012315519,0.000011643775,0.00082044833],"genre_scores_gemma":[0.99753463,0.00062746066,0.00061190705,0.0004962522,0.000017286518,0.000070693604,0.000016062846,0.000018909734,0.00060680247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858195,0.00010065921,0.00048805733,0.0003474995,0.00026290803,0.00021895632],"domain_scores_gemma":[0.9989443,0.0002821783,0.00024718887,0.00032291588,0.00013686575,0.00006656053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020979016,0.00019649173,0.0007468164,0.00024865588,0.00002918225,0.0000059577696,0.000091147755,0.00016778633,0.00035731384],"category_scores_gemma":[0.000027249693,0.00013220028,0.00008367183,0.00025723624,0.00014159459,0.000050959483,0.00005621527,0.00012327984,0.0000014220102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018078467,0.0017677539,0.6668163,0.00007809312,0.0006110499,0.000021440823,0.00023250715,0.000026530724,0.001040398,0.00021680766,0.00010874848,0.31100193],"study_design_scores_gemma":[0.048058927,0.0027055528,0.93888766,0.00015609729,0.00020331967,4.7156615e-7,0.000073964824,0.000070138725,0.0019320768,0.000053082123,0.00775907,0.00009966147],"about_ca_topic_score_codex":0.0006037057,"about_ca_topic_score_gemma":0.00033224656,"teacher_disagreement_score":0.31090227,"about_ca_system_score_codex":0.0002620783,"about_ca_system_score_gemma":0.00039267266,"threshold_uncertainty_score":0.53909713},"labels":[],"label_agreement":null},{"id":"W4413920704","doi":"10.1200/po-25-00588","title":"Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Germline; Somatic cell; Germline mutation; Breast cancer; Oncology; Genetics; Medicine; Biology; Mutation; Cancer; Gene","score_opus":0.018202773317583652,"score_gpt":0.38088604077919874,"score_spread":0.3626832674616151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413920704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9179176,0.0023288196,0.0027590278,0.07042512,0.00048503885,0.0013122396,0.000060481478,0.000111178364,0.004600468],"genre_scores_gemma":[0.9837302,0.0005624221,0.0063672904,0.0061546625,0.00011842829,0.0006183797,0.000015614005,0.000021550219,0.002411455],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988276,0.00007217698,0.00038326267,0.00036417707,0.00011451582,0.0002383115],"domain_scores_gemma":[0.9990833,0.0003484425,0.00007691794,0.00028279665,0.000102533464,0.00010602152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012809255,0.00016863068,0.00046518512,0.00029173208,0.000060619368,0.000018298091,0.000065327666,0.000097920514,0.00019020122],"category_scores_gemma":[0.000050924635,0.000133197,0.000043854685,0.0003871729,0.00008935769,0.000114578535,0.000051649793,0.000121381476,0.00001639971],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015879391,0.0005501807,0.01422263,0.000064618966,0.000098596654,0.0000833911,0.0019335835,0.0008474781,0.011471858,0.00070400117,0.0006849124,0.9677508],"study_design_scores_gemma":[0.013397496,0.0017856462,0.6447515,0.0009822665,0.00024339936,0.0004962638,0.0035847316,0.00079950865,0.0028095522,0.013131383,0.3176637,0.00035453614],"about_ca_topic_score_codex":0.000539858,"about_ca_topic_score_gemma":0.00077447685,"teacher_disagreement_score":0.96739626,"about_ca_system_score_codex":0.00082361145,"about_ca_system_score_gemma":0.00071383733,"threshold_uncertainty_score":0.54316163},"labels":[],"label_agreement":null},{"id":"W4415068958","doi":"10.1200/po-25-00696","title":"Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pancreatic cancer; Risk stratification; Risk assessment; Family history; Pancreatic ductal adenocarcinoma; Clinical Practice","score_opus":0.04217056952120794,"score_gpt":0.41723676095551926,"score_spread":0.3750661914343113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415068958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870142,0.0012500185,0.00031633838,0.0028805297,0.0011091331,0.0012783243,0.00014063087,0.000035892393,0.005974944],"genre_scores_gemma":[0.99121124,0.0033449908,0.00007510179,0.00045480445,0.00013161285,0.00080895587,0.000036252655,0.000020603668,0.0039164326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962293,0.0010878152,0.0010094331,0.00054550456,0.0005514609,0.00057651143],"domain_scores_gemma":[0.99317855,0.00500401,0.00036020248,0.00055340084,0.00077711616,0.00012673762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034751934,0.00025645844,0.0012221579,0.00029596992,0.00015386341,0.000027052261,0.00045449403,0.00042183878,0.00081734045],"category_scores_gemma":[0.0033638303,0.00017745148,0.00014711906,0.00090435764,0.0005150566,0.000077918055,0.0002474344,0.000661063,0.000021389575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004585599,0.00033492336,0.9427797,0.00007863168,0.00042084182,0.000017631013,0.0007698339,0.00021313247,0.0025030954,0.000041358293,0.0012030959,0.047052156],"study_design_scores_gemma":[0.004078741,0.00052904384,0.9841968,0.0003760507,0.00013087076,0.000021297423,0.0004301883,0.0050939093,0.0006524866,0.00031180494,0.0040413793,0.0001374675],"about_ca_topic_score_codex":0.035251565,"about_ca_topic_score_gemma":0.107641816,"teacher_disagreement_score":0.07239025,"about_ca_system_score_codex":0.0013672148,"about_ca_system_score_gemma":0.0017892566,"threshold_uncertainty_score":0.97117275},"labels":[],"label_agreement":null},{"id":"W4415711782","doi":"10.1200/po-25-00557","title":"Virtual CNS Tumor Board Rounds Within the Canadian Adolescent and Young Adult Neuro-Oncology Network","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; London Health Sciences Centre; Sunnybrook Health Science Centre; Western University; St. Michael's Hospital; University Health Network; SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"","keywords":"Young adult; Radiation therapy; MEDLINE; Cancer; Work (physics); Primary care","score_opus":0.014684526868310671,"score_gpt":0.29760949252447805,"score_spread":0.28292496565616737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415711782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9149341,0.0012701742,0.00009371011,0.0562701,0.0045490153,0.0016183056,0.000016801312,0.000078038975,0.021169743],"genre_scores_gemma":[0.97786653,0.00015185225,0.00043131222,0.02042455,0.00035149182,0.00019097909,0.000017193328,0.000022323415,0.0005437684],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979277,0.00033206306,0.0004934125,0.0005028986,0.0002259067,0.00051799574],"domain_scores_gemma":[0.99801606,0.0007603835,0.00015806695,0.00046570503,0.00021168585,0.00038811003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005194056,0.00024810038,0.0005820656,0.00021765541,0.00045910108,0.000055172444,0.00018795521,0.00029144145,0.0000836088],"category_scores_gemma":[0.00057025277,0.00016296623,0.0001094383,0.00037024377,0.00022970952,0.000046865167,0.00016542294,0.0005171771,0.000054033182],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015406157,0.0014005945,0.37535846,0.000037139118,0.00043138704,0.002426639,0.001250218,0.00038321933,0.00093915535,0.02394661,0.384552,0.20773396],"study_design_scores_gemma":[0.0068699317,0.0039028144,0.43997288,0.00026607598,0.00053728657,0.00063241343,0.0007260962,0.0018495801,0.00040890204,0.0012774876,0.54330087,0.00025565104],"about_ca_topic_score_codex":0.023863101,"about_ca_topic_score_gemma":0.47601852,"teacher_disagreement_score":0.4521554,"about_ca_system_score_codex":0.0012054141,"about_ca_system_score_gemma":0.001624231,"threshold_uncertainty_score":0.9826371},"labels":[],"label_agreement":null},{"id":"W4415973611","doi":"10.1200/po-25-00245","title":"Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology","funders":"National Cancer Institute; National Institutes of Health","keywords":"Foundation (evidence); Quality (philosophy); Control (management); Circulating tumor DNA; Quality control; Disease control","score_opus":0.06694180683768487,"score_gpt":0.40673108948978015,"score_spread":0.3397892826520953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415973611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97374684,0.0001247523,0.021717746,0.0018232376,0.0015477489,0.00063073053,0.0002898779,0.0000026782036,0.000116381554],"genre_scores_gemma":[0.9976846,0.00015295275,0.00022755776,0.0014134403,0.00023970894,0.00007037768,0.00013187437,0.0000045908014,0.00007488195],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99875313,0.00027289137,0.0006340858,0.00017110583,0.0000941689,0.000074622614],"domain_scores_gemma":[0.99801284,0.00092694635,0.000543895,0.00013400854,0.00036626996,0.000016051492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018650996,0.00006189156,0.00020846704,0.00003279998,0.00011702798,0.000010360272,0.000086709064,0.00005693367,0.000011179233],"category_scores_gemma":[0.0015656152,0.000043553824,0.000045337933,0.00008453884,0.00013513785,0.0000044249305,0.00007116732,0.000038461432,2.398673e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011330813,0.00023549453,0.021996899,0.00007114566,0.00011622703,4.3918625e-8,0.000040279778,0.00010438651,0.92691296,0.01614491,0.0017143292,0.031530213],"study_design_scores_gemma":[0.0017800474,0.00045133,0.93554246,0.0000333134,0.000028489168,7.8093336e-7,0.000023710043,0.00011666179,0.022891164,0.0007167725,0.038357943,0.000057337395],"about_ca_topic_score_codex":0.00007065288,"about_ca_topic_score_gemma":0.00016283484,"teacher_disagreement_score":0.91354555,"about_ca_system_score_codex":0.00004973937,"about_ca_system_score_gemma":0.00091227447,"threshold_uncertainty_score":0.18743007},"labels":[],"label_agreement":null},{"id":"W4417062080","doi":"10.1200/po-25-00279","title":"Clinical Utility of Multicancer Detection in Symptomatic Patients: A Decision-Making Perspective","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Perspective (graphical); Referral; Retraining; MEDLINE; Clinical judgment","score_opus":0.014525397196960348,"score_gpt":0.4011360747315419,"score_spread":0.38661067753458156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417062080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640265,0.00037471837,0.029206809,0.00009615525,0.0011079321,0.00045546482,0.000011533333,0.000010077208,0.004710796],"genre_scores_gemma":[0.9916647,0.0001265658,0.007751756,0.00023705098,0.000063378175,0.000079578036,0.0000053202116,0.0000104055225,0.00006124221],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99811023,0.0003284778,0.0007362277,0.0004982919,0.0001489446,0.00017783728],"domain_scores_gemma":[0.9981795,0.00068392075,0.0002161057,0.00043920375,0.00044805615,0.000033214186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007586343,0.0001250181,0.00031560808,0.00018898406,0.000047076086,0.0000065497816,0.00022784951,0.00037236058,0.00007605083],"category_scores_gemma":[0.0037593956,0.00012027958,0.00012805316,0.0003384381,0.00017396924,0.000006355405,0.00022389773,0.00019013853,0.000006883187],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001116662,0.00068622956,0.07375321,0.000017530334,0.00007097456,0.0000012511989,0.00021681955,0.00018678837,0.0032846895,0.000089986796,0.0011013601,0.9194745],"study_design_scores_gemma":[0.004291446,0.0013166047,0.9428836,0.00027896577,0.00006121796,0.0000031976501,0.0008230005,0.0057370854,0.01267439,0.009179392,0.022488568,0.00026251515],"about_ca_topic_score_codex":0.000033020475,"about_ca_topic_score_gemma":0.0007487487,"teacher_disagreement_score":0.919212,"about_ca_system_score_codex":0.00038987634,"about_ca_system_score_gemma":0.00049972784,"threshold_uncertainty_score":0.4904859},"labels":[],"label_agreement":null},{"id":"W4417208883","doi":"10.1200/po-25-00709","title":"Development and Validation of an Intratumor Heterogeneity–Based Prognostic Model for Clear Cell Renal Cell Carcinoma","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Clear cell renal cell carcinoma; Kidney cancer; Renal cell carcinoma; Immune system; Clear cell; Set (abstract data type); Prognostic model; Cell","score_opus":0.041305229038433956,"score_gpt":0.3198779747995676,"score_spread":0.2785727457611336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417208883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808525,0.00019933088,0.015691802,0.00017385406,0.000118984084,0.0014740648,0.00001125332,0.000027669788,0.0014505277],"genre_scores_gemma":[0.9096385,0.0000039925358,0.089351475,0.00015229206,0.000026652053,0.00020061764,0.00010721229,0.000019914525,0.0004993011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984522,0.00010507547,0.00053721835,0.00045093964,0.00021162759,0.0002429405],"domain_scores_gemma":[0.9987921,0.0003331948,0.00018420292,0.0003111606,0.00022578095,0.00015355246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039666347,0.00019409008,0.00046482874,0.00024055317,0.0000798787,0.000012343001,0.00009870795,0.0001945916,0.0000107411915],"category_scores_gemma":[0.000084978485,0.00016373475,0.00008078161,0.00013184967,0.00006038091,0.000054988748,0.00006790109,0.000121103454,0.000004176811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018395688,0.008051672,0.019679641,0.0021981227,0.00016984489,0.0001848415,0.0026870165,0.011488266,0.7556579,0.00025296467,0.00187601,0.17935802],"study_design_scores_gemma":[0.005605449,0.0033581038,0.013435531,0.00007097705,0.00025061888,0.000012541708,0.00007913485,0.08344715,0.8922042,0.00018333914,0.0012101115,0.00014281391],"about_ca_topic_score_codex":0.000005919162,"about_ca_topic_score_gemma":0.000016335425,"teacher_disagreement_score":0.17921521,"about_ca_system_score_codex":0.00030119217,"about_ca_system_score_gemma":0.00090879586,"threshold_uncertainty_score":0.66769093},"labels":[],"label_agreement":null},{"id":"W7116663774","doi":"10.1200/po-25-00221","title":"CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"National Cancer Institute","keywords":"Monoclonal antibody; Solid tumor; Phase (matter); Cancer; Antibody; Tumor cells","score_opus":0.026661932388642968,"score_gpt":0.42918210070895435,"score_spread":0.4025201683203114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116663774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98896974,0.00027144732,0.000024997547,0.00558309,0.00025930107,0.002611891,0.000020985608,0.000013621499,0.002244907],"genre_scores_gemma":[0.9983457,0.00014140473,0.00014023861,0.00038231973,0.000040398634,0.000065754175,0.0000027172252,0.000019240084,0.000862233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718386,0.0006982777,0.00075005513,0.00042679434,0.0006200936,0.00032089523],"domain_scores_gemma":[0.9974754,0.0010547392,0.00024866828,0.00088233466,0.00024050208,0.00009834477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010200772,0.00018881712,0.00073850347,0.00021111504,0.00021684778,0.000006579759,0.0004934437,0.00015938937,0.0000941908],"category_scores_gemma":[0.00077681494,0.00009955046,0.000081101694,0.0011000499,0.0005496825,0.000038175356,0.00094707124,0.00074122916,0.0000012041527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055727158,0.039594818,0.41245493,0.0005288325,0.0004981459,0.00040159302,0.01495572,0.0012845068,0.2132316,0.00059642585,0.0106678745,0.2500584],"study_design_scores_gemma":[0.039928652,0.02073255,0.90304476,0.001605349,0.00020761864,0.00017024598,0.0018423463,0.0009781234,0.011952962,0.00021655821,0.01913043,0.00019042742],"about_ca_topic_score_codex":0.00032588272,"about_ca_topic_score_gemma":0.0010845438,"teacher_disagreement_score":0.49058983,"about_ca_system_score_codex":0.00018181949,"about_ca_system_score_gemma":0.0014812093,"threshold_uncertainty_score":0.405955},"labels":[],"label_agreement":null},{"id":"W7116688526","doi":"10.1200/po-25-00507","title":"Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Protocol (science); Consolidation (business); Control (management); Hybrid system; Bayesian probability; Control system","score_opus":0.5109775295074659,"score_gpt":0.6108634696134609,"score_spread":0.09988594010599505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116688526","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025202972,0.0000012341997,0.83409685,0.0005379752,0.00074292405,0.16050352,0.000065576,0.00007980875,0.001451813],"genre_scores_gemma":[0.010151039,2.8200017e-7,0.8002053,0.0004226485,0.0002631888,0.1882428,0.0000018279048,0.000030502808,0.0006824465],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9948176,0.0024724961,0.0014379256,0.0005654692,0.0003278017,0.00037868],"domain_scores_gemma":[0.870138,0.12839814,0.00051399943,0.0004671239,0.00037057823,0.0001121705],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0071098823,0.00023789491,0.0010261326,0.00016033924,0.00012566804,0.00005913107,0.00029929867,0.0002778498,0.00034897125],"category_scores_gemma":[0.08103342,0.00016636336,0.00015403154,0.00017929912,0.00019786262,0.000039787785,0.00007613523,0.00026739185,0.000035929097],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6082537,0.004277406,0.000013204995,0.00017852653,0.00024028926,0.000031033018,0.00007939844,0.00018582902,0.0005541914,0.05660319,0.025760887,0.30382237],"study_design_scores_gemma":[0.32249096,0.015583454,0.0000146630855,0.00016249408,0.0002985418,0.0000063005814,0.000014817139,0.011113655,0.004905131,0.6168429,0.028327417,0.00023965944],"about_ca_topic_score_codex":0.0000012745711,"about_ca_topic_score_gemma":9.4874673e-7,"teacher_disagreement_score":0.56023973,"about_ca_system_score_codex":0.00018030909,"about_ca_system_score_gemma":0.00045468024,"threshold_uncertainty_score":0.92670745},"labels":[],"label_agreement":null}]}